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Abstract
One of the most common complications associated with the use of central venous 
catheters (CVCs) is catheter-associated infection. Traditionally, when an infection is 
suspected, the CVC is removed and replaced, with the CVC tip being retrospectively 
analysed. Techniques that involve sampling of the CVC whilst it remains in situ, are 
hindered by the requirement for conventional laboratory culture of the sample for 
diagnosis. Some more rapid methods of detecting microorganisms have been developed 
but none are routinely used CVC management. The aim of this study was to develop a 
rapid method, which could potentially aid in the diagnosis of catheter-associated 
infections whilst the CVC remains in situ.
The FAS Endoluminal Brush (FASEB)-retrieved sample has high predictive values for 
the confirmation or elimination of a catheter-associated infection and it was chosen as the 
sampling device for use in this study. ATP bioluminescence was chosen as a possible 
detection technique for use in conjunction with FASEB-retrieved samples.
Much of the development involved, the exposure and degradation of non-microbial ATP 
and the subsequent lysis and detection of microbial ATP. A TCA-based extraction 
method was found to be of little clinical utility when evaluated with FASEB samples 
retrieved from 114 CVC tips. Further work involving a DTAB-based extraction method 
in combination with a-cyclodextrin, resulted in a sensitivity and specificity of 70.6% and 
86.7% respectively, in combination with plate culture, when challenged with 47 FASEB- 
retrieved samples.
This study indicates that ATP bioluminescence is a useful technique that may have an 
application for use in conjunction with FASEB -retrieved samples. However, further work 
is required to improve upon the sensitivity and specificity of the technique, with the main 
emphasis being on the sample preparation so that contaminating ATP is degraded and all 
microbial cells are exposed to the microbial lysis agent prior to ATP detection.
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Figure 1.1 Triple lumen CVC (Arrow 7Fr, 20cm). This particular CVC is 20cm long
(manifold to tip) and has three lumens extending into three hubs; brown is 
distal (16G), white is proximal (18G) and blue is medial (18G). The 
manifold is located at the junction of the leader tubes from the hubs to the 
7Fr tube. The black line on the yellow tube marks 10cm from the tip (blue) 
to the manifold.
Figure 1.2 Two common insertion sites for a double lumen permanent haemodialysis 
catheter (Quinton PermCath). On the left the CVC is tunnelled into the 
internal jugular vein, whilst on the right the CVC is inserted into the 
subclavian vein. In both cases the CVC tip is placed at the junction of the 
superior vena cava and the right atrium. (Source: promotional poster from  
Sherwood Davis and Geek, USA).
Figure 1.3 Groshong double lumen catheter (BARD, lOFr, 40cm). This particular
CVC is 40cm long (manifold to tip) and has two lumens extending into 
two hubs; red is distal and green is proximal. The black tip contains a 
valve, which is the unique feature of the Groshong catheter. Note that the 
Dacron cuff is located midway between the manifold and the tip.
Figure 1.4 Double lumen Hickman catheter (BARD, 9Fr, 60cm). This particular CVC
is 60cm long (manifold to tip) and has two lumens extending into two 
hubs. Both lumens are the same length. Note that the Dacron cuff is 
located approximately 15cm between the manifold and the tip.
Figure 1.5 Quinton Mahurkar® catheter (Quinton, 12Fr, 24cm). This particular short­
term CVC is 24cm long (manifold to tip) and has two lumens extending 
into two hubs; blue is distal which is used for the venous side and brown is 
proximal which is the arterial side.
Figure 1.6 The PermCath® (Quinton, 16Fr, 28cm). This particular long-term CVC is
28cm long (manifold to tip) and has two lumens extending into two hubs; 
blue is distal which is used for the venous side and brown is proximal 
which is the arterial side. There is a Dacron cuff located between the 
manifold and the tip.
Figure 1.7 The Ashsplit® catheter (MedComp, 14Fr, 28cm) is a long-term CVC
which is 28cm long (manifold to tip) and has two lumens extending into 
two hubs; blue is distal which is used for the venous side and red is 
proximal which is the arterial side. There is a Dacron cuff located between 
the manifold and the tip.
Figure 1.8 The Tesio® catheters (MedComp, lOFr, 50cm) are long-term, single
lumen CVCs, which are supplied up to 55cm long and are designed to be 
trimmed at time of insertion for an appropriate fit. Again the lumen of 
each extends into a hub; with the blue CVC used for the venous side and 
red for the arterial side. Again the Dacron cuff is located between the 
manifold and the tip
List o f fîmres____________________________________________________________________________xiv
Figure 1.9 The Dialock device (Biolink). This device consists of two 11.5Fr catheters,
which extend into the venous system from the implanted titanium port.
Figure 1.10 Causative organisms from 35 studies of CRS (Fletcher and Bodenham
1999a).
Figure 1.11 Sources and routes taken of infecting microorganisms in central venous
catheters (Elliott 1993). Reproduced with permission o f the PHLS 
Communicable Disease Surveillance Centre ©PHLS.
Figure 1.12 A scanning electron micrograph (SEM) of a longitudinal cross section of a
double lumen CVC. Source: work carried out by the author as part of this 
study.
Figure 1.13 A SEM of a CVC lumen showing the biofilm on the extraluminal and
intraluminal surfaces. Source: work carried out by the author as part of this 
study.
Figure 1.14 The FAS Endoluminal Brush and CVC hub (Tranter and Donoghue 2000).
Figure 2.1 A FASEB travelling through the leader tube of a CVC on its way into the
CVC lumen. The bristles compact when the FASEB is travelling in a 
forward motion and these bristles will compact further when the brush 
enters the smaller diameter CVC lumen.
Figure 2.2 The Statspin Cytofuge microcentrifuge (Statspin, USA).
Figure 2.3 The Questor (MicroMed Limited, UK).
Figure 2.4 Structure of adenosine triphosphate (ATP).
Figure 2.5 The LI luminometer (Mediators, Austria). The drawer to the right of the
luminometer is in the open position and a sample is contained within a 12 
X 75mm glass tube held in position in the reading chamber. In order to 
determine the ATP concentration in the sample the drawer needs to be 
closed and the RLU’s are determined.
Figure 2.6 The Bioprobe luminometer (Hughes Whitlock Limited, UK).
Figure 2.7 A flow chart showing the major steps that need to be followed in order to
develop a system based on ATP bioluminescence.
Figure 3.1 Protocols used when evaluating FASEB-retrieved samples (DTAB and 
TCA methods) in conjunction with the LI luminometer at room 
temperature.
Figure 4.1 Relative light units detected before (blue) and after (yellow) lysis o f a
serial dilution of S. aureus. Each bar represents the mean (±SD) of four 
experiments.
Figure 4.2 Relative light units detected before (blue) and after (yellow) lysis o f a
serial dilution of E. coli. Each bar represents the mean (±SD) o f four 
experiments.
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Figure 4.3 Relative light units detected before (blue) and after (yellow) lysis of a 
serial dilution of C. albicans. Each bar represents the mean (±SD) of four 
experiments.
Figure 4.4 Relative light units detected in serial dilutions of S. aureus. Each bar
represents the mean (±SD) of four experiments where RLU values were 
determined before ATPase was added, after ATPase (10% v/v) was added 
and after bacterial lysis agent was added.
Figure 4.5 Effect of a combination of lOx ATPase and various concentrations of
isolator reagent on the ATP concentration remaining in fi*esh heparinised 
blood (1:66.7 v/v). Each bar represents the mean (±SD) of four 
experiments. The control was the ATP concentration observed in a blood 
sample that was not exposed to isolator reagent.
Figure 4.6 The RLU values detected fi*om a serial dilution of E. coli, where the ATP
is extracted using either 50pl or lOOpl (18.5% or 31.1%) of bacterial lysis 
agent. Each bar represents the mean ± SD of four experiments.
Figure 4.7 A standard curve showing the relationship between the RLUs and S.
epidermidis cells (CFU) using the SL and HS reagents (Biothema AB, 
Sweden). Each point represents the mean ± SD of four experiments.
Figure 4.8 Effect of TCA on the signal emitted by the SL reagent and an ATP
standard in Tris-EDTA buffer. Each bar represents the mean (±SD) of four 
experiments.
Figure 4.9 Effect of TCA on the signal emitted by the HS reagent and an ATP
standard in Tris-EDTA buffer. Each bar represents the mean (±SD) of four 
experiments. Note that six concentrations were originally selected 
(between 0 and 0.125%(v/v)) as in the SL work above in section 4.3.2b, 
however an extra three concentrations (0.15, 0.175 and 0.20%(v/v)) were 
required investigated as <60% had not been achieved at 0.15%(v/v).
Figure 4.10 Effect of Tris concentration in the buffer used in the reaction between the
HS reagent and an ATP standard. Each bar represents the mean (±SD) of 
four experiments.
Figure 4.11 Effects of various concentrations of Bactolyse-extracted sample on the
signal produced by the SL reagent (9.5% v/v) and an ATP standard. The 
control does not contain any Bactolyse-extracted sample (just Tris-EDTA, 
SL and ATP standard). Each bar represents the mean (±SD) of four 
experiments.
Figure 4.12 The concentration of ATP remaining in blood cells (diluted 1:100) after
lysis with various concentrations of Triton X-100 and subsequent 
treatment with apyrase and TCA. Each point represents the mean (±SD) of 
four experiments.
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Context of Study
When a CVC is suspected to be involved in a bloodstream infection, it is often removed 
from the patient and retrospectively analysed. Studies bave shown that up to 80% of 
CVCs that are removed from catbeterised patients on suspicion of being implicated in an 
episode of bloodstream infection are removed unnecessarily (Kite et al. 1997, Padberg et 
a l 1981, Pettigrew et a l 1985, Ryan et a l 1974). Catheter removal is generally based on 
the clinician’s judgement as to whether the clinical signs of fever are related to the CVC. 
Various groups have attempted to develop methods that involve the sampling of a CVC 
whilst it remains in situ within the patient, thus obviating CVC removal. One such group 
(Markus and Buday 1989) developed a device known as the FASEB that could be used to 
sample the internal lumen of a CVC whilst it remains within the patient. FAS Medical 
Ltd, UK, have carried out further developed work on this device, achieving FDA and CE 
mark approvals, in addition to proving its efficacy in independent clinical studies 
(Dobbins and Kite 1999, Kite et a l 1997). However, FASEB use has not become routine 
in contemporary catheter management, as one of the major objections to its use is the fact 
that the CVC will remain within the patient until the FASEB-retrieved sample is cultured. 
Sample culture often requires 24 hours and therefore the CVC would need to be left in 
situ overnight. In reality, this rarely happens, as the Consultant in charge of the patient 
will initiate treatment on the basis of clinical judgement. Therefore the culture result from 
the FASEB-retrieved sample is often retrospective.
Current techniques used to rapidly detect the presence of microorganisms associated with 
CVCs (Blot et al 1999, Kite et al 1999) are not routinely used in clinical microbiology 
laboratories. Consequently, there is a requirement for an adequate rapid technique, which 
should not require CVC removal from the patient (Farr 1999). In order to meet this 
requirement, the directors of FAS Medical Ltd formed a strategy to develop a rapid 
laboratory-based method that could be used in conjunction with a FASEB-retrieved 
sample. Through an agreement between the RCPEH at the University of Surrey and FAS 
Medical Ltd, the present study was conducted with research and development work 
carried out in an attempt to achieve the goal of developing a rapid test for catheter- 
associated infections. This study was funded by FAS Medical Ltd, with clinical samples 
supplied by St George’s NHS Trust, London.
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Aims of this study
The overall aim of this study was to develop a laboratory-based technique to rapidly 
detect microorganisms that have colonised a CVC without having to remove that CVC. 
Such a technique could be used to diagnose or exclude a catheter-associated infection. 
The technique should not only reduce the number of CVCs that are removed 
unnecessarily, but it would also provide information that could lead to earlier intervention 
and correct diagnosis, should the CVC not be the source of the problem. In the present 
study the aim could be simplified into the following two questions:
• Have any microorganisms colonised the CVC?
• If there are, then how many organisms are present?
It is therefore critical that the sampling method and the detection technology that are 
chosen will be appropriate to answer these questions.
A successful rapid technique that would be used routinely in the laboratory should have a 
simple enough methodology so that it could to be routinely carried out both by trained 
staff and “on call” staff who provide emergency cover outside the normal 9 to 5pm 
working day. Other features that are important include:
• An assay should not be labour intensive,
• It should be cost-effective in terms of initial capital outlay on equipment, reagents 
and consumables,
• The turn-around time between sampling and obtaining a result should be within the 
working day.
• The entire system should at least equal, if  not improve, on the current technology 
with respect to sensitivity and specificity and it is important that the system has a 
low rate of false negative results.
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Objectives
The major objectives that were identified at the beginning of this project were to:
1. Conduct a review of relevant literature in the areas of catheters, catheter-associated 
infections, catheter colonisation, diagnosis of catheter infections and rapid methods 
used to detect microorganisms.
2. Obtain information on procedures that do not involve CVC removal in order to obtain 
a sample. Review these techniques and chose an appropriate method for use in this 
study.
3. Obtain and review technical information on “rapid” technologies that are currently 
available to detect microorganisms. Conduct a search for information on clinical as 
well as environmental and food-related industries.
4. Identify at least two technologies and evaluate which would be the most appropriate 
technology for detecting organisms within a clinical sample, based on ease of use, 
cost and potential performance.
5. Chose one of the technologies and develop a method based upon this technology 
which could be used to detect the presence of microorganisms in a laboratory 
simulated environment.
6. Optimise the developed method so that it could be used routinely within a clinical 
pathology laboratory. In doing this, identify a hospital where it may be possible to 
obtain true clinical samples (CVC tips) and fulfil appropriate hospital approvals to 
secure the samples.
7. Evaluate the developed method using samples obtained from catbeterised patients.
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Plan of thesis
This thesis describes the development and evaluation of a technique for rapidly detecting 
microbial colonisation associated with CVCs. The thesis is made up of seven chapters, 
the contents of which are summarised below.
Chapter 1 is a review of literature, which focused on CVCs, the types that are available 
and their use in modem medical practice. The pathogenesis of catheter-associated 
infections was reviewed as well as the techniques that have been developed to accurately 
diagnose catheter-associated infections.
Chapter 2 reviewed the techniques that are currently available to obtain a sample from a 
CVC without having to remove the CVC from the patient. The most appropriate 
technique, based on published studies, was chosen for use in this study. Three 
technologies used to rapidly detect microorganisms in both clinical and environment 
samples were compared and one chosen for further evaluation in this study.
Chapter 3 details all the method and materials used in the course of conducting this study.
The Results section is made up of three chapters (Chapters 4, 5 and 6).
• Chapter 4 details research conducted using an off-the-shelf luminometer system and 
a stand-alone tube luminometer with recommended reagents. The off-the-shelf 
system was found to be inappropriate as few parameters could be varied and 
therefore optimisation of the technique was not possible. The tube luminometer was 
selected for further development.
• Chapter 5 details research carried out using a tube luminometer and laboratory- 
developed reagents. A method was developed and evaluated; however areas of 
improvement were identified so as to increase the performance of the technique.
• Chapter 6 describes the further development and optimisation of a technique 
evaluated in Chapter 5. This technique was evaluated and the results analysed to 
determine the potential usefulness of the assay.
Chapter 7 contains a discussion of the findings of this study both in the context of the 
study and in the context of the literature reviewed in Chapter 1. The major findings are 
presented as well as recommendations for future work.
CHAPTER ONE 
Literature Review
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1.1 Overview
This review of literature will focus on central venous catheters, the types that are 
available, their use in medical practice and complications associated with their use. Much 
of the review will centre on the post-insertion complication of catheter-associated 
infection, where the pathogenesis of this infection will be discussed, as well as measures 
and strategies to prevent such infections. Finally, the techniques that have been developed 
for use in diagnosis of catheter-associated infections will be reviewed.
1.2 Catheters and Catheterisation
A catheter is a tube, which allows fluid to be delivered to, or taken from, the body. 
Meyers (1945) first described catheterisation of human blood vessels, where a technique 
for extending intravenous (IV) therapy by introducing a 9-12 inch plastic catheter through 
a steel needle was described. Since then the use of catheters or vascular access devices 
(VADs) has grown quite dramatically, with over 150 million used per year in the USA 
alone (Raad 1998). By 1996, it was observed that IV catheters were used in more than 
50% of hospitalised patients in the USA (Adal and Farr 1996).
One particular type of VAD, the central venous catheter (CVC), has become increasingly 
important in modem medical practise. Some 200,000 CVCs (Waghom 1994) and 5 
million CVCs (Maki 1991) are inserted in the UK and USA respectively each year. 
Although CVCs have revolutionised patient care in the second half of the twentieth 
century, a number of problems, such as sepsis and thrombosis, are associated with their 
use (Decker and Edwards 1988) and there continue to be major complications of CVC 
application (Fletcher and Bodenham 1999a).
There are many other different types of VADs, including Pulmonary Artery catheters, 
which are used in an acute setting when an accurate assessment of the pulmonary and 
cardiac status is necessary (Dawkins 1987, Mermel and Maki 1994) and specialist 
haemodialysis catheters used by patients with renal failure (Canaud 1999). However it is 
central venous VADs or CVCs, used throughout medical practise, with which this study 
is most concerned.
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Since 1945, CVCs have gone through a series of design changes, modifications and 
improvements (Broviac et al. 1973, Hickman et al. 1979, Trooskin et al. 1985). They can 
now be used for the administration of different therapies and are tailored for specific 
functions and patient types (Orr and Ryder 1993). They have had an enormous impact on 
many branches of medicine, such as intensive care, oncology, gastroenterology, 
haematology, nephrology, trauma and bums and modem medical practise is dependent 
upon their use (Dobbins et al. 1999).
1.2.1 Development and functions of CVCs
CVCs are used to administer medications such as antibiotics, antimitotics (dmgs used to 
treat cancer) or inotropes (dmgs to stimulate the heart). In addition CVCs are used for the 
administration of total parenteral nutrition (TPN), or for specialised functions such as 
haemodialysis (Adal and Farr 1996, Elliott et al. 1994a, Maki 1991, Olson et al. 1992).
As can be seen in Figure 1.1, CVCs consist of a tube, referred to as a lumen, ending in a 
capped hub, which is situated at the proximal end. The catheter extends firom the hub to 
the distal end -  known as the catheter “tip”. A single catheter may have up to four 
lumens, each of which may be used separately, and independently, to infuse solutions, 
take venous pressures or withdraw blood samples. CVCs are manufactured for all patient 
groups, fi*om paediatric to adult. They generally differ in the number of lumens that are 
present (from single lumen CVCs to those with multiple lumens), lumen diameter and 
length, and according to their intended use (Goldmann and Pier 1993, Orr and Ryder
1993). The hub has a Luer lock, which aids attachment of the device to an extemal supply 
of nutrition or therapy. Many CVCs are radiopaque, so that they can be x-rayed and their 
intemal position determined post-insertion (Campisi et al. 2000, Elliott 1993). CVCs 
vary in the number of lumens found within the catheter,
CVCs are inserted into the major veins, as described in Table 1.1, with the tip located in 
the superior vena cava above its junction with the right atrium and the distal portion 
placed parallel to the vessel wall. Access to the large veins is important as better dilution 
of the fluid is achieved and repeated venepuncture is avoided, thus preventing peripheral 
vein sclerosis (Brovaic et al. 1973). The insertion of a CVC should always be performed 
under aseptic conditions by trained personnel (Collins 1991, Elliott et al. 1994a).
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Figure 1.1 Triple lumen CVC (Arrow 7Fr, 20cm). This particular CVC is 20cm long (manifold to 
tip) and has three lumens extending into three hubs; brown is distal (16G), white is 
proximal (18G) and blue is medial (18G). The manifold is located at the junction o f the 
leader tubes from the hubs to the 7Fr tube. The black line on the yellow tube marks 10cm 
from the tip (blue) to the manifold.
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The most frequently used insertion sites include the right and left intemal jugular veins, 
the right and left subclavian veins shown in Figure 1.2 and the right and left femoral 
veins (Reed et al. 1995). On occasion the supra-clavicular and ante-cubital fossa can also 
be used (Elliott et al. 1994a).
a) A single lumen CVC
Single lumen CVCs were the first variant of catheters to be developed (Broviac et al. 
1973, Meyers 1945) and they are frequently used in an acute setting or for the provision 
of long-term access to a central vein for nutritional support, antibiotics or cancer 
chemotherapy (Adal and Farr 1996). Should this type of catheter be in place for a 
prolonged period of time, then it may be tunnelled under the skin prior to entry into the 
vein (Broviac a/. 1973, Hickman a/. 1979).
b) A multiple lumen CVC
Multiple-lumen CVCs vary in the lumen number from at least two to four (generally 
named double, triple and quad-lumen catheters). In cases where a patient may require the 
administration of two or more incompatible infusions, it is preferable to employ a multi­
lumen CVC. This avoids the use of multiple access sites for a number of single lumen 
CVCs. Multiple-lumen catheters have widespread use and are important in providing all 
the fluids that a patient requires, both in acute care settings and in long-term delivery of 
antibiotics and chemotherapy (Orr and Ryder 1993). The Arrow triple lumen CVC shown 
in Figure 1.1 is a frequently used multiple-lumen CVC within acute care settings.
1.2.2 CVCs currently used
In addition to the number of lumens that are present, CVCs also differ in function due to 
lumen size, proposed insertion site and their “life expectancy”. There are a wide variety 
of CVCs used in modem medicine and it is important that the most appropriate CVC is
used in a particular patient (Elliott et al. 1994a). The choice of CVC will depend upon the
chosen method of CVC introduction, the catheter material, its composition and design, as 
well as the intended function of the catheter (Elliott et al. 1994a).
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Figure 1.2 Two common insertion sites for a double lumen permanent haemodialysis catheter 
(Quinton PermCath). On the left the CVC is tunnelled into the intemal jugular vein, whilst 
on the right the CVC is inserted into the subclavian vein. In both cases the CVC tip is 
placed at the junction of the superior vena cava and the right atrium. (Source: 
promotional poster from  Sherwood Davis and Geek, USA).
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a) Long-term (tunnelled) CVCs
During prolonged therapy, the CVC is often implanted or tunnelled under the skin. This 
involves the catheter being inserted into the vein at a site distal to the point at which it 
exits the skin. These catheters, which are generally made of silicon, are specially adapted 
and have the distal tip positioned in the central vein, near the right atrium (Broviac et a l 
1973, Tenenbaum and Brennan-Scelsi 1994). The proximal end of the catheter generally 
consists of a manifold which gives rise to multiple hubs.
It was Broviac and colleagues who first reported the use of a narrow (1mm diameter) 
silicone rubber catheter, which was inserted into a central-vein and exited the skin at a 
distant site, after passing through a subcutaneous tunnel (Broviac et a l 1973). This 
catheter was developed specifically to administer TPN. It has a small Dacron® cuff, 
which encircles the catheter at the point where it becomes fixed, by the fibrotic tissue, to 
the subcutaneous portion. It holds the catheter in place (Johnson and Oppenheim 1992) 
and acts as a physical barrier to prevent microorganisms from migrating down the outside 
of the catheter (Decker and Edwards 1988). Silicone rubber is used in this CVC as it is a 
less thrombogenic alternative to polyvinyl chloride (Bozzetti et a l 1983, Broviac et a l 
1973). Hickman et a l (1979) introduced a modified Broviac catheter which is basically a 
wider bore catheter - a larger intemal diameter of 1.6mm instead of 1mm - and is used to 
administer blood products, dmgs and IV infusion; also blood can be withdrawn through it 
(Johnson and Oppenheim 1992). The two most popular commercially available tunnelled 
CVCs are the Groshong® CVC (Campisi et a l 2000), shown in Figure 1.3 and the 
Hickman® CVC (Hickman et a l 1979), shown in Figure 1.4. These can be used for long­
term administration of antibiotics, TPN, cancer chemotherapy or other fluids and are 
generally placed for periods of more than 10 days (Cmich and Maki 2002b).
b) Short-term catheterisation
“Short-term” CVCs are used mostly in acute care settings, such as the intensive care unit 
(ICU) of a hospital (Cyna et a l 1998) and are generally placed for periods of 10 days or 
less (Cmich and Maki 2002a). They can have up to four lumens and generally do not 
have the Dacron® cuff that is associated with the long-term tunnelled CVCs. They are
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Figure 1.3 Groshong double lumen catheter (BARD, lOFr, 40cm). This particular CVC is 40cm long 
(manifold to tip) and has two lumens extending into two hubs; red is distal and green is 
proximal. The black tip contains a valve, which is the unique feature o f the Groshong 
catheter. Note that the Dacron cuff is located midway between the manifold and the tip.
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Figure 1.4 Double lumen Hickman catheter (BARD, 9Fr, 60cm). This particular CVC is 60cm long 
(manifold to tip) and has two lumens extending into two hubs. Both lumens are the same 
length. Note that the Dacron cuff is located approximately 15cm between the manifold 
and the tip.
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usually made of polyurethane or Teflon (Keegan-Wells and Stewart 1992) and are placed 
within a patient for administration of antibiotic therapy inotropic drugs, and to provide 
nutritional support whilst in the ICU. They are generally placed for up to seven days 
(Elliott et al. 1994a) although they can stay in situ for longer if they are properly cared for 
and maintained (Cyna et al. 1998). The disadvantage of using these CVCs is an increased 
risk of infection because they are neither tunnelled under the skin nor have a Dacron® 
cuff (Keegan-Wells and Stewart 1992). However, they are much more easily removed 
than the cuffed catheters. As well as the Arrow catheter shown in Figure 1.1, the Quinton 
Mahurker® catheter shown in Figure 1.5 is another example. This particular catheter is 
used when patients require dialysis after acute renal failure.
c) Haemodialysis Catheters
CVCs used for haemodialysis maybe used to either;
• provide temporary vascular access for haemodialysis, until permanent access via a 
native fistula or graft is available, or
• provide permanent access for haemodialysis (Canaud 1999).
Therefore these types of CVC can be inserted for a short period of time, like the Quinton 
Mahurker® catheter shown in Figure 1.5, or they can be placed indefinitely. Generally 
such CVCs are double lumen catheters with two large-bore lumens (the arterial and 
venous lumens). These lumens are connected to the blood tubing of the dialysis machine 
in order to complete a circuit for the removal and return of the patient’s blood during the 
dialysis procedure. Examples of haemodialysis catheters are shown in Figure 1.6 and 1.7, 
the Quinton Permcath® and MedComp Ashsplit® catheters respectively. Another type is 
the Tesio® catheter where two single lumen CVCs are placed within the patient in 
parallel (Figure 1.8).
d) Peripherally Inserted Central Catheters (PICC)
PlCCs are inserted into the ante-cubital fossa (at the elbow) and advanced until the end of 
the catheter is located in the central vein (Ryder 1993). They can be single or double 
lumen and are used to deliver either continuous or intermittent therapy. PlCCs can be
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Figure 1.5 Quinton Mahurkar® catheter (Quinton, 12Fr, 24cm). This particular short-term CVC is 
24cm long (manifold to tip) and has two lumens extending into two hubs; blue is distal 
which is used for the venous side and brown is proximal which is the arterial side.
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Figure 1.6 The PermCath® (Quinton, 16Fr, 28cm). This particular long-term CVC is 28cm long 
(manifold to tip) and has two lumens extending into two hubs; blue is distal which is used 
for the venous side and brown is proximal which is the arterial side. There is a Dacron 
cuff located between the manifold and the tip.
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Figure 1.7 The Ashsplit® catheter (MedComp, 14Fr, 28cm) is a long-term CVC which is 28cm long 
(manifold to tip) and has two lumens extending into two hubs; blue is distal which is used 
for the venous side and red is proximal which is the arterial side. There is a Dacron cuff 
located between the manifold and the tip.
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Figure 1.8 The Tesio® catheters (MedComp, lOFr, 50cm) are long-term, single lumen CVCs, which 
are supplied up to 55cm long and are designed to be trimmed at time of insertion for an 
appropriate fit. Again the lumen of each extends into a hub; with the blue CVC used for 
the venous side and red for the arterial side. Again the Dacron cuff is located between the 
manifold and the tip
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used in an acute setting, although, they are commonly used for long-term venous access 
providing nutritional support, antibiotic therapy or cancer chemotherapy (Ryder 1993). 
PlCCs gained popularity in the late 1980’s due to the increase of home intravenous 
therapies (Orr and Ryder 1993) and the fact that nurses in addition to surgeons are now 
inserting PlCCs (Ryder 1993). The advantages of PlCCs include the elimination of 
insertion-related complications of the neck and chest (Tenenbaum and Brennan-Scelsi 
1994), a decrease in the cost of therapy (reduced hospital stay, with more patients in 
home care environments) and a reduced potential for catheter-related infection (Fletcher 
and Bodenham 1999a, Orr and Ryder 1993). However, PlCCs are not useful for high 
volume exchange and their use can induce stenosis of the smaller veins.
e) Implantable Ports
A port is a device that is a totally implanted under the skin (subcutaneous) and consists of 
a small reservoir with a rubber seal to which is attached an outlet catheter (Keegan-Wells 
and Stewart 1992, Levin et ah 1998). Ports are ideal for patients who do not require 
continuous medication but only require intermittent therapy. The Dialock™ port (shown 
in Figure 1.9) is used for haemodialysis access and it consists of a titanium reservoir to 
which two silicon catheters are attached (Canaud et a l 1999, Levin et a l 1998, 
Megerman et a l 1998). Administration to, or flushing of, the port is relatively simple, as 
it requires a subcutaneous injection using a special needle to pierce the rubber seal 
(Canaud et a l 1999, Keegan-Wells and Stewart 1992). Whilst ports offer some
advantages to the patient over tunnelled CVCs, such as giving the patient the freedom to
(
bath or swim (Tenenbaum and Brennan-Scelsi 1994), they do require significant surgical 
intervention if they become infected or blocked (Whitman and Boatman 1995).
1,23 Materials used in CVC manufacture
Intravascular catheters need to be made from biocompatible materials which can 
withstand conditions inside the patient’s body without causing further complications: 
additional desirable properties include thromboresistance, flexibility, a smooth surface 
and a resistance to kinking (Elliott et a l 1994a). The most popular materials are 
polymers, such as polyethylene. Teflon (a fluoropolymer), polyvinyl chloride (PVC),
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Figure 1.9 The Dialock device (Biolink). This device consists o f two 11.5Fr catheters, which extend 
into the venous system from the implanted titanium port.
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silicon, elastomeric hydrogel and polyurethane (Canaud 1999, Orr and Ryder 1993). All 
have advantages and disadvantages: for example, silicon is generally thought to be the 
most biocompatible, however it has a poor tolerance to pressure, whereas polyethylene 
has a high inherent strength but it can easily bend (kink) within the patient.
All catheter materials are thrombogenic to some degree, however polyurethane, and 
silicone are less thrombogenic than Teflon and polyvinyl chloride (Orr and Ryder 1993). 
Catheters that have irregular surfaces have also been associated with increased 
thrombogenicity (Hecker 1981). In some cases it is the physico-chemical properties of the 
catheter surface that influence bacterial attachment in vitro (Jansen and Peters 1991).
1.3 Complications associated with CVCs
Despite the many benefits that CVCs offer, complications arising from their use have 
been noted since their introduction (Collins 1991). CVC related complications can occur 
during the insertion procedure and at any time whilst the patient is catbeterised (post­
catheter placement). The many improvements that have been made in catheter design, 
manufacture and materials science, together with improvements in insertion techniques, 
have not led to the reduction of complications. Reports to the Food and Drug 
Administration (FDA) in the USA indicated that 55% of the complications between 1984 
to 1986 were related to the management of CVCs by healthcare professionals (Scott 
1988). This data was based upon device malfunction but did not include complications 
related to infection.
1.3,1 Complications associated with insertion of CVCs
Complication rates associated with the insertion of CVCs vary according to chosen 
insertion site, technique, catheter type (Cobb et a l 1992, DeJong et a l 1985, Mansfield et 
a l 1994, Michel et a l 1988 and Newsome et a l 1984) and the skill and experience of the 
operative (Rothschild 2001). However, the type and relative frequency of complication is 
similar in most studies. In decreasing order of frequency the complications associated 
with insertion are: failure of access, misplacement of the catheter, laceration of adjacent 
arteries, pneumothorax (collection of air within the pleural cavity), air embolism (bolus 
of air within the venous circulation), hydromediastinum (water collecting in the space
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separating the lungs), haemothorax (collection of blood within the pleural cavity) and 
perforation of the myocardium. Other less common complications include cardiac 
tamponade (excessive fluid in the pericardial space leading to circulatory abnormalities), 
catheter embolus/rupture, cardiac dysrhythmia and nerve injury (Elliott et al. 1994a).
1.3.2 Post-insertion complications
Following successful placement of a CVC, approximately 10% of patients will 
experience a complication that is secondary to catheter insertion or use (Collins 1991). 
These complications generally fall into one of three categories, namely occlusion, 
thrombosis and infection (Elliott et al. 1994a, Orr and Ryder 1993). Other less common 
post-insertion complications include hydrothorax due to vessel erosion and mechanical 
complications not related to occlusion such as CVC leakage (Scott 1988).
a) Catheter occlusion
Catheter occlusion is evident when blood cannot be withdrawn nor solutions infused 
through the catheter (Wickham et al. 1992). Loss of patency (a reduction in flow rate 
through the catheter) or a complete blockage of the CVC can result from a number of 
scenarios. These include the CVC being positioned incorrectly in the vein, the CVC 
kinking (where the CVC has partially folded over itself resulting in restricted flow), a 
build up of a fibrin resulting in a sheath on the CVC or clot formation (thrombosis) 
within the CVC (Raad et al. 1994a). Precipitated TPN, drugs or IV solutions can also 
cause an obstruction (Wickham et al. 1992).
b) Catheter thrombosis
Thrombosis formation occurs when a CVC is inserted into the bloodstream and the 
device surface is immediately coated with plasma proteins. Two types of thrombosis are 
associated with CVCs. These are known as fibrin sheath thrombosis and vascular 
occlusive thrombosis (Raad et al. 1994a). Fibrin sheath thrombosis occurs on the 
extraluminal surface of the catheter and can occur on the whole length of the catheter, 
whereas vascular occlusive thrombosis occurs when clots of material form and come 
together to block the passage of solutions from the CVC through the vein -  this usually 
occurs at the tip of the catheter (Davenport 2000).
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Generally, thrombosis can be related to the characteristics of the catheter itself, for 
example, polyvinyl chloride is more thrombogenic than silicone (Bozzetti et ah 1983, Orr 
and Ryder 1993). However, thrombosis can also be induced by the infusate and the low 
rate of blood flow at the catheter tip (Orr and Ryder 1993). In some cases thrombolytic 
agents such as urokinase can be used to break down thrombus and therefore, restore 
patency to a blocked CVC (Orr and Ryder 1993). In cases where there is a kink or a 
mechanical blockage then catheter removal can often be the only solution available.
c) Catheter associated infections
Catheter-related bloodstream infections (CRBSI)or catheter-related bacteraemia are the 
most frequent and serious complication associated with successfully inserted CVCs 
(Norwood et al. 2000). Bacteraemia is defined as the presence of bacteria in the 
circulating blood as demonstrated by blood culture (Norwood et al. 1991). It is 
asymptomatic, but can lead to septicaemia, which is a bacteraemia with clinical 
manifestations of the pathogenic activity of the bacteria in blood. Septicaemia can result 
in widespread damage to the host tissues and cells. Bentley and Lepper (1968) reported 
from a study in their hospital that CVCs were responsible for almost 50% of nosocomial 
septicaemias (bloodstream infections that have occurred as a result of hospitalisation and 
treatment). However, device-related infections are perhaps the least fi’equently recognised 
of all noscomial infection (Maki 1991).
By the end of the 1990’s the infection rate in successfully placed CVCs was accepted to 
be about 4%, with a range 1-10% (Bozzetti et al. 1982, 1983, Goldman and Maki 1973, 
Kite et al. 1997, Nehme 1980, Padberg et al. 1981, Pettigrew et al. 1985, Snydman et al. 
1982). This figure is, however, thought to be considerably underestimated (Maki 1991).
It has also been observed that microbial colonisation occurs in 6-40% of indwelling 
catheters (Bozzetti et al. 1982, 1983, Goldman and Maki 1973, Kite et al. 1997, Nehme 
1980, Padberg et al. 1981, Pettigrew et al. 1985, Snydman et al. 1982). This reported 
variation is due, in part, to the use of different diagnostic criteria, diverse study 
populations (from ICU patients to those receiving TPN) and varying practises, such as the 
length of time the catheter dwells within the patient (Dobbins et al. 1999).
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In a review article by Crump and Collignon (2000) it is suggested that over 500,000 cases 
of catheter-associated bloodstream infections occur annually in Western Europe and the 
USA; and these may be associated with up to 100,000 deaths.
Catheter-associated infections are reviewed in greater detail in Section 1.4.
1.3.3 Catheter removal
a) Conventional CVC removal
The procedures undertaken for catheter removal will vary depending on the type of CVC 
that is in place and the reason for its removal. Temporary CVCs are in situ for a relatively 
short period of time (less than ten days) and can be easily ‘pulled’ when CVC removal is 
necessary.
However, long-term CVCs, such as the Hickman® catheters are more difficult to remove 
(Adal and Farr 1996). This is because the patient's tissue has grown into the cuff and 
therefore surgical intervention is required.
Traditionally CVCs used in intensive care units (generally short-term non-cuffed CVCs) 
are routinely removed and replaced (Cyna et a l 1998). This is based upon the premise 
that routine replacement will lower infection rates, as it is generally believed that the 
longer a CVC is in place then the higher the risk of infection. However, routine 
replacement of CVCs does not, per se, prevent infection (Adal and Farr 1996) and there 
is no evidence to support this general belief (Cyna et a l 1998, O’Leary and Bihari 1998, 
Timsit 2000). Additionally, CVC replacement and reinsertion increases the risk of 
mechanical complications associated with CVC insertion (Bozzetti et a l 1983). Cobb et 
al (1992) stated that CVCs should remain in place until there are clinical indications 
requiring a CVC change. Long-term tunnelled CVCs such as Broviac® and Hickman® 
catheters can, however, be used almost indefinitely as some infections can be treated in 
situ using an antibiotic lock (a concentrated dose of antibiotic instilled into the catheter 
for 12 hours) technique rather than catheter removal (Messing et a l 1990, Norwood et a l 
1991).
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b) Catheter replacement by guide wire exchange
Guide wire exchange (GWX) involves a guide wire being fed through one lumen of the 
CVC. The CVC is then pulled out over the guide wire leaving the guide wire in place in 
the patient’s vein and a new CVC is then fed over the guide wire (Bozzetti et al. 1983, 
Michel et al. 1988). The tip is cut from the removed CVC and this is sent to the 
laboratory for analysis. If significant levels of microorganisms are found, the newly 
inserted CVC is removed and a new CVC is inserted at another site (Bozzetti et al. 1983, 
Norwood et al. 1991, Pratt et al. 2001). GWX is therefore, only useful if  there is not a 
significant number of microorganisms colonising the exhausted CVC. This technique is 
best employed in situations where the number of available new sites is limited, especially 
in the chronic haemodialysis population who are dependent on long-term CVC use 
(Shaffer 1995). GWX is also a favoured technique if the CVC has undergone some sort 
of mechanical damage, such as bending or kinking or the CVC needs to be repositioned 
within the patient. In such cases GWX reduces morbidity as there is no infection and the 
complications associated with insertion of a CVC at a new site are avoided (Michel et al. 
1988, Orr and Ryder 1993). The use of GWX versus insertion at a new site gives a 
fourfold reduction in the risk of insertion complication (Cobb et al. 1992). However, 
exchanging an infected or heavily colonised CVC over a guide wire invariably leads to 
the need for yet a further replacement as a consequence of contaminating the exchanged 
CVC (Cobb et al. 1992, Olson et al. 1992, Pettigrew et al. 1985, Roberts 1993).
1.4 Catheter-associated infections
1,4,1 Background
Over 90% of diagnosed CRBSIs are associated with CVCs (Maki 1991), with the 
remainder being associated with peripheral catheters. The extent at which CRB SI affect 
the hospitalised population is increasing steadily, with Safdar and Maki (2002) reporting 
that noncuffed short-term CVCs cause at least 250,000 bloodstream infections in United 
States hospitals each year.
Infections associated with catheters have been referred to by different terms over the past 
30 years. Some authors (Dobbins et al. 1999, Kite et al. 1997) have referred to this type 
of infection as catheter-related sepsis (CRS), whilst others prefer terms such as catheter-
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related bacteraemia (Reed et al 1995) or CRSBI (Fletcher and Bodenham 1999a, 
Gowardmann et al 1998, Raad 1998).
Pulmonary artery catheters have a similar sepsis rate to CVCs (Fletcher and Bodenham 
1999a). On the other hand PICCs are reported to have a much lower incidence of sepsis 
(Maki 1991), with Collingnon (1994) reporting a level of 0.036%. The reason for lower 
infection rates with PICCs is that PICCs are inserted at sites such as the arms whilst 
CVCs are placed in the neck and chest (Ryder 1993). Generally the cooler and drier 
extremities, such as the arms, have lower levels of bacterial colonisation than the moist 
neck region. Another possible reason is that PICCs are located further away from mouth 
and nose - which are often the source of organisms through oral and nasal secretions - 
than CVCs which are placed in the neck or chest (Ryder 1993).
1.4.2 Defining catheter-associated infections
Historically, no definition of a catheter-associated infection has found universal approval 
and agreement. The reasons for this emanate from the number of methods that have been 
developed to culture catheters (Siegman-Igra et al 1997) and the large variation in what 
is considered to be an “infected catheter” (Dobbins et al 1999, Elliott et al 1994a). In 
addition, the variable definition of terms such as “catheter-related infection” and 
“catheter-associated infections” when used by different investigators has led to confusion 
and difficulties in comparing results of various clinical studies (Raad and Bodey 1992). 
What was accepted was the fact that proof could only be obtained by culture of the 
removed catheter (Johnson and Oppenheim 1992, Maki et al 1977). Moreover, there was 
no true definition as to what constitutes an infected catheter (Orr and Ryder 1993). This 
difficulty leads to many catheters being incorrectly suspected as the source of infection 
and being inappropriately removed. Currently, suspected catheters are removed with 
approximately 80% (Padberg et al 1981, Ryan et al 1974) of these proving to have been 
removed unnecessarily. More recent studies (Kite et al 1997, Pettigrew et al 1985) have 
shown a similar high rate of inappropriate catheter removal suggesting that accepted 
clinical methods for diagnosing CRS have not improved in 25 years.
It is also important to remember that often the patients who require a CVC are frequently 
those at greatest risk of acquiring infection at other sites. Therefore, it is often difficult to
Chapter One________________________________________________________________________ Pa2e 27
determine whether the CVC is the source of a given systemic infection (Rancher et al. 
1984). Elliott et al. (1994a), as part of a joint working group (Hospital Infection Society 
and Research Unit of the Royal College of Physicians) published guidelines for good 
practice in central venous catheterisation. Within these guidelines “infection” associated 
with catheterisation is defined as either localised infection or systemic infection: these 
definitions are shown in Table 1.2.
No-one has defined levels at which microorganisms may be said to contribute to infection 
or colonisation, nor indeed what level may result due to contamination (the presence, in 
the specimen taken for culture, of organisms introduced by the person collecting the 
specimen during the course of obtaining the sample (Norwood et al. 1991)). It should be 
noted that the occurrence of bacteraemia is much less frequent than the level of 
colonisation seen in CVCs (Raad 1998). Nevertheless the degree of colonisation does 
vary and a high level of colonisation is generally thought to be a precursor to bacteraemia 
(Cleri et al. 1980, Dittmer et al. 1999, Kite et al. 1997, Maki et al. 1977). Dittmer et al. 
(1999) demonstrated that post-dialysis transient bacteraemia is very common and the 
duration of catheterisation and the degree of colonisation increase the risk of bacteraemia. 
Fortunately, from a diagnostic point of view, most cases of clinically proven CRS 
produce colony counts of much greater than 1000 colony forming units (CFUs) on the 
catheter tip (Cleri et al. 1980, Kite et al. 1997, Maki et al. 1977).
The most accepted definition of a catheter-associated infection is that provided by the 
members of the Hospital Infection Control Practices Advisory Committee (HICPAC) 
members, shown in Table 1.3 (Pearson et al. 1996).
1,4.3 Implications and effects o f sepsis
a) Cost implications to the hospital
CRS is the most frequent cause of nosocomial bacteraemia in the critically ill (Waghom
1994) and complicates up to 16% of catheters (Segura et al. 1996) leading to increased 
morbidity, mortality and cost. From the beginning of 1992 to end of 1993 the direct 
mortality rate in one UK hospital was approximately 16%, where 6 patients died from 37
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that were diagnosed as suffering with CRS (Waghom 1994). On average CRS prolongs 
an ICU stay by 6.5 days, with the excess cost per survivor, in the USA, put at $28,690 
(Pittet 1994a, Pittet et al. 1994b). Amow et al. (1993) estimated that it costs US$3,707 to 
treat a CRS patient and US$6,064 for CRS caused by the microorganism Staphylococcus 
aureus. These figures were calculated by combining the total costs for laboratory tests, 
therapy and the hospital room. During 1991 there were 3,883 cases of CRS (or line- 
associated bacteraemia) in England and Wales reported to the Communicable Disease 
Surveillance Centre (Elliott 1993). However, Elliott (1993) comments that this figure is 
probably a conservative estimate and suggests that if CRS occurs in 4% of placed CVCs 
(as observed in many clinical studies) then the tme figure would be around 8,000 patients 
per year.
b) Treatment o f CRS
The treatment of CRS varies depending on the catheter type and underlying pathology of 
the patient. In some cases CRS is initially treated by removal of the CVC, however this is 
dictated by the availability of alternative access. Following this, the clinician can 
administer antibiotics or, in uncomplicated cases, antibiotic therapy may be withheld. The 
antibiotic of choice should reflect the most likely organism to be present. Vancomycin 
should be considered if coagulase-negative staphylococci are suspected to be present. 
Initial antibiotic therapy, such as cephalosporin or aminoglycoside, should also attack 
Gram-negative organisms. Antifungal therapy, such as Amphotericin B could be 
considered for Candida albicans infection (Fletcher and Bodenham 1999b).
c) Consequences o f untreated sepsis
Sepsis has the same consequences no matter whether it originates from a post-operative 
wound, an abscess, peritonitis or an implanted device such as a catheter. It is the body’s 
systemic response to infection (Martin 1998). When there is a bloodstream invasion by an 
infecting organism, various mediators are released within the body. The cell walls of 
invading bacteria and/or fungi contain endotoxins such as lipopolysaccharide, which 
trigger the activation of host blood cells such as macrophages (Bullard and Dunn 1996).
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The macrophages then synthesise and secrete cytokines such as Interleukin-1, Interleukin- 
2 and Tumour Necrosis Factor (TNF-a) (Bullard and Dunn 1996), with Interleukin-1 and 
TNF-a often being over-produced (Kuby 1994a). These mediators stimulate a number of 
responses in the body, including vasoconstriction and other vascular effects, as well as 
direct myocardial effects. If the patient reaches this stage without intervention, then there 
is little that can be done. Severe multiple organ system dysftmction ensues, followed by 
multiple system organ failure and death (Kuby 1994a).
1,4.4 Factors influencing the risk of catheter-associated infections
A catheter-associated infection will ultimately have resulted from microbial contact with 
the CVC. The actual bacteria and yeasts that are involved in CVC colonisation are 
discussed in detail in Section 1.5. However, it is important to highlight the factors that 
can lead to microbial colonisation and infection of a CVC. Some of these factors are 
considered in the following sections.
a) Underlying health status o f the patient
The risk of catheter colonisation leading to infection and ultimately CRS is higher in 
certain hospitalised patient groups. There is a higher incidence of CRS in those patients 
that have immune deficiencies such as, AIDS (Acquired Immune Deficiency Syndrome) 
or neutropenia - a low level of neutrophils or white blood cells (Fletcher and Bodenham 
1999a). However, even though CRS rates are 3-7% and higher in neutropenic patients, 
the positive aspects of catheterisation far outweigh any alternative (Johnson and 
Oppenheim 1992).
In the critically ill there is also a higher risk of the patients suffering CRS. This is due to 
their immune systems having defective surveillance, the underlying disease processes, 
such as trauma or bums, and the type of surgery that the patient has undergone.
The basic microbial environment in which the patients are nursed is also important as this 
can render the patient more susceptible to colonisation and infection (Fletcher and 
Bodenham 1999a). Moreover, the hospital environment can act like a reservoir for 
microorganisms, especially antibiotic resistant strains, such as MRSA - Methicillin- 
resistant S. aureus (Herwaldt and Wenzel 1995), with the result that there has been an
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ever increasing problem with hospital related or nosocomial infections (Cheung and 
Fischetti 1990).
b) Catheter insertion
The skill of the person carrying out the CVC insertion is critical (Rothschild 2001) and 
studies have shown that CVC insertion carried out by a well-trained team can lead to 
improvements in catheter site care (Elliott et al. 1994a). Generally, CVCs are inserted, by 
either, an anaesthetist, a surgeon or an interventional radiologists, with PICCs insertion 
carried out by each of these as will as clinical nurse specialists (Ryder 1993). It is 
important that the insertion site is well swabbed and that the environment where the 
procedure is carried out is sterile (Collins 1991). This is why long-term tunnelled 
catheters are inserted in theatre. However many short-term CVCs are often inserted at the 
bedside in the hospital ward. Carrying-out an insertion procedure in this type of non- 
sterile environment would increase the risk of exposing the CVC and patient to a 
potentially pathogenic organism.
The site of CVC insertion may also be important, with placement of a CVC in the 
internal jugular vein or the femoral vein resulting in higher incidence of CRS th ^  
subclavian catheterisation (Adal and Farr 1996). However, much of the work done on site 
of placement has been observational and there is little data available that compares CRS 
rates of femoral, subclavian and jugular vein insertion sites.
c) Catheter use
The administration of TPN through a CVC may increase the incidence of catheter- 
associated infections (Snydman et al. 1982). Estrada (2002) reports that the presence of a 
CVC and TPN administration were identified as significant risk factors for BSI in the 
neonatal population. However, further analysis has shown that it may not be TPN 
administration alone, that is the problem but the poor routine care of the catheter by the 
hospital staff (Adal and Farr 1996). The issue here is that a balance needs to be sustained 
between the period of time one session of TPN administration should last and the number 
of catheter manipulations that are carried for adequate TPN administration. If a large 
volume of TPN is continuously administered to the patient over a long period of time,
then the risks of this TPN getting contaminated increases as each day passes. However, if
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a TPN administration set is changed daily then there is an increased risk that the patient 
or member of hospital staff may inadvertently contaminate the hub of the CVC thus 
increasing the potential for infection. In an attempt to solve this dilemma, studies into 
catheter hub contamination show that 72 hours is the optimum time period between 
changing the TPN administration sets. (Fletcher and Bodenham 1999a).
d) Duration o f catheterisation
Increased duration of catheterisation has been thought to correlate with increases in CRS 
(Cobb et al. 1992). Thus some clinicians recommend routine replacement of CVCs, but 
this has never been shown to reduce CRS rates (Cyna et al. 1998, Fletcher and Bodenham 
1999a). Nonetheless, there is conflict as to whether the risk per catheter per day (risk 
incidence) increases with duration of catheterisation (Adal and Farr 1996). The Centre for 
Disease Control (CDC) in the USA recommend that the incidence of CRS should be 
expressed in terms of episodes per 1000 days of catheterisation to reflect the variation in 
duration of catheter-residence (Fletcher and Bodenham 1999a). Using this definition it 
has been observed that in oncology out-patients there is an incidence of CRS in 0.08 days 
per 1000, compared to 19 days per 1000 days in the hospitalised critically ill (Fletcher 
and Bodenham 1999a).
e) Post-insertion care
Strict aseptic procedures are necessary for both the insertion and post-insertion care of the 
CVCs. By using maximal sterile barrier procedures during insertion Raad et al. (1994b) 
significantly reduced the risk of subsequent catheter-associated infections.
The choice of dressing that is used to cover the CVC, after it has been inserted, is 
important. Ideally the dressing needs to be water permeable as those that accumulate 
moisture have higher levels of microflora. Maki et al. (1994) found that gauze had low 
cutaneous colonisation, but there was no difference in catheter colonisation and CRS.
f)  Catheter removal
The use of a guidewire exchange procedure to replace an infected CVC may lead to more 
rapid colonisation of the new CVC followed by CRS if  the insertion site of the previous 
catheter was significantly colonised (Cobb et al. 1992, Olson et al. 1992). However, this
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procedure does reduce the incidence of insertion complications through avoiding a new 
site replacement (Orr and Ryder 1993).
g) Catheter manufacture
Since 1997 all manufacturer of CVCs who want to sell CVCs with Europe, have had to 
meet the requirements of the European Union Directive 93/42/EEC concerning medical 
devices. This means that all aspects of catheter material and component selection, 
assembly, packaging, labelling and sterilisation, have to be approved and are fully 
traceable. The “CE mark” symbol is displayed on medical device packaging to 
demonstrate that that medical device meets with the directive and therefore is “fit for 
purpose”. This directive has helped to ensure that the CVC itself will not pose a risk to 
the patient, however in countries outside Europe and the United States there are often no 
such regulations and therefore inadequate CVCs can be an issue.
1.5 Pathogenesis of catheter-associated infections
The pathogenesis of catheter-associated infections is complex and not fully understood 
(Crump and Collignon 2000). Nevertheless, what is accepted is that for microorganisms 
to cause catheter-associated infections they first must gain access to the internal and/or 
external lumens of the catheter where adherence and subsequent colonisation can occur 
(Cmich and Maki 2002a, 2002b). Raad (1998) suggests that adherence of 
microorganisms to the catheter surface depends on the physical characteristics of the 
catheter surface, the surface characteristics of the adherent bacteria, the presence of host- 
derived proteins and phenotypic changes of the adhering organisms. This section will 
discuss how various microorganisms gain access to CVCs and their subsequent 
implication in catheter colonisation and catheter-associated infections.
1.5.1 Microorganisms implicated in catheter-associated infections
Fletcher and Bodenham (1999a) grouped 35 studies together to determine which 
microorganisms where implicated as the causative organisms in CRS. Figure 1.10 shows 
coagulase negative staphylococci (CNS) to be the most common (37%) source of CRS
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□ Coagulase negative 
staphylococci (37%)
□ Staphylococcus aureus 
^22%;
□ Enteric Gram-negative 
bacilli (12.4%)
□ Yeasts (9.3%)
U Pseudomonas sp (5.5%)
□ Enterococci and 
Streptococci (4.9%)
□ Others (8.9%)
Figure 1.10 Causative organisms from 35 studies of CRS (Fletcher and Bodenham 1999a).
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followed by Staphylococcus aureus (22%). Indeed S. aureus and CNS, such as 
Staphylococcus epidermidis, are generally the most common cause of infections 
associated with all types of implantable medical devices (Krimmer et al. 1999).
a) Staphylococcus species
Members of the genus Staphylococcus are Gram-positive, non-motile, non-spore forming 
cocci, which are 0.5 to 1.5pm in diameter and occur in “bunch of grape-like” clusters as 
well as individually and in pairs. They are ubiquitous in nature, but are mainly found 
living on the skin, skin glands and mucous membranes of mammals and birds (Kloos and 
Bannerman 1995).
CNS constitute a major component of the normal surface microflora of humans. In many 
studies CNS, particularly S. epidermidis, are frequently isolated from intravascular 
devices (Brun-Buisson et al. 1987, Cleri et al. 1980, Fletcher and Bodenham 1999a, Kite 
et al. 1997, 1999, Kristinsson et al. 1989, Maki et al. 1977, Pettigrew et al. 1985).
S. aureus is coagulase-positive and has been well documented as an opportunistic 
pathogen in humans (Kloos 1998). S. aureus infections have been a major cause of 
morbidity and mortality in hospitals for many years. MRSA has become a major clinical 
and epidemiologic problem in hospitals since the 1970’s. From 1975 to 1991 the 
percentage of S. aureus isolates that were resistant to methicillin increased from 2.4% to 
29% (Herwaldt and Wenzel 1995). The increased use of CVCs will only increase the 
level of CRS due to Staphylococcus species (Cheung and Fischetti 1990).
b) Pseudomonas species
These are aerobic, motile, non-spore forming, gram-negative rods, approximately 1 pm to 
5 pm long and 0.5 pm to 1pm wide. They are usually resident in water and soil, hut are 
also found in the bowel microflora of healthy humans (Gilligan 1995). In addition to 
catheter-associated infections, Ps. aeruginosa is a leading cause of nosocomial 
respiratory tract infection and nosocomial urinary tract infections (Gilligan 1995). Ps. 
aeruginosa is a nosocomial pathogen that is very difficult to treat. It has been found in a 
variety of fluids (disinfectants, soaps, ointments) and equipment that is in contact with 
water, such as shower heads and anaesthetic equipment. Additionally, Ps. fluorescens -
Chapter One________________________________________________________________________ Pase 37
another opportunistic pathogen - has been isolated from dental chair unit output water 
(Tuttlebee et al. 2002). Its presence in this environment creates a potential risk both to 
dental staff and patients, particularly those that are immunocompromised.
c) Candida species
Candida species are yeasts that are found in all areas of the human gastrointestinal tract. 
Candida species are responsible for at least 9% of nosocomial bloodstream infections 
(Fletcher and Bodenham 1999a) and the incidence of Candida fimgaemia represents a 
serious problem in this clinical situation. Moreover, fimgal infections are extremely 
difficult to treat and often the treatments, such as Amphotericin B (Bullard and Dunn
1996), can be highly toxic to the patient.
In hospitals, Candida species cause bloodstream infections especially in 
immunocompromised patients (Warren and Hazen 1995). Historically, C. albicans is the 
species most commonly isolated from patients with candidiasis and evidence for person- 
to-person transmission of this organism in hospital wards has been put forward (Fanello 
et al. 2001). Moreover, the recently discovered species, Candida dubliniensis (Sullivan et 
al. 1995), has been implicated in a growing number of cases of ftmgemia around the 
world (Brandt et al. 2000, Marriott et al. 2001, Meis et al. 1999). The clinical 
identification of C. dubliniensis as the causative pathogen in cases of Candida ftmgemia is 
important, as concerns have been expressed that resistance strains of C. dubliniensis may 
develop in HIV-infected patients treated with fluconazole (Moran et al. 1997). This 
suggests that the widespread use of fluconazole, may have contributed to the emergence 
of C. dubliniensis as an opportunistic pathogen.
d) Other organisms
Other organisms that have been implicated in bacteraemia include, gram-negative bacilli 
(Fletcher and Bodenham 1999a, Kite et al. 1997, Turnbull and Kramer 1995), coliforms, 
corynebacteria and various gram-positive organisms (Fletcher and Bodenham 1999a).
1,5.2 Modes o f  colonisation
Five major paths or routes have been identified whereby microorganisms can gain access 
to the catheter and colonise it (Bouza et al. 2002, Elliott 1993, Linares et al. 1985). The
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schematic diagram (Figure 1.11) from Elliott (1993) displays these various routes of 
colonisation and also suggests contamination from hospital staff as well as the patient’s 
skin as possible sources of the organisms. Table 1.4 shows these five mechanisms and 
definitions for four of them as suggested by Linares et a l (1985).
Of the five mechanisms, it is unlikely that a remote infection could produce bacteraemia 
and seed the catheter (Anaissie et a l 1995). However, in non-central venous catheters 
this route has been implicated in over 50% of yeast infections seen in hospitals and some 
other infections that involved Escherichia coli and Klebsiella species. The risk of a 
catheter-associated infection resulting from contaminated commercially prepared infusion 
fluid - a problem in the past - is now very remote due to much improved manufacturing 
procedures and regulations (Norwood et a l 1991).
There has, however, been much debate in recent years about which of the remaining 
mechanisms are the most important in the development of catheter-associated infections.
a) Extraluminal spread
Maki (1989) proposed that cutaneous organisms contaminate the catheter during insertion 
or migrate along the outside of the catheter into the patient, post-insertion. Some studies 
have shown that there is a good correlation between organisms isolated from skin 
cultures (swabs from the insertion site), the catheter and blood cultures taken from the 
patient (Raad et a l 1995, Maki et a l 1997). Further work has demonstrated that the use 
of silver impregnated cuffs and the technique of tunnelling the catheter may also reduce 
CRS rates by impeding the migration of organisms along the subcutaneous track (Timsit 
et a l 1996). Other evidence comes from studies where an antiseptic solution used to 
clean the site prior to catheter insertion reduced CRS rates by removing cutaneous 
microorganisms (Maki et a l 1991).
fri recent years Maki, an original advocate of the skin hypothesis, has concluded that hub 
colonisation was the cause of a significant proportion of CRS (Maki et a l 1991, 1994,
1997). Furthermore studies by Dobbins and Kite (1999) indicate that endoluminal 
colonisation of the catheter is more important in the development of CRS and that 
bacterial counts in these cases exceed extraluminal counts by up to 100 fold.
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Contaminated
infusate
Contaminated 
entry portHospital stall
Extralum Inal 
spread ._ Intraluminal spread
Skin — 
microflora
'  S K IN  ^  -
S U B C U T yK N E O U S  T IS S U E
Haematogenous
spread
Catheter tip contaminated
on insertion through skin
Figure 1.11 Sources and routes taken o f infecting microorganisms in central venous catheters (Elliott 
1993). Reproduced with permission o f  the PHLS Communicable Disease Surveillance 
Centre ©PHLS.
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Using Scanning Electron Microscopy (SEM), Raad et a l (1993) have shown that there 
are more organisms on the inside of the CVC lumen than on the external part of the CVC 
when it has been inserted for longer than 10 days. It is now generally accepted that in 
short-term catheters (those dwelling for less than 10 days)extraluminal spread is the most 
likely mechanism of pathogenesis and in long-term tunnelled catheters (generally in place 
for >10 days) intraluminal spread is more relevant (Bouza et a l 2002, Cmich and Maki 
2002a, 2002b).
b) Intraluminal spread
The intraluminal theory is based upon the fact that the same organisms have been 
recovered from the hub of the CVC and the blood of patients with CRS. It is thought that 
the hub is colonised by organisms from the patient’s skin or health care worker’s hands 
(Sitges-Serra et a l 1983). Microorganisms then migrate down the internal lumen of the 
catheter to colonise it (Sitges-Serra et a l 1985a, 1985b). If there is endoluminal 
colonisation of the CVC, then the infusate that is introduced into the CVC will flow over 
the planktonic and sessile microoganisms in the biofilm. The planktonic organisms inside 
the CVC can then enter the infusate, as it travels into the patient’s systemic circulation 
(Dobbins et a l 1999) and this can result in systemic infection. Linares et a l (1985) tried 
to determine the route taken by the organisms causing CRS in patients receiving total 
parenteral nutrition. Twenty of 135 catheterised patents were diagnosed with CRS 
(14.8%). Of these 20 CRS cases, 14 resulted from a colonised hub and only two from 
skin infection. They concluded that the catheter hub is the most common site of origin of 
organisms causing catheter tip infection and bacteraemia.
Kite et a l (1997), using a sampling tool called the FASEB, showed that sampling and 
culturing biofilm from the internal lumen of a catheter predicted CRS with greater 
specificity and sensitivity than extraluminal techniques like the Maki roll technique. In 
addition, the controlled study of a “new hub” containing 3% iodinated alcohol, led to a 
reduction in the incidence of CRS. In this study Segura et a l (1996) showed that the 
number of true CRS cases was lower in the “new hub” group (3 of 78) than the control 
group (12 of 73). Furthermore, it was demonstrated that the number of days of 
catheterisation prior to CRS diagnosis was greater in the “new hub” group (19 days) than 
the control group (12.3 days). Evaluations that have involved antimicrobially coated
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catheters have shown the catheters that are coated both endoluminally and extraluminally 
are more effective than those coated only on the outside (Darouiche et al. 1999).
1.5,3 Biofilms
Microorganisms can adhere to and colonise surfaces found within industrial systems, 
natural aquatic environments and medical devices implanted in the body (Potera 1998). 
Some of the implantable devices that are commonly affected are hip and knee 
replacements, continuous ambulatory peritoneal dialysis (CAPD) catheters, shunts and 
CVCs (Bayston 1999). Additionally, biofilm colonisation has been evident in other 
medical devices, such as prosthetic heart valves, urinary catheters, contact lenses and 
intrauterine devices (Donlan and Costerton 2002). Indeed urinary catheters can rapidly 
become contaminated with microorganisms and this generally leads to colonisation with 
biofilm. Strickler (1996) notes that all patients undergoing long-term (>28 days) urinary 
catheterisation will develop urinary tract infections due to the presence of biofilms.
Clinical isolates of S. aureus and S. epidermidis can adhere to catheter material by the 
generation of thick multilayered biofilms consisting of bacteria and extracellular 
polysaccharides (Krimmer et ah 1999). Biofilms can also form on devices and tubing 
which are associated with medical instrumentation, such as the silicon tubing attaching a 
dialysis machine to the dialysis patient (Marion-Ferey et al. 2003) or dental unit 
waterlines (Tuttlebee et al. 2002).
As with any biofilm structure, microorganisms on catheter surfaces can be found growing 
in one of two different environments (Dickinson and Bisno 1989, Potera 1998, Raad 
1998). The “sessile bacteria” grow on the surface of the catheter inside a biofilm, whilst 
the “planktonic bacteria” grow fi-eely in the surrounding fluids, where they live at the 
surface of the biofilm and fluid interface (Raad 1998). There are a number of differences 
between organisms of the same species, when they exist in either the planktonic or sessile 
state. These phenotypic differences are discussed in the sections below.
a) Definition o f a biofilm
The definition of a biofilm has evolved over the last 25 years as more research has been 
performed on the subject. Donlan and Costerton (2002) have provided an updated
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definition of a biofilm, which is pertinent in that the biofilm cells have to exhibit both the 
observable and phenotypic traits of a true biofilm.
“....a microbially derived sessile community characterised by cells that are irreversibly 
attached to a substratum or interface or each other, are embedded in a matrix o f  
extracellular polymeric substances that they have produced, and exhibit an altered 
phenotype with respect to growth rate and gene transcription ” (Donlan and Costerton 
2002).
b) Biofilm formation
Generally, the adherence of microorganisms to the biomaterial surface depends on the 
physical characteristics of the biomaterial and the surface characteristics of the adhering 
bacteria (Raad 1998). Adhesion of bacteria to a surface is thought to occur in a sequential 
manner and the most common theory is that it involves the four phases shown in Table 
1.5 (Tunney et a l 1996). This is based on the DLVO theory of colloid stability, named 
after Deqaquin, Landau, Verway and Overbeek (Dickinson and Bisno 1989). This theory 
describes the electromagnetic forces that attract and repulse colloidal particles.
It is accepted that three components are important in the initial adhesion process of 
bacteria to a biomaterial: namely the bacteria themselves, the suspending fluids and the 
substrata (Raad 1998, Tunney et a l 1996).
Bacterial cell-surface components, such as filamentous structures extending fi*om the 
bacterial cell surface (fimbriae and polysaccharides), are thought to promote adhesion to 
surfaces (Tunney et a l 1996). Exopolysaccharide production is important in phases two 
to four (Table 1.5), where bacteria, such as S. epidermidis, are known to secrete a 
glycocalyx coating (Norwood et a l 1991).
When medical devices, such as a CVC, are implanted into the body they become coated 
with fibrin, thrombin, fibronectin and immunoglobulins (Dickinson and Bisno 1989). The 
resulting film of plasma, which coats the device, can then itself promote adhesion 
(Cheung and Fischetti 1990) through hydrophobic adsorption. Bacteria and fiingi, such as 
Candida sp., adhere well to this protein coating or “sleeve” (Raad et a l 1994a) as they
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have a great affinity for the plasma proteins. However, different microorganisms adhere 
to different proteins, for example, S. aureus adheres tightly to fibronectin, fibrinogen and 
laminin, whilst S. epidermidis only adheres to fibronectin (Raad 1998).
As CVCs can be manufactured from a various materials such as silicone or polyurethane, 
the properties of these materials can influence bacterial and host protein adhesion as well 
as biofilm formation. Norwood et al. (1991) demonstrated that S. epidermidis adhered to 
Teflon, silicon and some polyurethane catheters. Mermel and Maki (1994) also showed 
that Teflon™ and polyurethane are more resistant to colonisation by CNS than 
polyethylene, polyvinyl chloride or silicon. The colonisation process has been shown to 
be enhanced by components of the catheter material that can impair polymorphonuclear 
leucocyte activity (Lopez-Lopez et al. 1990). Biomaterial surfaces, for example the 
surface of a CVC, can in many cases be uneven and have numerous irregularities and 
these defects can provide niches for bacterial adhesion (Tunney et al. 1996). The 
microrugosity or roughness of the surface can also increase over time, post-insertion. 
This was observed by Gorman et al. (1993) in a study of CAPD catheters, where the 
adherence of S. epidermidis to the rough implanted catheters was significantly greater 
than to unused (control) catheters. The factors that may be involved in the production of 
increased roughness during medical device implantation may include shear forces arising 
from fluid dynamics and bacterial or host degradation of the device biomaterial (Tunney 
et al. 1996).
c) Biofilm growth and maturation
Once the bacteria have attached and are actively colonising a surface, they synthesise and 
secrete exopolymeric substances such as extracellular polysaccharides. It has been 
observed that extracellular polysaccharide adhesins have a major role to play in the 
formation of S. epidermidis biofilms on plastic surfaces. S. epidermidis produces the 
capsular polysaccharide adhesin (PSA) which mediates the initial adherence of cells to 
the surface and polysaccharide intercellular adhesin (PIA) which is responsible for the 
accumulation of cells (O’Gara and Humphreys 2001). The combination of these 
exopolymeric substances forms a matrix which is known as a “glycocalyx” (Tunney et al.
1996). Further bacterial cell division leads to the formation of microcolonies within the
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matrix and in appropriate conditions a continuous biofilm can rapidly become established 
(Douglas 2003). The biofilm can also grow larger due to the further attachment of 
bacteria from the surrounding fluid as well as additional exopolysaccharide production 
(Tunney et al. 1996). Living, fully hydrated biofilms are composed of cells (±15% by 
volume) and matrix material (±85% by volume) with open water channels interspersed 
between the microcolonies containing the sessile cells (Donlan and Costerton 2002).
Biofilm populations exhibit highly co-ordinated ‘social behaviour’ with respect to 
population density under the control of quorum sensing regulatory systems (McKeegan et 
al. 1999). Quorum sensing is defined by Allison et al. (1999) as the accumulation of a 
low molecular weight signalling molecules beyond a critical threshold concentration, 
enabling individual cells to ‘sense’ when a minimum population unit of bacteria has been 
achieved in order to initiate a co-ordinated population response. Quorum sensing may 
play a specific role in the development of biofilms through the accumulation of 
extracellular signalling molecules that modulate the transcription of target opérons. 
Accumulation of the signal might be brought about through achieving a localised high 
cellular density or “trapping” of both the signal molecule and the cells at a common 
interface (McKeegan et al. 1999). Signalling molecules associated with biofilm formation 
include the 7V-acyl homoserine lactones (HSLs) of Gram-negative bacteria (Davies et al.
1998) and small cyclic hydrophobic peptides in Gram-positives (Kleerebezum et al.
1997).
In Gram-negative bacteria HSLs are thought to be involved in different aspects of biofilm 
differentiation and development. As quorum sensing requires a sufficient density of cells 
to be present it is generally accepted that HSL signals are unlikely to be involved in the 
initial stages of biofilm proliferation (Allison et al. 1999). Nevertheless, the involvement 
of HSLs in the maturation of biofilms has been observed, with a twelve carbon 
(dodecanoyl) HSL being implicated in the maturation of Ps. aeruginosa biofilms through 
modulation of exopolymer production (Davies et al. 1998).
d) Biofilms associated with CVCs
Passerini et al. (1992) demonstrated, using SEM, that there was extensive biofilm 
formation on all the 42 arterial catheters and 26 CVCs, inserted in ICU patients, that they
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examined. These catheters dwelt within the patients for between 1 and 14 days and 
bacteria were observed within the biofilms of 69% (29/42) of arterial catheters and 88% 
(23 of 26) of the CVCs. Three of the four single lumen CVCs that were in situ for only 
one day showed coccoid bacterial cells on the surface.
Although most CVCs are colonised with microorganisms (Dittmer et a l 1999, Passerini 
et a l 1992, Raad et a l 1993), only a small percentage of these catheters cause 
bloodstream infections (Raad 1998). SEM performed on removed CVCs by Raad et a l 
(1993) showed that almost all CVCs have visible adherent microorganisms on their 
surface, but only about 3% in this study led to CRBSI. It may be that infection depends 
upon whether or not the organisms on the catheter surface, exceed a certain quantitative 
threshold (Raad 1998) and/or the length of time the CVC is left in situ within the patient 
(Dittmer a/. 1999).
Figure 1.12 is a SEM of a longitudinal cross section of a CVC tip. On the right lumen a 
small build up of biofilm can be seen (within the blue box). Irregularities in the catheter 
surface can also be seen on the left lumen. Figure 1.13 is a SEM of the transverse cross 
section of a CVC tip showing both the extraluminal biofilm (blue box) and intraluminal 
biofilm (red box) formation. Both of these SEMs were taken as part of the current study 
and details of preparation are contained within Appendix 1.
e) Resistance to antimicrobial agents
The nature of biofilm structure and physiology gives biofilms an inherent resistance to 
antimicrobial agents (Fletcher and Bodenham 1999a, Potera 1998, Vorachit et a l 1993). 
An example are the biofilms of Candida albicans, which can consist of matrix-enclosed 
microcolonies of yeasts and hyphae, arranged in a bilayer structure resulting in resistance 
to antifungal agents such as amphotericin B and fluconazole (Douglas 2003).
Often there are dramatic differences in susceptibility of planktonic and biofilm organisms 
to microbial agents. For example is the action of imipenem on Ps. aeruginosa (ATCC 
27853) where Ipg/ml of the antibiotic was adequate to treat the planktonic phenotype, 
but >l,024pg/ml was required to eradicate the biofilm phenotype (Donlan and Costerton 
2002). The mechanisms responsible for this resistance may be due to one or more of the 
following:
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Figure 1.12 A scanning electron micrograph (SEM) of a longitudinal cross section of a double lumen 
CVC. Source; work carried out by the author as part of this study.
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Figure 1.13 A SEM of a CVC lumen showing the biofilm on the extraluminal and intraluminal 
surfaces. Source: work carried out by the author as part of this study.
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The biofilm matrix could act as a simple diffusion barrier to delay penetration of the 
antimicrobial agent (Wilcox et a l 2001).
• Negatively charged glycocalyx would bind positively charged antibiotic molecules; 
however, this does not account for the resistance to neutral and negatively charged 
antibiotics (Potera 1998).
• Production of extracellular enzymes such P-lactamase, which would inactivate 
antibiotics diffusing into the biofilm thereby reducing the concentration reaching the 
bacteria in the biofilm (Tunney et ah 1996).
• The altered growth rate of the biofilm organisms and other physical changes 
associated with the biofilm state (Bayston 1999). This has been observed where 
planktonic and young (2 days old) biofihn cells have been inactivated by an antibiotic 
but older (10 day old) biofilm cell counts were reduced by only 20% with the same 
dose of antibiotic (Donlan and Costerton 2002).
f)  Relationship between biofllm production and infection
The exact process by which biofilm-associated organisms elicit an infection is poorly
understood (Donlan and Costerton 2002). Some of the suggested mechanisms include:
Detachment or sloughing off of cells or cell aggregates from the implanted device 
resulting in a bloodstream infection.
• The production of endotoxins by gram-negative bacteria, which may elicit an immune 
response.
• The biofihn cells are in some ways resistant to the host immune system; an example 
is where the macrophage’s (a white blood cell) normal phagocytic activity is 
ineffective against S. epidermidis cells in the biofilm state (Donlan and Costerton 
2002).
It has been observed, however, that there is no clear association between biofihn 
production and virulence. In an in vitro study by Vogel et a l (2000), the association 
between biofilm production and virulence was investigated by comparing the biofilm 
production between 22 S. epidermidis isolates associated with CRB SI and 31 nasal-
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colonising isolates from healthy individuals. Of the 22 catheter-related isolates only 
seven had significantly higher levels of biofilm production compared to all other catheter- 
related and nasal isolates. This suggests that biofihn production may be an adaptive 
response of some strains of microorganisms to the presence of an indwelling device 
rather than a necessary factor for virulence (Vogel et al. 2000).
g) Phenotypic changes and organism detection
As a biofilm matures phenotypic modification of the cells in the deeper layers can often 
take place (Bayston 1999). They include a slow-down and change in the metabolism of 
the cells, as a response to nutrition deprivation, resulting in virtually no cell wall material 
being synthesised. Therefore these cells grow very slowly and this “small-colony 
phenotype” is often difficult to detect using conventional microbiological techniques 
(Krimmer et al. 1999). These small colony variants (SCVs) may be why the 
microbiological diagnosis of device-associated infections frequently remains uncertain, 
since some staphylococci have the capacity to reduce their growth rate considerably 
(Bayston 1999, Krimmer et al. 1999).
Improved detection and identification of S. aureus and S. epidermidis by an in situ 
hybridization method with fluorescence-labelled oligonucleotide probes specific for 
staphylococcal 16S rRNA has been reported (Krimmer et al. 1999). In their study of hip 
replacement patients, Krimmer et al. (1999) successfully used the technique for the 
detection of intracellularly persisting bacteria, including SCVs of S. aureus, and the 
differentiation of S. epidermidis from other clinically relevant staphylococci even when 
they were embedded in biofilms. The authors suggest that the 16S rRNA hybridization 
technique may be useful for the detection and differentiation of many other 
microorganisms.
1.6 Measures to reduce catheter-associated infection rates
There are a number of improvements in clinical practice currently being investigated, 
which could lower the rates of infection in catheterised patients. These include 
improvements to insertion techniques, better aseptic technique, modifications to the 
catheters, hub modifications and the introduction of intravenous therapy teams. 
Guidelines for preventing infections associated with the insertion and maintenance of
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CVCs have been developed (Pratt et al. 2001). These are outlined in Table 1.6 and have 
been developed by a nurse-led, multi-professional team composed of clinical 
microbiologists, infection control practitioners and researchers amongst others. The 
guidelines cover all interventions from catheter selection through to strategies for 
removing and replacing catheters.
1.6.1 Insertion technique
The use of maximal aseptic precautions whilst inserting a CVC will reduce the incidence 
of CRS (Raad et al. 1994b). For insertion of all CVCs it is recommended that the surgeon 
uses a cap, mask, sterile gown, sterile gloves and a wide sterile drape (Collins 1991). As 
the skin is the main source of many of the microorganisms that are implicated in CRS, 
the use of a disinfectant or antiseptic solution to reduce the microbial bioburden and thus 
reduce the risk of contamination during insertion is necessary. In the United States 
solutions such as 10% povidone-iodine are the most widely used antiseptic for the 
disinfection of the catheter insertion site (Cmich and Maki 2002a). However even lower 
rates of colonisation have been observed when a 2% aqueous solution of chlorhexidine 
was compared with 10% povidone-iodine solution and 70% alcohol in a randomised trial 
(Maki et al. 1991). Chlorhexidine-containing solutions are now recommended as the first 
choice for vascular access (Cmich and Maki 2002a).
1.6.2 Catheter modifications
a) CVCs with anti-infective surfaces
One recent advance in catheter design has been the introduction of catheters with 
antimicrobial and antiseptic properties. Antimicrobial bonding of catheters was first 
demonstrated in a rat model, where microbial colonisation was lower in penicillin- 
bonded polyethylene catheters when compared to control catheters (Trooskin et al. 1985). 
Since then several other antimicrobial compounds have been incorporated into catheters 
to give a number of different so called “coated catheters”.
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Catheters coated on both the internal and external surface with benzalkonium chloride 
have demonstrated a significant decrease in colonisation (Elliott et a l 1994b) but no 
reported improvements have been observed in CRBSI rates in any of the trials using this 
type of catheter (Cmich and Maki 2002a).
The chlorhexidine - silver sulphadiazine catheter, where the combination of the two 
compounds has a synergistic activity against species such as Staphylococcus aureus, and 
the minocycline -  rifampicin catheter, which has a synergistic effect on Staphylococcus 
species, gram negative bacteria and yeasts. Results fi"om trials have, however, been 
conflicting (Civetta et a l 1996, Logghe et a l 1997, Mabubula et a l 2000, Pemberton et 
a l 1996, Raad et a l 1997, Saint et a l 2000, Veenstra et a l 1999a). Both Civetta et a l 
(1996) and Veenstra et a l (1999a) demonstrated that catheters impregnated with silver 
sulfadiazine and chlorhexidine reduce catheter-associated infections. However, 
Pemberton et a l (1996) found no difference in CRS rates between the antimicrobial- 
impregnated CVCs and a standard triple lumen CVC (7.3% and 7.5% respectively) in 
their study of 72 CVCs.
A meta-analysis of eleven studies, totalling some 2603 catheters, showed that CVCs 
impregnated with a combination of chlorhexidine and silver sulfadiazine are effective in 
reducing the incidence of both catheter colonisation and CRBSI in patients at high risk 
for catheter-associated infections (Veenstra et a l 1999b). However Schierholz et a l 
(2000a) questioned the exclusion of the largest clinical trial by Logghe et a l (1997) 
which showed that there was no significant difference between the incidence of catheter- 
related infection for impregnated and non-impregnated catheters (5.0% and 4.4% 
respectively) in long-term catheterised patients. Veenstra et a l (1999b) excluded this trial 
because the definition of CRS was based on the culture of blood taken both through the 
CVC and fi*om a peripheral site, and the CVC was not always removed in suspected 
cases. Schierholz et a l (2000b) conclude that chlorhexidine and silver sulfadiazine 
coated catheters may be of little benefit for long-term use (>10 days) as there is no 
intraluminal protection.
A study by Darouiche et a l (1999) comparing the minocycline - rifampicin catheter and 
the chlorhexidine - silver sulphadiazine catheter, demonstrated the minocycline - 
rifampicin catheter to be more effective than the chlorhexidine - silver sulphadiazine
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catheter against microbial colonisation of the catheter. However, the explanation for this 
may depend as much on the lack of coating on the inside of the chlorhexidine - silver 
sulphadiazine catheter, as on the compounds coated on each CVC (Wilcox et a l 1998).
A further more recent study by Ranucci et a l (2003) also demonstrated that an oligon- 
treated (polyurethane combined with silver, carbon, and platinum) catheter was effective 
in limiting the rate of microbial colonisation. However there was no significant difference 
between oligon-treated catheters and control catheters in terms of the rate of CRBSI.
Some concerns about the use of both of these antimicrobial-impregnated CVCs have been 
voiced and are highlighted below:
• The chlorhexidine - silver sulphadiazine CVC is coated on the external surface only, 
therefore it has no effect against endoluminal colonisation (Fletcher and Bodenham 
1999b, Schierholz et a l 2000b). To be effective this type of CVC requires 
antimicrobial coating on both the internal and external lumen surfaces, including the 
extension pieces at the manifold (Wilcox et a l 1998).
• Even-though chlorhexidine is associated with a lower rate of catheter colonisation 
and CRS (Orr and Ryder 1993, Norwood et a l 2000), it can cause allergic or 
anaphylactic responses in some individuals. It has been observed that the native 
Japanese are particularly prone to anaphylaxis caused by chlorhexidine (Burlington
1998). As a result, the chlorhexidine - silver sulphadiazine CVC was withdrawn in 
Japan after twelve reported cases of severe anaphylaxis and at least one death 
(Y asukawa a/. 1999).
There are issues with the use of antibiotics in this situation; for example Rifampicin 
which is a first line drug against tuberculosis, as this may create resistant strains of 
organisms (Fletcher and Bodenham 1999b).
There may be problems with sterilisation of chlorhexidine-coated catheters. Sherertz 
et a l (1996) demonstrated that a chlorhexidine-coated catheter loses its antimicrobial 
activity after gamma irradiation is used for sterilisation. The ethylene oxide method is 
recommended as an alternative for these catheters.
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• Tacconelli et al. (2000) have raised concerns about the efficacy of the chlorhexidine - 
silver sulphadiazine CVC against Candida species, as the combination of 
chlorhexidine - sulphadiazine will only affect bacterial growth and yeasts, such as 
Candida species, may not be adversely affected.
b) Active iontophoresis
Active iontophoresis is the newest strategy to reduce infection rates associated with 
CVCs (Cmich and Maki 2002a). In an in vitro study, Liu et al. (1993) found that when a 
constant electric current of low amperage (lOpA) is applied to a catheter, there is a 
reduction in microorganism adherence to the CVC. Liu et al. (1993) then concluded that 
this low amperage current may be useful in reducing bacterial colonisation of indwelling 
intravascular catheters. Although promising, this technology has yet to be evaluated in a 
clinical trial (Cmich and Maki 2002a).
7.6.3 Hub m odiflcations
The new type of hub, evaluated by Segura et al. (1996), has given a fourfold reduction in 
the incidence of CRBSI when compared to controls. This hub contains iodinated alcohol 
and a needle must be passed through a chamber containing iodinated alcohol, before it 
can be used.
Needleless connectors have been used in conjunction with TV catheters to reduce the time 
spent manipulating intravenous connections and prevent the occurrence of needlestick 
injury. They have also been shown to reduce significantly the likelihood of microbial 
colonisation via the intemal route (Brown et al. 1997). However their net benefit has 
been questioned by reports of increased rates of bloodstream infection (Cmich and Maki 
2002a). This may however be due to the contamination of flush solutions (Worthington et 
al. 2001) and a combination of pre-filled sterile syringes (and therefore sterile flush 
solution) and needless connectors may lead to further reduced contamination rates (Casey 
et al. 2002).
1.6.4 Therapy teams
Studies have shown that the use of a well-trained team, responsible for insertion and 
maintenance of VADs within the hospital can lead to a dramatic improvement in catheter
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site care (Elliott et al. 1994a), An overall reduction in the level of CRS, especially in 
patients receiving TEN, has also been observed (Fletcher and Bodenham 1999b, Nehme 
1980). In the study by Nehme (1980) it was observed that CRS rates varied from 1.3% (5 
of 211) in the group of patients that were managed exclusively by a nutrition support 
team to 26.2% (43 of 164) in the control group that were managed by a variety of 
physicians.
1.7 Diagnosis of catheter-associated infections
A case of true CRBSI is almost always accompanied by clinical symptoms (Dobbins et 
al. 1999). CRBSI is suspected in a catheterised patient when fever or other signs of sepsis 
are observed even when that patient is otherwise well. Should the symptoms abate after 
catheter removal, further confirmatory testing may not be required. However, there may 
be an alternative source of the sepsis, therefore, good clinical practise would demand that 
further tests be carried out (Fletcher and Bodenham 1999a). When CRBSI is suspected 
and/or diagnosed conventional wisdom would deem that it should be treated, either by 
antibiotic therapy and/or catheter replacement. However, no data exists to predict whether 
intervention on suspicion is better than intervention on data.
A number of laboratory-based techniques have been developed specifically to aid in the 
diagnosis of catheter-associated infections (Collignon and Munro 1989, Fletcher and 
Bodenham 1999a, 1999b, Siegman-Igra et al. 1997). Indeed, Siegman-Igra et al. (1997) 
conducted a meta-analysis of published studies which involved some sixteen methods for 
diagnosing CRBSI. These techniques use a number of different types of samples, ranging 
from culture of the removed distal tip of the suspected catheter (Brun-Buisson et al. 1987, 
Cleri et al. 1980, Maki et al. 1977), to blood withdrawn directly from the catheter lumen 
(Wing et al. 1979). In the following section some of these techniques and methods are 
described in detail.
1.7.1 Central Venous Catheter tip culture
a) Qualitative catheter tip culture
Druskin and Siegel (1963) introduced a technique that was to be known as a qualitative 
catheter tip culture. This involved the immersion in nutrient broth of the distal catheter
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tip after removal from the patient. Using this technique any microbial growth is 
significant so consequently it has a high sensitivity for diagnosing catheter-associated 
infections. However a potentially contaminated catheter or catheter with a low level of 
colonisation would also give a positive result, therefore this method has a poor 
specificity. This was highlighted in a study by Norwood et al. (1991) where 50% of the 
tips were falsely diagnosed as positive for CRS when in actual fact they were simply 
contaminated or colonised. For the same reasons Nahass and Weinstein (1990) found that 
the qualitative culture of catheter tips was not predictive of catheter-related bacteraemia 
because they calculated a positive predictive value of 17% in their study.
Therefore, a problem with this technique is that there is no distinction between true 
infection leading to sepsis and the non-pathogenic levels of colonisation and 
contamination. Other quantitative and semi-quantitative methods have since been 
developed, so as to improve upon this technique (Brun-Buisson et al. 1987, Cleri et al. 
1980, Maki et al. 1977); this are reviewed below.
b) Semi-quantitative catheter tip culture - the Maki roll technique
Maki et al. (1977) described a catheter culture technique where they evaluated 250 
catheters that were removed from the peripheral veins of 198 patients. They found that 
they could distinguish between colonisation associated with localised inflammation or 
systemic infection and contamination (the procedure for removal of a catheter creates the 
opportunity for contamination) by using a cut off of 15 CFU or more on a blood agar 
plate culture of the catheter tip.
The technique itself involves removal of the catheter from the patient when CRBSI is 
suspected. The distal tip (approximately 6cm long) is then severed from the rest of the 
catheter. In the laboratory the tip is rolled on a blood agar plate which is then incubated 
for 24 hours. The colonies are counted and if there are >15 CFUs the count is considered 
significant as the infection is distinguished from contamination at this level (Maki et al. 
1977). Collignon et al. (1986) used the same technique but found that five or more 
colonies was a more appropriate cut-off for a positive result. Using this new cut-off they 
determined the sensitivity and specificity to be 92% and 83% respectively, in a cohort of 
780 catheter tips.
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This semi-quantitative method based on >15 CFUs has become the gold standard in 
catheter analysis in the past twenty years (Dobbins and Kite 1999). Initially it was 
thought that this technique was an accurate method of catheter culture as well as being 
inexpensive and simple. Unfortunately it does have a number of inherent flaws (Sitges- 
Serra and Linares 1988). Like the qualitative broth culture described in Section 1.7.1a, it 
involves the sacrifice of the catheter, which renders it a retrospective test as the CVC has 
been replaced. The results gained from both techniques can also be influenced by 
possible contamination of the external catheter tip surface by organisms on the skin.
Moreover in the case of the Maki et al. (1977) technique the outside of the catheter is the 
only portion that is cultured, with possible intemal colonisation going undetected. This 
coupled with its low positive (>15 CFUs) criteria, and the potential for heavy 
contamination from leakage of endoluminal fluid during specimen transit, are reason 
enough to exclude the method as a ‘gold standard’ (Dobbins and Kite 1999).
c) Quantitative catheter tip culture - the Cleri flush technique
Cleri et al. (1980) developed a technique to culture a sample from the intemal lumen of 
the catheter. This study looked at 189 intravenous and intravascular catheters and 
determined that all catheters associated with bacteraemia had catheter cultures of at least 
1000 CFUs. The technique, now known as the “Cleri method” involves flushing and 
culturing of the contents of the removed CVC tip on blood agar. Those catheters with 
>1000 CFUs are defined as infected (Cleri et al. 1980). Those catheters with <1000 
CFUs are described as either colonised or contaminated during removal.
Using 1000 CFUs as a cut off level, this method was used successfully in a study 
involving catheterised patients receiving TPN (Pettigrew et al. 1985). It was also 
successfully used in a study by Linares et al. (1985), who compared the method used by 
Cleri et al. (1980) with the semiquantitative method (Maki et al. 1977). Kristinsson et al. 
(1989) evaluated three methods for culturing intravascular catheters. The methods used 
were the semiquantitative method (Maki et al. 1977), followed by the quantitative flush 
method (Cleri et al. 1980) and finally a sonication method involving 10ml of phosphate 
buffered saline (PBS). They found that the culture of the inside of the catheter (Cleri et 
al. 1980) was the best predictor for infection at a level of 100 CFUs rather than 1000
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CFUs which was the level set by Cleri et a l (1980). They also found that almost all 
infected catheters were colonised both on the inside and the outside (Kristinsson et a l 
1989).
The technique described by Cleri et a l (1980) suffers similar problems to the Maki et a l 
(1977) technique. This is because the CVC also needs to be removed in order for a 
diagnosis to be made, although it is the microbial composition of the outside of the 
catheter that is ignored in this case. Rello et a l (1992) suggested that semi-quantitative 
culture of the external surface (Maki et a l 1977) is adequate for CRS diagnosis in the 
critically ill and intraluminal methods, such as the Cleri et a l (1980) technique be 
restricted to long-term CVCs used for the administration of TPN.
d) Quantitative tip culture -  other methods
Brun-Buisson et a l (1987) examined 331 CVCs from 232 patients. They used a similar 
method as Cleri et a l (1980) with the additional step of vortex mixing the CVC tip in 
order to obtain a sample from the outside of the CVC. Those catheters with >1000 CFUs 
per ml after culture on a blood agar plate were defined as clinically significant and this 
cut-off level was 97.5% sensitive and 88% specific for the diagnosis of CRS in this study 
(Brun-Buisson a/. 1987).
Sherertz et a l (1990) conducted a three-year study using a similar quantitative sonication 
method, where 1,681 consecutive catheters were cultured and a total of 46% of these 
were positive. They concluded that sonication is an effective means of removing 
organisms from CVCs and it greatly increases the number of organisms that can be 
counted compared to the Maki roll technique. The level of significance for CRS was set 
at >100 CFUs in the sample matched by positive blood cultures for the same organism.
e) Disadvantages associated with CVC tip culture
There are a number of problems associated with each of the techniques described in 
Sections 1.7.1(a) to 1.7.1(d). The main problem that they all share is the requirement for 
CVC removal so that the laboratory diagnosis can be made. This is inappropriate and 
unnecessary when studies have shown that approximately 80% of CVCs that are removed 
in this situation are actually not the source of the suspected infection (Kite et a l 1997,
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Pettigrew et a l 1985, Ryan et a l 1974). Catheter removal is generally based on the 
clinician’s judgement as to whether the clinical signs of fever are related to the CVC. To 
improve this, the clinician needs to be more certain that it is the CVC that is the source of 
infection. The only way that this can be done is to use methods that can determine the 
number of organisms in the CVC whilst the CVC remains within the patient. Thus, the 
requirement is for techniques that do not involve CVC removal.
1.7,2 In situ CVC sampling techniques
The assessment of the microbial status of a CVC whilst it remains in situ can be done 
using catheter blood culture, exit-site culture, hub culture, or culture of a sample retrieved 
by a FASEB (Fan et a l 1988, Kite et a l 1997, Wing et a l 1979). The advantage of these 
“/« situ” methods is that the unnecessary sacrifice of catheters not associated with 
infection is avoided.
a) Peripheral blood culture
If a patient is showing signs of suffering a catheter-associated infection, a peripheral 
blood sample can be taken from the patient whilst the CVC is still in place. The presence 
of a systemic infection or bacteraemia can then be determined, however it should be 
noted that, on its own, this technique is not useful in determining if  a CVC is the source 
of the bacteraemia or infection. Nevertheless, the confirmation of a peripheral 
bacteraemia is crucial to the diagnosis a catheter-associated infection when used in 
conjunction with other tests (Dobbins et a l 1999).
b) Quantitative blood cultures
It is possible to draw blood through the CVC and then culture this blood to determine if 
any microorganisms are present. This technique of culturing blood samples aspirated 
fi*om the CVC has been used by a number of authors in various studies (Paya et a l 1989, 
Snydman et a l 1982, Wing et a l 1979). A paired quantitative blood culture (QBC) is 
based on the principle that blood is withdrawn firom both the catheter and a peripheral 
vein and the two isolates compared (Paya et a l 1989, Wing et a l 1979).
If blood is drawn through a colonised catheter then planktonic microorganisms will enter 
the blood. This blood sample will then contain organisms firom the CVC, and therefore
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can be used to determine if these are the same organisms as those in the peripheral blood 
sample. The blood samples are cultured and if the culture from the CVC yields a 4 to 10 
times greater colony count per millilitre than peripheral blood, then the CVC is the most 
likely source of sepsis. Wing et al. (1979) found blood withdrawn through the peripheral 
vein grew 25 colonies per ml whereas blood drawn through the catheter had greater than 
10,000 colonies per ml. On this basis the catheter was removed and the tip cultured to 
confirm infection. If a patient is bacteraemic then culture of blood drawn through the 
catheter will give a positive result, but this does not necessarily implicate the catheter as 
the source of sepsis (Fletcher and Bodenham 1999b). This is because the bacteraemia 
could have its source in another region of the patient’s body, such as a post-operative 
wound.
The blood culture technique cannot, however, be employed when it is not possible to 
aspirate blood from the CVC (Dobbins and Kite 1999, Moyer et al. 1983). Moyer et al. 
(1983) were unable to obtain blood samples from 34 of the 101 catheters in their 
comparative study of diagnostic techniques. Other studies have reported that in up to 50% 
of catheters blood cannot be aspirated (Dobbins and Kite 1999).
Whilst QBC may be useful in making a decision as to whether or not to remove a CVC, 
negative CVC cultures cannot be assumed to rule out infection (Dobbins et al. 1999). 
Paya et al. (1989) found that blood drawn through a catheter gives high rates of both 
false-negative and false-positive results. They concluded that differential quantitative 
blood cultures drawn simultaneously from a suspected CVC and a peripheral vein are not 
useful for predicting a CRBSI. Blot et al. (1998, 1999) and Rogers and Oppenheim 
(1998) suggested alternatives to traditional plate culture of the blood. The continuous 
monitoring blood culture system and differential positivity times for blood cultures are 
described in Section 1.8.2.
c) Hub culture
Swabs can be taken from the hub of the catheter to provide a sample for analysis (Atela et 
al. 1997, Fan et al. 1988, Sitges-Serra and Linares 1988). In the past hub culture was 
generally used as a means of assessing the route taken by microorganisms which travel to 
the catheter tip rather than as a sample for CRS diagnosis (Sitges-Serra and Linares
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1988). Swabs of the CVC hub have been cultured in very few controlled studies and 
therefore data on the usefulness of the results provided by such cultures are limited 
(Goldmann and Pier 1993). In a study by Fan et a l (1988), 29 of 142 (20.4%) catheters 
studied were found to have resulted in CRS, however only 10 of the 29 were detected 
through the hub cultures to give a sensitivity of 34.5%.
The catheter hub has frequently been treated as a separate part of the CVC as it is 
regularly cleaned, often with an antiseptic. Thus a result could prove to be falsely 
negative, because the hub would not be a true reflection of the remainder of the CVC as it 
is cleaned more often (Dobbins et a l 1999).
d) Exit-site swabs
The site where the CVC exits the skin can be swabbed and this sample cultured (Atela et 
al 1997, Bjomson et a l 1982, Fan et a l 1988). Exit-site cultures can go some way in 
predicting and diagnosing CVC infections and correlations between positive skin cultures 
and catheter tip culture have been reported (Bjomson et a l 1982, Fan et a l 1988). 
However, this good correlation could have resulted from contamination of catheter tip by 
organisms at the exit site upon removal (Dobbins et a l 1999).
It should be noted though, that clinical signs of wound infections, such as suppuration 
(pus formation) and tract erythema (reddening) do not necessarily correlate with CRBSI 
as they may be a separate, local, infective complication (Dobbins et a l 1999, Elliott et a l 
1994a, Safdar and Maki 2002) as outlined in Table 1.2.
Both the hub and the exit site have been used in surveillance cultures where swabs can be 
taken to detect organisms at the sites most likely to be the source of a CRBSI. Fan a l 
(1988) recommend that a combination of skin and hub cultures are required for 
satisfactory surveillance of catheters in order to detect colonisation and possible CRS.
e) FAS Endoluminal Brush
The FASEB is designed to retrieve a sample of fibrinous material from the intemal lumen 
wall of a CVC that is suspected as being infected (Markus and Buday 1989). The sample 
can then undergo microbiological examination. The objective of FASEB use is to prevent 
the unnecessary removal of catheters wrongly suspected as the source of sepsis (Kite et
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al. 1997, Tighe et al. 1996a). Information on the microbial status of a sample, obtained 
using the FASEB, would allow the clinician to make an informed judgement as to the 
continued management of the patient. Endoluminal brushing has been investigated by a 
number of authors and has been shown to be an adequate tool for the retrieval of a sample 
from a CVC, whilst it remains in situ (Dittmer et al. 1996, Dobbins and Kite 1999, Kite 
et al. 1997, 1999, 2001, Llancaqueo et al. 1996, van Heerden et al. 1996). In addition, 
use of the FASEB, in conjunction with plate culture methods, has been shown to be the 
most sensitive and specific technique available to determine if a CVC is infected whilst it 
remains in situ (Dobbins and Kite 1999, Kite et al. 1997, 1999, Tighe et al. 1996a). Kite 
et al. (1997) reported sensitivity and specificity levels for the FASEB to be greater than 
those for catheter tip cultures -  assessed by the Maki roll technique (Maki et al. 1977) 
and a modified Cleri-flush technique. Dobbins and Kite (1999) have since reported that 
the FASEB technique is 95% sensitive and 96% specific for detecting CRBSI. Further 
work by Kite et al. (2001) has shown that the FASEB method has a sensitivity of 100% 
for CRBSI in a patient population with double lumen haemodialysis catheters.
The FASEB, shown in Figure 1.14 consists of a wire handle, a brush and a protective 
microbially impervious bag disposed over the handle and brush. It is a sterile device that 
is connected to a CVC via a Luer lock. As the FASEB is advanced through the catheter it 
is simultaneously removed from the protective bag. Then it is withdrawn from the 
catheter, back into the bag. The tip of the FASEB can then be cut off (approximately 
7cm) and placed in a plastic tube. In the microbiology laboratory, the FASEB head is 
immersed in 1ml of buffered phosphate. Following vortex mixing lOpl and / or lOOpl 
aliquotes of the resulting suspension are spread on each of two blood agar plates, which 
are left for 24 hours at 37 ° C. A significant result is >100 CFUs (Kite et al. 1997).
f i  Advantages o f in situ techniques over the traditional tip culture methods
Unnecessary insertion procedures, induced by unnecessary removal of viable catheters 
cause significant morbidity. Therefore, it is critical that in situ methods of CVC analysis 
are used more frequently so that functional CVCs are not removed and replaced 
unnecessarily, when they are wrongly suspected as infected. The risk of complication in 
the management of suspected catheter-associated infection by the use of in situ sampling
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Figure 1.14 The FAS Endoluminal Brush and CVC hub (Tranter and Donoghue 2000).
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techniques such as the FASEB is significantly less than the risk associated with current 
techniques requiring the removal and replacement of suspected CVCs. In addition to the 
reduction in risk afforded by the accurate in-situ identification of non-infected CVCs 
there can also be considerable savings in the cost associated with patient management 
(Archis et al. 2000, Dobbins and Kite 1999, Farmer et al. 1997, Tranter and Donoghue 
2000).
1.8 Rapid diagnosis of catheter-associated infections
Traditional sample culture methods require at least 24 to 48 hours before a result can be 
obtained (Cleri et al. 1980, Kite et al. 1997, Maki et al. 1977). More rapid alternatives to 
this overnight culture have been developed and evaluated (Blot et al. 1999, Cooper et al. 
1985, Kite et al. 1999, Rogers and Oppenhiem 1998, Rushforth et al. 1993, Tighe et al. 
1996b, Worthington et al. 2002a, Zufferey et al. 1988). A review of these techniques is 
below.
1,8,1 Staining techniques
Gram staining and the use of metachromatic dyes, such as acridine orange, have been 
applied to the rapid diagnosis of CRBSI (Cooper et al. 1985, Kite et al. 1999, Tighe et al. 
1996b, Zufferey et al. 1988). Staining has been used on both catheter tip samples (Cooper 
et al. 1985) and blood samples aspirated from that CVC (Tighe et al. 1996b).
Acridine orange is a fluorochrome, which can differentially stain double-stranded and 
single-stranded nucleic acids (Chapin 1995). When acridine orange intercalates into DNA 
(double-stranded) it emits green fluorescence upon excitation at 480-490 nm. On the 
contrary, it emits red-orange it when interacts with RNA and indeed single stranded DNA 
(Chapin 1995). This intercalated into either RNA or DNA can take place both in the 
native and denatured state. Acridine orange is particularly useful in situations where the 
Gram stain is not interpretable, for example in blood specimens. Consequently it has been 
used as a stain in the rapid detection of organisms in blood aspirated from CVCs in both 
neonatal (Rushforth et al. 1993) and adult (Tighe et al. 1996b) patient groups.
However, as acridine orange stains nucleic acids in all bacteria and fungi, including both 
living and dead cells, it may be a less sensitive method of cell enumeration than viable
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cell counts. One way in which the sensitivity of the technique can be improved, is to use 
acridine orange in conjunction with fluorescent redox probes. These lead to the direct 
visualisation of actively respiring bacteria only (Heidelberg et a l 1997). One such 
fluorescent redox probe is j^-iodonitrotetrazolium violet (INT), which has been used in 
conjunction with acridine orange to detect viable but non-culturable gram-negative 
bacteria (Heidelberg et a l 1997).
Another problem that can occur in fluorescence microscopy is the decomposition of the 
fluorescent molecules, due to the presence of molecular oxygen. This, fortunately, can 
now be avoided through the use of anti-fade agents, which enhance the sample and make 
visualisation better (Pawley 1995). One such agent is diazabi-cyclo-octane (DABCO), 
which can be added to the sample prior to staining with the fluorescent molecule (Jolly et 
a l 1997).
a) Staining samples derived from the removed catheter
Cooper et a l (1985) reported the use of a Gram stain method for diagnosis of CRBSI. 
The catheter was stained and then examined under oil immersion light microscopy. Using 
Gram staining the authors detected organisms on all 41 catheter tips that were associated 
with infection. However the anticipated high sensitivity and specificity of the assay was 
premature when it was subsequently found that seven samples that were reported as Gram 
positive were infected by yeast, and not Gram positive bacteria.
This technique was repeated by Coutlee et a l (1988) who looked at the staining of the 
catheter tip, using both Gram stain and an acridine orange direct stain. Coutlee et a l 
(1988) found acridine orange easier to use than Gram staining, but generally they were 
not satisfied with the overall correlation with true infection. Moreover they observed that 
the direct staining techniques were laborious and the results from some catheters could 
not be interpreted. They did suggest, however, that this technique could be useful in 
detecting fungal infections, especially when normal culture is producing negative results. 
Another study concluded that acridine orange staining was easier to perform than Gram- 
staining, where direct acridine orange staining of the catheter tips was found to be 84% 
sensitive and 99% specific (Zufferey et a l 1988).
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Collignon et al. (1987) have carried out some work on Gram staining impression smears 
of catheters, and it was shown to be useful, however, the patient group had a low rate of 
CRBSI.
Although these techniques are useful, rapid, inexpensive and relatively simple to perform, 
they are flawed by the fact that they rely on the removal of the CVC in order to provide a 
result. Because of this the only real benefit of using these techniques is to get a rapid 
result which would lead to the provision of appropriate treatment, such as antibiotic 
therapy, at an earlier stage (Dobbins et al. 1999).
b) Staining o f “in situ ” samples
The usefulness of staining blood drawn from the catheter has been evaluated with varying 
results. Moonens et al. (1994) concluded that Gram-stained blood was useful in cases 
where there was a definitive positive result, but that a negative Gram stain could not rule 
out catheter infection. Kleiman et al. (1984) concluded that acridine orange, although not 
a differential stain like the Gram-stain, was useful in providing information on the 
presence of microorganisms and this may be useful in the selection of antibiotics.
c) The acridine orange leucocyte cytospin (AOLC) test
The AOLC test was found to be a sensitive, rapid (<1 hour) in situ test for the detection 
of infected intravenous catheters in neonates, using a small volume of blood (Rushforth 
et al. 1993). A positive result in the AOLC test is the presence of one or more viable or 
denatured bacteria (Tighe et al. 1996b).
Four studies involving the AOLC method in conjunction with blood drawn through adult 
CVCs have been reported (Gowardman et al. 1998, Kite et al. 1999, Tighe et al. 1996b 
and von Baum et al. 1998). Tighe et al. (1996b) concluded that the use of the AOLC 
method with blood drawn through the catheter was not sensitive enough to detect CRS in 
adults. However, when used in combination with the FASEB, the AOLC method has 
been shown to be much more sensitive (Tighe et al. 1996b). von Baum et al. (1998) 
reported that the AOLC method used in conjunction with blood was not useful and they 
concluded that it should not be used as a routine method for the CRS in adults. In another 
study of 499 CVCs placed in 400 patients, where there were 12 proven cases of CRS, the
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AOLC test was negative in all 12 cases (Gowardman et a l 1998). The studies by von
Baum et a l (1998) and Gowardman et a l (1998) involved ICU patients and the poor 
results may have been due to the short duration of catheterisation of the patients 
(generally <10 days).
d) Combination o f AOLC and Gram staining
Kite et a l (1999) published a technique that used Gram-stain and AOLC in combination 
to detect organisms in blood drawn through the catheter. They found this technique to be 
an accurate approach to diagnosing CRS as it correlated well with other methods such as 
the FASEB culture and the Maki roll plate technique. The assay had a sensitivity of 96% 
and specificity of 92%. However, in this study, blood could not be obtained from 16 of 
128 patients (Kite et a l 1999). However, in their review of intravascular catheter- 
associated infections Crump and Collignon (2000) commented that this technique is 
labour intensive and smaller laboratories may not have all the facilities needed to perform 
a test. They also felt that the technique should be used selectively in patient populations 
with a high pre-test probability of sepsis due to the catheter.
1,8,2 Rapid blood culture techniques
a) A continuous monitoring blood culture system
Rogers and Oppenheim (1998) suggested an alternative to quantitative blood cultures. 
This technique involves the use of a continuous monitoring blood culture system, for 
example the BacT/Alert system (Organon Teknica, USA). They found that the time it 
takes to culture a blood sample containing microorganisms (in addition to length of lag 
phase) and therefore obtain a positive result, is directly related to the initial inoculum of 
microorganism. Therefore the higher the concentration of microorganisms in the initial 
sample then the more quickly a positive result will be obtained. Rogers and Oppenheim 
(1998) found that the time to positivity of blood withdrawn from a peripheral vein was on 
average 4.1 hours longer than blood aspirated from the CVC of patients that were 
subsequently diagnosed with CRS.
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b) Differential positivity times for blood cultures
Blot et al. (1998) evaluated the differential time to positivity (DTTP) of cultures of blood 
drawn simultaneously from CVC and peripheral sites. This technique involves the use of 
a blood culture system, for example the Vital-Duo (bioMerieux, France), which detects 
microbial growth in blood cultures. In the case of this technique peripheral and through 
the CVC blood samples are taken. If the DTTP between peripheral and catheter blood 
samples is short then it is unlike that the patient has CRS, however if the blood obtained 
through the CVC gives a positive result and there is a long period (hours to days) before 
the peripherally obtained sample becomes positive then CRS is likely.
By measuring the time to blood culture positivity Blot et al. (1998) found a cut-off limit 
of >120 minutes had a specificity of 100% and a sensitivity of 96.4% for the diagnosis of 
CRS in this retrospective study. In a further prospective study Blot et al. (1999) 
demonstrated 91% specificity and 94% sensitivity for the diagnosis of catheter-related 
infection using the same cut off of 120 minutes.
However Rijnders et al. (2001) found that the DTTP of hub-blood versus nonhub-blood 
cultures was not useful for the diagnosis of CRBSI in their prospective study of 100 
critically ill patients. This may have been due to the short length of time the CVCs were 
in place (Farr 1999).
1,8.3 A serological test
Elliott et al. (2000) described an enzyme linked immunosorbent assay (ELISA) for the 
diagnosis of CRS which takes 24 hours to perform. Optimisation of this assay led to an 
ELISA for the diagnosis of intravascular CRS specifically caused by CNS, which can be 
completed within four hours (Worthington et al. 2002a). This is a sensitive (70%) and 
specific (100%) indirect ELISA, which is based on the detection of specific IgG 
antibodies in the serum of patients. The serum IgG are present in response to a 
glycerophospholipid (lipid S) antigen, which is produced by CNS. Worthington et al. 
(2002a) found that there was a significant difference in serum IgG to lipid S between 
patients with CRS and controls who had no clinical symptoms of sepsis. In the control 
group the blood was withdrawn immediately after CVC insertion.
CHAPTER TWO 
Method Selection
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2.1 Background
The major objectives of this section of the study were to choose a sample, sampling 
procedure and method of sample analysis that could be used to detect microorganisms, 
which have colonised a CVC. Firstly a literature search of published studies involving 
various catheter-sampling procedures, used in the detection of catheter-associated 
infections, was carried out. From this, one sampling procedure was chosen and a 
rationale for its selection, based on its performance in various publish studies was given. 
A second literature search of scientific publications and corporate technical information 
was subsequently performed to identify a list of technologies that may have the capability 
of rapidly detecting the presence of microorganisms in clinical and non-clinical samples. 
Each of these technologies were then reviewed and an assessment was made, based upon 
published studies and technical performance data. In addition, three technologies were 
evaluated in detail and this involved conversations directly with the manufactures as well 
as brief equipment tests to determine how user-fiiendly each technique would be. One 
was finally chosen and put forward as a possible method, which could routinely be used 
to detect microorganisms in conjunction with the sampling procedure already selected.
2.2 Choice of CVC sampling technique
The assessment of the microbial status of a CVC whilst it remains in-situ has been 
carried out using a number of different types of sample, which have been described in 
Section 1.7. All of these technologies have been shown to be of varying use in the 
detection of microorganisms associated with possible catheter-associated infections and 
the merits of each of these sample types are reviewed below.
2.2,1 Hub and skin cultures
When evaluating hub culture results, it should be remembered that the hub is regularly 
cleaned before and after CVC manipulation. Hence the hub may not reflect the extent of 
colonisation of the remainder of the CVC, thus giving false negative cultures (Dobbins et 
al. 1999). A combination of both hub and skin cultures has been shown to have a high 
negative predictive value (Atela et al. 1997, Fan et al. 1988). However the positive 
predictive values were less than 45% in both of these studies. Fan et al. (1988) 
recommend that a combination of skin and hub cultures are required for satisfactory
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surveillance of catheters in order to detect microbial colonisation and possible CRS. 
However neither has been used solely to aid in the diagnosis of catheter-associated 
infections. On the basis of this neither of these two techniques were thought to be 
suitable for use in this study.
2,2,2 Blood aspirated versus FASEB sampling
Blood drawn through the CVC has been used by a number of groups in an attempt to aid 
in the detection of CRBSI (Blot et al. 1999, Paya et al. 1989, Wing et al. 1979). Blot et 
al. (1999) demonstrated a 91% specificity and 94% sensitivity for the diagnosis of 
catheter-related infection using the DTTP technique in conjunction with blood aspirated 
from the CVC and a peripheral blood sample. However when Rijinders et al. (2001) 
aspirated blood fi-om the CVCs of 100 patients with suspected CRBSI, they were unable 
to detect CRS without associated bacteraemia in five patients using the DTTP technique. 
Rijnders et al. (2001) did comment that 78 of the 100 patients were receiving antibiotics 
at the time of catheter removal and this may be why more patients had CRS than had 
CRBSI. However this does raise an issue that if patients are undergoing systemic 
antibiotic therapy then they may not have bacteria in the blood sample, even though they 
have the clinical indications of sepsis, and therefore a false negative result would be 
reported. In addition to this possible issue, blood drawn through the CVC could 
potentially contain microorganisms from another septic focus within the body. Thus the 
fact that microorganisms are cultured from a blood sample does not necessarily mean that 
the bacteria originated from the CVC (Rijnders et al. 2001).
Another difficulty is that in up to 50% of cases blood cannot be aspirated from the CVC 
due to blockages within the catheter (Dobbins and Kite 1999). Paya et al. (1989) found in 
their prospective study that quantitative blood cultures failed to predict intravascular 
device related infection in over 50% of cases where infection was subsequently 
diagnosed. Infection was defined in this particular study as >15 CFU of the same 
organism fi-om catheter tip culture as grown from peripheral blood.
The FASEB has been identified as the only device that can provide an uncontaminated 
sample that is definitively from the inside of the CVC, without removal of the CVC fi-om 
the patient (Kite et al. 1997). The technique has been found to be have a higher 
sensitivity and specificity (95% and 96% respectively) than other laboratory techniques
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for the diagnosis of clinically and microbiologically proven CRS (Dobbins and Kite 
1999) and it is the only in situ method capable of retrieving a sample in all suspected 
CVCs (Dobbins and Kite 1999).
A study by Tighe et a l (1996b) demonstrated that only 12% of blood samples drawn 
through infected CVCs gave a positive result using the AOLC technique. In contrast 83% 
of blood samples drawn through the CVC after prior passage of the FASEB through the 
catheter were positive using the AOLC technique. Therefore, blood aspirated through the 
CVC may contain planktonic organisms that have originated fi*om the CVC but few 
sessile biofihn organisms will form part of the sample. By using the FASEB to disturb 
the biofihn, more of the sessile biofilm associated cells are sampled and this may be 
critical when a clinical decision is made to treat on the basis of the sample (Donlan and 
Costerton 2002).
Donlan and Costerton (2002) in a recent review article on biofilms suggest that use of the 
FASEB could be extremely useful in determining the biofilm cell count within CVCs as 
it does not involve CVC removal. However they point out that the recovery efficiency of 
the technique (percentage of cells that are actually removed from the CVC lumen) needs 
to be determined. Recent in vitro studies carried out by Worthington et a l (2002b) have 
in part addressed this point by suggesting that 25% of the bioload of the intemal lumen of 
a CVC is removed through bmshing. Furthermore it was observed that a combination of 
FASEB use and withdrawal of 10ml of blood through the CVC post bmshing may lead to 
the removal of up to 70% of the microbial bioload (Worthington et a l 2002b).
From the evidence above it can be seen that there are a number of problems associated 
with using blood aspirated from the CVC. Often blood cannot be aspirated fi*om the CVC 
and when it is there is no guarantee that it will contain organisms associated with the 
CVC. However, even if it does these are generally planktonic organisms and are not 
phenotypically similar to the sessile biofilm organisms (Donlan and Costerton 2002). The 
FASEB on the other hand provides a sample that is definitely from the inside of the CVC 
and contains both planktonic and sessile bacteria (Dobbins and Kite 1999). Therefore it 
was decided that the FASEB technique should be chosen as the sampling technique for 
use in this study.
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2,2.3 Safety concerns o f using the FASEB
A number of groups (Bouza et a l 2002, Donlan and Costerton 2002, Raad 1998, Rogers 
and Oppenheim 1998) have questioned the safety of using the FASEB technique, 
suggesting that the introduction of a brush into a CVC could potentially cause any 
number of complications. However any complications that have arisen, such as cardiac 
arrhythmias, embolisation or transient bacteraemia, have done so in very low frequency 
where none have required clinical intervention (Bouza et ah 2002, Tighe et a l 1996a) or 
not at all (Archis et a l 2000, Dittmer et a l 1996, Dobbins et a l 1997, Dobbins and Kite 
1999, Farmer et a l 1997, Kite et a l 1997, McLure et a l 1997, Tighe et a l 1996a, 
Tranter and Donoghue 2000, van Heerden et a l 1996). Generally complications have 
arisen in cases where the FASEB has not been used in accordance with the manufacturers 
current instructions (Bouza et a l 2002, Tighe et a l 1996a, 1996b). Moreover, FASEB 
use inherently avoids the complications associated with catheter replacement and the 
technique is no more hazardous than the analogues procedure of GWX, which is accepted 
as a safe clinical practice (Dobbins and Kite 1999, Fletcher and Bodennham 1999b).
The FASEB is an approved medical device and has been designed with safety in mind. 
The bristles on the brush are spirally wound such that the bristle ends are orientated to 
the rear of the brush and therefore do not abrade the surface of the biofilm in a forward 
motion. This can be observed in Figure 2.1 where the FASEB has been passed through 
the hub into the leader tube of a CVC. The bristles flattened when the FASEB is 
travelling in a forward motion. The advantage of this is that material within the catheter 
lumen is not pushed forward in front of the brush. When the motion is reversed and the 
FASEB is withdrawn from the catheter, all of the bristle ends are “turned” to abrade the 
biofilm and thus remove material, which is then retained by the body of the bristles.
There are fifteen types of FASEBs available for use in conjunction with the various types 
of commercially available catheters; depending on the length and lumen diameter of the 
catheter. Therefore, if the correct brush is used with a particular CVC then the technique 
is both effective and safe (Dobbins and Kite 1999). Worthington et a l (2002b) confirmed 
that the FASEB was an adequate tool for sampling CVC and they demonstrated that no 
microorganisms are expelled from the CVC if brushing did not include the 2cm distal tip 
of the CVC. This supported the findings of Dobbins et a l (1997) where FASEB use was 
a clinically safe technique in 226 patients.
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Figure 2.1 A FASEB travelling through the leader tube of a CVC on its way into the CVC lumen.
The bristles compact when the FASEB is travelling in a forward motion and these bristles 
will compact further when the brush enters the smaller diameter CVC lumen.
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2.3 Choice of technology
2.3.1 Rapid tests currently in use
Some novel techniques, based on samples retrieved in situ, have been used to detect 
microorganisms in an attempt to reduce the number of CVCs that are unnecessarily 
removed. These have been described in Section 1.8 (Blot et al. 1998 and 1999, Kite et a l 
1999, Rogers and Oppenhiem 1998, Tighe et a l 1996b, Worthington et a l 2002a). They 
are all laboratory-based techniques and provide a result well within the 24-hour period 
that traditional culture methods usually require. These “rapid tests” with a total assay 
time from as little as 30 minutes to as long as 6 hours have been developed for use in 
conjunction with in situ retrieved samples (Blot et a l 1998 and 1999, Kite et a l 1999, 
Kleiman et a l 1994, Moonens et a l 1994, Rogers and Oppenheim 1998, Tighe et a l 
1996b, Worthington et a l 2002a). Many of these techniques involve the use of staining 
and microscopy, and all require blood samples drawn through the CVC.
The problems with these rapid techniques lie both in the sample that is used and in the 
technique used to evaluate the sample. Staining of samples can be time consuming and 
requires specialised training for a result to be determined. In addition, many of these use 
blood samples, which cannot be obtained from all patients. An example of this is the 
study by Kite et a l (1999) where blood could not be obtained from 16 of 128 patients. 
This was, however, not taken into consideration when the authors determined the 
sensitivity and specificity values, which were based on 112 patients and not 128. 
Therefore the true specificity for the assay should be reported as 73% and not 92%.
2.3.2 Preliminary requirements o f a rapid technique
A number of different technologies were identified as suitable rapid direct counting 
procedures. These included, fluorescence microscopy, ELISA, ATP bioluminescence and 
particle counting.
For a technology to be useful in this particular application it is critical that any 
microorganisms that may be present in a sample are actually detected, meaning that the 
positive and negative predictive values of a detection system need to be high. The terms 
positive and negative predictive values are often used to measure the extent to which the
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result of the assay reflects the true status of the patient. Positive predictive values (PV^) 
are determined by using the total number of samples that give positive results (false 
positives and true positives when compared to the reference method) in the patient 
population. Negative predictive values (PV) are determined by using the total number of 
samples that give negative results (false negatives and true negatives when compared to 
the reference method) in the patient population. The closer both of these are to 100% then 
the more specific the assay and the greater the chance of obtaining a correct result which 
will lead to appropriate clinical action.
It is critical that a CVC that is associated with a bloodstream infection is identified and 
quickly removed from the catheterised patient. This would indicate that a high PV^ is 
important and therefore an assay with high specificity is required. However, it may be 
equally as important clinically, that a CVC which has been diagnosed as negative is a 
true negative because this CVC will allowed to remain in situ within the patient. Should a 
CVC that has tested negative actually be positive (a false negative by definition) it may 
cause a CRBSI which could result in mortality from a full-blown sepsis. Therefore, it is 
critical that such false negative results are kept to a minimum and the P V  should be as 
close to 100% as possible.
A positive sample retrieved by the FASEB is reported as >100 CFU/ml and a negative 
sample reported <100 CFU/ml (Kite et al. 1997). Therefore, the selected technology will 
need to have the capability of detecting this level of microbial colonisation. If this level 
cannot be detected using a specific technique then there may be cases where low levels of 
colonisation or even infection are not detected therefore leading to a lower P V  and a less 
sensitive and specific test.
2.3.3 Technologies that met the initial requirements
The three technologies listed in Table 2.1 were selected because they met the preliminary 
requirement of having the potential of detecting as few as 100 CFU/ml. Additionally, 
each have been shown to be useful in the rapid detection of microorganisms in other 
clinical and non-clinical applications, such as routine urine screening, food microbiology 
or environmental monitoring and testing. In addition all three technologies have been
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used in clinical settings in the past (Lundin 1989, Medcraft et al. 1993, Tighe et al. 
1996b) with the Questor, LI and Bioprobe used in conjunction with urine samples and 
the Statspin used with blood samples.
Each of these technologies, as well as instrumentation based upon these are discussed in 
detail in Section 2.4.
2.3.4 Technologies that did not meet the initial requirements
Some other technologies were examined but these did not meet with the preliminary 
requirements set out above. These included techniques based on technologies such as 
immunoassay and fluorescence microscopy.
The major disadvantage that could be foreseen when an ELISA-based assay is used to 
rapidly detect a catheter-associated infection is that there no single antibody that would 
specifically detect all the microbial species that could be implicated in an episode of 
catheter-associated infection. To accurately detect a particular organism, approximately 
ten different assays would need to be performed so that each of the microbial species in 
Figure 1.10 could be detected or ruled out. Additionally, as up to 80% of CVC’s that are 
removed on suspicion of causing pyrexia are in fact negative, it would be unnecessary 
and expensive to perform a number of assays on a sample that could actually be negative. 
The method described by Worthington et al. (2002a) is an ELISA based on the detection 
of specific IgG antibodies that are present in response to a glycerophospholipid (lipid S) 
antigen, which is produced by CNS. Even-though such an assay is useful for the 
detection of infection caused by CNS, it will not be useful in detecting infection caused 
by other microorganisms (up to 63%). Therefore, a negative result obtained using this 
ELISA cannot be assumed to mean that a catheter-associated infection has not occurred.
The use of a specific molecular probe dye (Molecular Probes Inc., USA) was also 
thought to be of potential use for the differential staining of microorganisms that may be 
present in CVC samples. However, it was pointed out by the manufacturer that many of 
the dyes that may be most appropriate for this application, are approved only for use in 
development work, and are much too toxic for use in a routine diagnostic test. Therefore 
their application was not investigated further.
Chapter Two________________________________________________________________________ Pase 80
2.4 Microbial detection technologies
This section contains details on each of the three technologies listed in Table 2.1. The 
principle behind each of the three technologies is given, in addition to applications and 
examples of equipment that are based on the technologies.
2.4,1 Staining and Microscopy
a) Acridine orange
Staining, such as the Gram stain, has been used in conjunction with microscopy to aid in 
clinical diagnostics for many years. Other stains such as acridine orange have also been 
useful tools in many aspects of clinical and environmental microbiology (Heidelberg et 
al 1997, Tighe et a l 1996b). Kleiman et a l (1984) concluded that acridine orange was 
useful in providing information on the presence of cocci and rods in blood samples, 
drawn through a CVC. Since then the application of acridine orange in the detection of 
catheter-associated infections has been attempted in other studies (Collignon et a l 1987, 
Coutlee et a l 1988, Gowardman et a l 1998, Rushforth et a l 1993, Tighe et a l 1996b, 
von Baum et a l 1998, Zufferey et a l 1988). However, problems related to the use of 
acridine orange have been identified and these have been outlined in Section 1.8.
b) The AOLC method
The acridine orange leucocyte cytospin (AOLC) test is performed using a method that 
requires two major pieces of equipment, a cytology centrifuge and an UV microscope. In 
most routine pathology or microbiology laboratories access to a UV microscope is 
possible. However the presence of a cytology centrifuge, which can be used to 
concentrate cells, is less frequent.
The AOLC test uses approximately 1ml of blood which has been aspirated from a CVC 
in situ. Hypotonic formol saline (lyses red blood cells and fixes leucocytes) is added to 
the blood and then hypertonic saline is added and the suspension centrifuged. The 
resultant pellet is re-suspended and then transferred to a cupule, which is placed in a 
cytology centrifuge where the cells are dispersed onto a glass slide forming a layer of 
cells. The slide is then stained with acridine orange (~1:10,000 dilution) and left to dry in 
air. The preparation is then immersed in oil and examined under an ultraviolet
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microscope (xlOOO). As stated in Section 1.8, acridine orange fluoresces when it binds to 
either RNA or DNA. In their study of samples retrieved from CVCs, Tighe et a l reported 
that a positive result was the presence of one or more viable or denatured bacteria (Tighe 
et al. 1996b) on the microscope slide. Other studies where AOLC has been used have 
been described in Section 1.8.
c) Statspin Cytofuge
In this study the value of the Statspin Cytofuge (Figure 2.2) when used within the 
procedure for the AOLC technique was determined. The Statspin Cytofuge is smaller 
(163mm in length and 120mm tall) and more lightweight (2.5kg) than conventional 
dedicated cytology systems. During centrifugation a specially designed cell concentrator 
is used to spread a “film” of cells on a specific region of a microscope slight. This slide 
can then be stained as appropriate and the slide viewed under a microscope.
2.4.2 Particle counting
a) Background
Walter Coulter developed the “Coulter Principle” in 1953 and it has since become the 
accepted reference method for particle size analysis (Hobson and Mann 1973). The 
principle involves an electro-zoning technique to detect the number of particles passing 
through an orifice (Medcraft 1993). This method of counting and sizing particles is based 
on the movement of a liquid, containing particles in suspension, though a small opening 
or aperture (Hobson and Mann 1973). The aperture is situated between electrodes and 
this is collectively known as the sensing zone. As the liquid is an electrolyte, a current 
can be passed between the electrodes on either side of the aperture. If the aperture 
contains only the solution then the circuit has a minimum resistance and this is readily 
measured. When a non-conducting particle moves through the hole it obstructs the path 
of the current and causes the measured resistance to increase. The change in resistance is 
proportional to the size of the particle and is closely related to the size of the aperture 
(Hobson and Mann 1973). The quantity of suspension drawn through the aperture is 
precisely controlled, thus giving the most accurate possible result.
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Figure 2.2 The Statspin Cytofuge microcentrifuge (Statspin, USA).
Chapter Two_____________________ .__________________________________________________ Pase 83
This technique enables both the size distribution and the concentration of particles to be 
estimated, but does not distinguish between particle shape, colour and density (Hobson 
and Mann 1973). Therefore, coccoid or rod-shaped bacteria are counted and their size 
estimated as if  they were spherical in shape. It is only possible to count organisms in a 
mixed culture if there is a sufficient differentiation in size between each type of organism 
(Hobson and Mann 1973).
The sensitivity of the technique depends upon matching the aperture and diameter of the 
particles under analysis. If the particle is much smaller than the aperture then the 
sensitivity will be reduced and it may not be possible to distinguish the measured 
resistance signal from the background ‘noise’ of the detector. Thus samples which have a 
widespread range of particle sizes require more than one orifice for examination. This 
problem has been addressed by using apertures of different size diameter, for example 
10pm to 60pm, which are tailored for specific particle magnitude. This can be useful in 
the screening of urine samples so that there is good differentiation between bacterial and 
human cells (Stevens et a l 1993).
b) The variable orifice probe (VOP)
One solution to the problem of sensitivity mentioned above is to use one aperture which 
can be automatically varied in diameter. An apparatus with a variable orifice has been 
developed (Holley 1987, Stevens et a l 1993) in which a tapered spear is located within a 
fixed orifice. The orifice size may be effectively varied by adjusting the degree of 
insertion of the spear into the aperture. This provides the advantage of increased dynamic 
range compared to the open (fixed) orifice and therefore the size and number of smaller 
particles can be determined much more accurately (Holley 1987).
The Electro-Zoning Variable Orifice Probe (VOP) is used in the sizing and counting of 
particles of between 0.8pm to 40pm in diameter (Holley 1987). A small orifice is located 
at one end of the probe, where internal and external electrodes are situated. When a 
sample is introduced into the probe an electrical field is established between the two 
electrodes; a vacuum draws the sample through the orifice and any particles present in 
the sample will displace the electrolyte and change the impedance of the circuit. These 
changes are detected as pulses, which are measured and recorded. Larger particles cannot 
cause a blockage of the VOP as these particles are repelled fi*om the orifice (Holley
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1987). This is known as the “filter effect” (Stevens et al. 1993) and it happens because 
the flow pattern sets up a standing wave at the point where the probe enters the orifice 
(this is referred to as an annulus) and this wave sweeps larger particles away from the 
annulus but allows smaller particles to go through (Stevens et al. 1993).
MicroMed Limited have taken the VOP technology and combined it with an automatic 
pipetting system to form the Questor™m s im m Q n i  (Figure 2.3). The Questor™s y sXqvci is 
currently used as an automated, rapid (60 seconds per sample) urine analysis system, 
which counts white blood cells, red blood cells, epithelial cells and bacteria (Medcraft 
1993, Report 1993 and Stevens et al. 1993). This relatively large instrument (870mm x 
480mm x 435mm; weighing 25kg) is computer-controlled and this aids in the precision 
necessary for the tapered glass spear’s insertion into the orifice, thus giving the probe the 
accuracy to analyse particles of various sizes from 0.8 pm to 40pm.
Numerous evaluations and trials have been performed on the Questor system (Medcraft 
1993, MicroMed Limited unpublished data 1989-95, Stevens et al. 1993). The Questor 
has been successfully evaluated for use in routine of screening urine samples and the 
potential applications of the VOP technology outside the urine analysis sector are 
enormous. In the Reading Public Health Laboratory study, 2273 urine samples were 
examined both on the Questor system and by routine methods. The Questor system was 
found to be a satisfactory method for screening large numbers of urine samples, as it had 
a high (96%) P V  (Medcraft 1993). The Leicester Public Health Laboratory study used 
1023 urine samples and showed the Questor system to have a P V  of 98% (Stevens et al. 
1993).
c) Agglutination
Agglutination is the clumping or aggregating together of particulate antigens after 
primary reaction with antibody (Kuby 1994b). In some types of agglutination assays a 
specific antibody is attached to the surface of a larger particle e.g. a latex bead. When a 
sample containing a specific analyte, for example Escherichia coli 0157, is added to a 
solution containing antibody-head suspension, the specific antibodies will bind to 
antigenic determinant sites on the analyte. If there are many of these antigenic
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Figure 2.3 The Questor (MicroMed Limited, UK).
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determinant sites then more than one antibody may bind to the analyte - this is called 
“cross-linking”. When agglutination has taken place the resulting clump of material is 
larger than the latex beads themselves. The clumps are sometimes so large that they are 
visible (Kuby 1994b).
If a known number of beads are added to a urine sample, for example a concentration of 
10  ^ per ml, and agglutination takes place between the analyte and the antibodies, then 
clumps will form. These clumps of beads and analyte are too large to pass through the 
orifice and are repelled due to the “filter effect”. A decrease in the number of beads 
counted will indicate that the analyte was present (positive result). Thus there is an 
inverse relationship between the number of beads counted and the concentration of the 
analyte. This technique has been successfully used in detection of rheumatoid factor as 
well as other analytes in the body (Medcraft 1993, MicroMed Limited unpublished data 
1993-95).
It is the application of the VOP technology with reverse agglutination that could be most 
applicable to this study. By combining these technologies there is an opportunity to 
rapidly detect the organisms, at clinically significant concentrations, which could be 
implicated in the suspected catheter-associated infection.
2.4.3 ATP bioluminescence
a) Introduction
The generation of light by a biological process is called bioluminescence and it was 
McElroy (1947) who first analysed the method by which a firefly, Photinus pyralis 
produces a flash of light. McElroy found that there is a specific enzyme reaction, which 
involves the breakdown of adenosine triphosphate (ATP) and the amount of light emitted 
is directly proportional to the amount of ATP that is present.
ATP which is universally found in all living cells is now being used as a measure of the 
viability of living cells. The purification of the components of the bioluminescence 
reaction (luciferin and luciferase) has led to the development of an assay that is useful in 
the enumeration of bacteria (Stanley 1989). By using a luminometer the detection of 
relative light units (RLUs) indicates that the sample contains ATP. Furthermore, the 
higher the number of RLUs that are detected then the higher the ATP concentration. This
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is an extremely rapid and sensitive enzyme reaction, with light detection taking place 
within milliseconds (Stanley 1989).
ATP bioluminescence is now a well-established technology that is used in the rapid 
estimation of cell numbers, both microbial and somatic. It is widely used in the food 
industry as a rapid method of detecting if  work surfaces are clean as well as in food 
hygiene monitoring for rapid determination of the microbial content of food-stuffs 
(Hawronskyi and Holah 1997, Siragusa et al. 1996). The popularity of this technology in 
the food industry is due to the fact that it is such a rapid alternative to traditional 
microbiology techniques. The use of ATP bioluminescence for monitoring the various 
stages in food production allows information to be provided in time for corrective action 
to be taken, thus avoiding recall campaigns and food scares (Hawronskyj and Holah 
1997).
ATP bioluminescence is also a useful tool in research applications within biomedical 
sciences, such as its use in conjunction with reporter genes (Kricka 2000). It has 
however, not been as popular in routine clinical settings, even-though it has been shown 
to be of use in bacteriuria testing (Lundin 1989, Thore et al. 1975), with >2 million 
assays per year (Lundin 2000), as well as having possible applications for rapid drug 
susceptibility testing in TB patients (Hoffiier et al. 1999).
b) Adenosine triphosphate (ATP)
ATP is a molecule found in all living organisms and is the primary energy source within 
the cells of these organisms. Its structure is displayed in Figure 2.4. It is a carrier 
molecule of high-energy bonds consisting of an adenosine region, made up of adenine 
and ribose, and three phosphate units (each of which has one phosphorous atom and four 
oxygen atoms). When the high-energy bonds between the phosphate groups are broken, 
ATP is converted first to ADP (adenosine diphosphate) and then to AMP (adenosine 
monophosphate) and inorganic phosphate (Pi) is released. The energy that is liberated 
during these reactions (equations 1 & 2) is used in cellular reactions such as cell division, 
protein synthesis, nerve signal transmission and muscle movement (Cohen 1999).
ATP + H2 O ------------►ADP + P; + Energy (1)
ADP+ H2O ---------►AMP + Pi + Energy (2)
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Figure 2.4 Structure o f adenosine triphosphate (ATP).
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Much of the ADP is immediately converted back to ATP (equation 3) through an enzyme 
based process involving the conversion of glucose to pyruvate ions (Cohen 1999).
ADP + Pi + Energy ----------- ^  ATP + H2 O (3)
c) ATP concentration
The concentration of ATP within a living cell varies depending on the type of cell. In 
terms of human cells, neutrophils will have a large concentration of ATP, followed by 
the smaller red blood cells and the even smaller platelets (Lundin 1997). In terms of 
microbial cells yeasts are larger than bacterial cells and they too will have a larger 
concentration of ATP than bacterial cells. Lundin (2000) suggests that most bacterial 
cells contain 2 x 10'^  ^ moles of ATP, however this is questionable as microorganisms 
such as Campylobacter jejuni have been shown to have reduced ATP levels in response 
to adverse environmental conditions (Beumer et a l 1992).
d) ATP in the firefly reaction
The reaction that occurs during bioluminescence (equation 4) involves the following (De 
^ Q ie ta l  1986).
Luciferin + ATP + O2  Luciferase and Oxylucifcrin + CO2  + AMP + pyrophosphate + light (4 )
Luciferin in the presence of the enzyme luciferase and ATP is converted to oxyluciferin, 
with a by-product of this reaction being light. One photon of light is released as one 
molecule of ATP is broken down, thus the number of photons of light that are detected 
provides a direct correlation with the number of molecules of ATP that are broken down.
e) Luminometers
A luminometer typically contains a photo-detector to detect the number of photons of 
light that are emitted from a sample, a chamber to hold the sample and an LED to display 
the number of photons of light emitted as relative light unit (RLU) values (Stanley 2000). 
There are many luminometer manufacturers in the world today, with the result that many 
types of commercial luminometers are available. Indeed, Stanley (2000) has published a
E
E
g
X
E
E§
X
E
Eo
RI
LO
c\i
I
E0
■5
o
8
ED
C
0x:
Q .
0
8_c
CM
o
CL
0
"O
0
0
C
'0
E
.c
O) 0
3 "O
O a
a c
•o O)00
0 E"q. >\Q. 0 o3
0 2
<
E
*6
0
0
"2
o 0 oo 0
1a
§
a s
> co
DU
ooo
o 'oo
s
I
I
II
T - "O
o  0
"IW ü 
0
3 E
i l
> 8
"8a
•- ^  a  g
il
II
0X3
2ao
ffl
I
E
E
g
X
E
E
g
X
E
I
%
.go
cm'
2
î
i
«
o
0
E3
C
0
X :
Q .
0
'o
8_c
CM
ü
<
>
o
co
CM
a
Q.
0
T3
0
0
C
'0
E
ü
<
0
ü
0
X3
0
X3
0
0
g)
0
.C
ü
0 N
■0 I
C O
0 ss
g
I
O0
3
a
a>
0■D
a
c
C3)
0
E
o
20
E0
Ë1
3
É
Ooo
o"oo
o
CM
Q.
i
co
il
il
il'
II
3 0 E
i l
ô  Q
2
«i
(S
I
0 >*c .c 00 .5> Q .E 0 0
Q Q I
I ,
O) . F
I
0
Q .
O
0c0
(0
c
3
0  
ü
E
3
E
1 s
î
g
£
0
Q .
E
w
Chapter Two________________________________________________________________________ Pase 91
list of all luminometer manufacturers and the type of luminometer that is manufactured 
by each, from microtitre plate luminometers to specialist portable luminometers. From 
this list two luminometers were selected for evaluation. The first was the LI luminometer 
(Mediators, Austria) and the second was the more portable Bioprobe (Hughes-Whitlock, 
UK). These particular luminometers were chosen because they are relatively smaller in 
size and weight than other larger more dedicated systems. In addition, they are also 
relatively low cost (<£6,000) and have a relatively high sensitivity. The specifications of 
each of these two instruments are shown in Table 2.2, where it can be seen that there is 
little difference between the luminometers in terms of dimensions, weight, sensitivity and 
maximum RLU count. However the two instruments do differ in terms of what type, 
volume and format of sample can be used in conjunction with each luminometer. They 
also differ in the way the light is detected by the photo-detector.
The Mediators LI is a sensitive single sample luminometer, which has a number of 
features that differ from the Bioprobe. The sample can be contained within a standard 12 
X 75mm tube or a micro-centrifuge tube where it is introduced into the reading chamber 
by way of a sliding drawer that pulls out from the main body of the instrument (Figure 
2.5). In order to determine the ATP concentration of the sample the drawer is gently 
closed and the luminometer automatically determines (integrates) the RLUs over a 10 
second period after a 2 second delay (this can be adjusted) and the results given on an 
LED display on the instrument. When the drawer is closed the sample is 3mm away from 
the photo-detector, which is located beneath the drawer. If the sample is contained within 
a standard tube then the photo-detector can easily detect all the light emitted. After 
detection of the RLUs the sample can be discarded by simply opening the drawer and 
removing the tube.
The Bioprobe (Hughes-Whitlock Limited, UK) is a luminometer used mainly in the food 
industry for assessing the cleanliness of work surfaces (Report 1995). The Bioprobe can 
be seen in Figure 2.6 and consists of a stainless steel test plate, which fits to the base of 
the plastic cased luminometer. During operation the sample to be analysed in conjunction 
with the appropriate reagents is placed onto the stainless steel test plate. The sample can 
be on a plastic disk or an aluminium tray (otherwise known as a coupon), in a 1.5ml 
centrifuge tube or inside a syringe filter. The luminometer part is placed and gently
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Figure 2.5 The LI luminometer (Mediators, Austria). The drawer to the right o f the luminometer is 
in the open position and a sample is contained within a 12 x 75mm glass tube held in 
position in the reading chamber. In order to determine the ATP concentration in the 
sample the drawer needs to be closed and the RLU’s are determined.
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Figure 2.6 The Bioprobe luminometer (Hughes Whitlock Limited, UK).
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pressed down onto the stainless steel test plate. A vacuum automatically seals the space 
between the top and the bottom steel plate, creating a “light-tight” environment where the 
detector only measures light emitted from the sample. The luminometer then detects the 
number of photons of light and expresses these as RLUs on the LED display, with 
readings usually taken after 10 seconds. This instrument differs greatly from the LI in 
that the photo-detector is located over 20mm above the sample. In general this is 
adequate, however the photons of light need to travel further to be detected and this can 
cause sensitivity issues if  there is a low concentration of ATP to be assayed (Dr A. 
Lundin, personal communication).
f i  Reagents used in conjunction with the luminometers
In order to detect microbial ATP, there are a number of steps, which need to be followed 
prior to the determination of the ATP concentration. These involve the extraction and 
degradation of ATP from the non-microbial cells and the subsequent extraction of ATP 
from the microbial cells.
Besides the Bioprobe, Hughes-Whitlock Limited are also manufacturers of specialised 
bioluminescence reagents, which are optimised for use with the Bioprobe. These reagents 
include specific somatic and microbial cell lysis systems, ATPase (to degrade non- 
microbial ATP) and a luciferin-luciferase reagent. These reagents have been optimised 
for use specifically with the Bioprobe. On the other hand. Mediators do not supply 
reagents with the LI luminometer. However they do recommend the Biothema AB range 
of luciferin-luciferase reagents to be used in conjunction with their instrument. 
Unfortunately Biothema do not supply cell lysis agents or ATP removal reagents.
2.5 Selection Criteria
2.5.1 Investigations and evaluations
The value and feasibility of the Bioprobe and LI luminometers, the Questor and the 
Statspin cytofuge were investigated. Firstly the manufacturers of each of the instruments 
were approached and the specification of each was discussed. This was followed by an 
initial trial period with each of the instruments, where the author was allowed to test each 
system and determine how applicable that system would be in a hospital laboratory
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environment. Through this initial testing and the conversations with the manufacturers an 
assessment was made on how useful each instrument could be, should it be used to 
analyse a FASEB-retrieved sample.
The feasibility of the Bioprobe and LI, the Questor and the Statspin was assessed using a 
scoring system based on the three parameters described below.
a) Cost
Each of the three technologies were assessed on the basis of cost. The two areas that 
related specifically to cost in each case were:
• The initial cost of set up; which would include the capital investment for equipment 
and reagents.
• Subsequent running cost of the techniques on a day-to-day basis. The running costs 
include; the cost per test of the reagents required, the cost of personnel required to 
carryout the test (based on the time required to perform the assay) and the 
requirement for special facilities, such as safety cabinets or special waste disposal.
b) Time
The traditional method of culturing a FASEB sample takes at least 24 hours before the 
result is obtained. However, the time taken to process the sample and then determine the 
result after the incubation period is relatively short (<10 minutes in total). Thus the total 
assay time should include all incubation periods that are necessary.
Using a rapid assay will undoubtedly reduce the total length of time required to complete 
the assay but it may become more labour intensive. In addition the total time required to 
perform an assay will be influenced by set up times such as the thawing, reconstitution 
and / or dilution of reagents. Moreover, the total time between sampling and returning the 
result will be dependent upon the time required to transport of the sample to the 
laboratory and the procedures involved in reporting back the result.
Each of the technologies will be assessed in terms of how quickly a sample could be 
processed from the time it is received in the laboratory to the result being reported. 
Ideally the total turn-around time from the retrieval of the patient’s sample to the 
reporting of the result should be within the working day. This is because the clinician
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will need to make a decision on whether to give antibiotics to the patient, remove the 
CVC or look for an alternative source for the infection.
c) Ease o f use
Techniques that are difficult to perform, require a high level of operator skill or have a 
high number of time-consuming individual procedures are of little use as rapid tests in a 
routine clinical laboratory. It is important that the developed technique should have as 
few individual procedures as possible and each of these steps is not time consuming. It 
may be better to have two individual steps separated by a 15 minute long incubation 
time, rather than six short manipulations (vortex mixing, heating, washing) during a 10 
minute period. In a routine clinical laboratory a rapid test should have a simple enough 
method to allow it to be routinely carried out by both specialist staff and “on call” staff. 
An example of such a test would be the use of the Staphytecf^^ kit for identification of 
staphylococci. This kit is based on the principle of agglutination, is complete within five 
minutes and minimal steps are required to obtain a result.
2.5,2 The scoring system
In order to evaluate each technology a scoring system was devised to determine their 
feasibility, as well as show the difference between each technology. This was thought to 
be the least complex method of translating the subjective into the objective and 
quantitative. The assessment parameters, shown in Table 2.3, were broken down into the 
three groups (cost, time and ease of use) outlined in Section 2.5.1. Each parameter scored 
between 1, 2 or 3, with the better and more appropriate technology receiving a higher 
score for each section where it would perform well. The technology with the highest 
score was then selected as the most suitable technology to be used in conjunction with 
the FASEB. Each of the three parameters has been deemed to be equally important for 
the purposes of this investigation.
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2.6 Scoring and selection
2.6.1 Advantages and disadvantages of each technology
The advantages and disadvantages of each of the three technologies were summarised 
and these can be seen in Table 2.3. These advantages and disadvantages are again based 
upon the three selection criteria identified in Section 2.5.
2.6.2 Scoring each technology
Using the devised scoring method based on the three criteria described above, a total 
score was calculated for each of the technologies. Table 2.4 shows the values obtained by 
each of the technologies for each of the three criteria, as well as the total scores.
a) Staining and microscopy -  the AOLC method
The combination of the Statspin cytofuge and the AOLC method achieved a score of 5 
out of a possible 9. This scored well in the areas of cost and assay specificity. The initial 
capital outlay would be relatively low as an UV microscope is generally found in most 
clinical laboratories and a Statspin cytofuge costs less than £3,000. Moreover, on a day- 
to-day basis this would be a low cost detection system to use as it does not require any 
specific reagents with a short shelf-life or expensive components. Even-though the 
technology could achieve a result in approximately 20-30 minutes, the method does 
involve a number of individual steps and some of these are time consuming to perform.
Another problem is that a number of fields in the microscope view need to be examined 
(possibly up to 100) in order to obtain an accurate result. To do this a high level of 
specialised training may be required. Therefore it is important that the operator is well 
trained and can distinguish between microorganisms and somatic cell debris. However, it 
needs to be remembered that “on call” staff may need to use this method and they might 
not have the necessary expertise. This is especially important when put into the context 
of Gowardman et a l (1998) conclusions, that in their experience the AOLC test was 
labour intensive and demanding of skilled personnel for accurate performance and 
interpretation.
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Table 2.4 Scores achieved by each technology.
Technology Parameter Score Details
Acridlne Orange 
Leucocyte Cytospin
Cost
Time 1
Ease of use 1
TOTAL 5
Basic reagents required and the consumables 
are relatively cheap. Microscope already 
available. Statspin <£3,000.
Sample preparation is time consuming (>10 
minutes) and negative samples may take longer 
to analyse.
A significant amount of training would be 
necessary. On call staff may not find it simple to 
use.
Variable Orifice Probe
Cost
Time
Ease of use
1 Instrument costs £39,950. High cost of reverse 
agglutination beads and other consumable 
costs are relatively high.
2 A result can be obtained within 30 minutes 
depending on the level of sample preparation 
that is required.
3 It is an automated instrument so only the 
sample preparation could potentially be difficult.
TOTAL
ATP
Bioluminescence
Cost
Time
Instrumentation costs <£6,000. Reagents can 
be expensive and issues with the shelf lives 
after reconstitution.
Sample preparation could take -3 0  minutes. 
Sample analysis usually takes <1 minute.
Ease of use 2
TOTAL
Training is necessary, however using a 
luminometer is straightforward. Sample 
preparation is more labour intensive.
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b) Particle counting -  the VOP technology in the Questor ™
The VOP technology in the form of the Questor instrument and in combination with 
reverse agglutination achieved a score of 6 out of 9. One of the main issues with this 
technology is the cost of the instrumentation. A Questor would not normally be a 
standard piece of equipment in a clinical laboratory and therefore there would be an 
initial capital outlay of up to £39,950 (Stevens et a l 1993). In some hospitals the particle 
counting based VOP technology is routinely used to screen urine samples (Medcraft 
1993, Stevens et a l 1993). However, the number of urine samples received in a typical 
hospital laboratory is much greater than the potential number of CVC tip samples. 
Therefore, it is difficult to justify the expense of purchasing the Questor instrument for 
catheter sample screening. Additionally, the fact that antibody based agglutination assays 
may be required would increase the cost still further. This is because a panel of tests may 
be required so as to identify the species of organism that is present.
c) ATP bioluminescence -  the Bioprobe and LI luminometers
ATP bioluminescence based instrumentation and reagents scored 7 out of 9. Using ATP 
bioluminescence there is the capability of not only detecting the ATP in all the microbial 
cells present in the sample, but also determining the concentration of ATP present and 
therefore easily quantifying the number of microorganisms in the sample.
In terms of costs luminometers are not usually available in a routine microbiology 
laboratory and therefore there is an initial capital outlay. Luminometers vary in price and 
specification but an adequate luminometer for routine clinical use would cost 
approximately £6,000 (Report 1995). The day-to-day running of the system could be 
high as reagents tend to be expensive, due to their high enzyme content and the need to 
present them as freeze dried solids due to their short stability in liquid form. ATP 
bioluminescence is, nevertheless, a very straightforward system to use and the time 
required to perform an assay, including sample preparation, would be less than one hour 
(Lundin 2000).
2.6.3 Selection
As ATP bioluminescence scored the highest number of points it was chosen as a platform 
for the development work to be carried out in the next section. Although the nature of the
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selection process means that the points awarded (5, 6 and 7) are not statistically 
dissimilar, ATP bioluminescence technology does have a number of advantages over the 
other two techniques.
• ATP bioluminescence can be used to determine (indirectly) the total number of 
microorganisms in a sample. Particle counting in combination with agglutination can 
also be used to do this, however a number of specific agglutination assays many be 
required before a satisfactory result is obtained.
• The ATP bioluminescence reaction also occurs very quickly and the potential turn 
around time from sampling to reporting of the result could be well within the 
working day.
• The difficulty with using the AOLC as a screening method is that it takes a lot 
longer to obtain a negative result than a positive result using microscopy. This is 
because a minimum number of fields need to be analysed in order to say with 
confidence that there are no organisms present. The potential number of negative 
sample (-80%) would mean that this method would be time consuming.
A method based on a combination of the ATP bioluminescence and a sample retrieved 
with a FASEB was proposed for further development. With the use of appropriate “front 
end” sample preparation and a specific reagent system then microbial and non-microbial 
ATP can be differentiated and the microbial ATP measured. There is, however, a 
significant amount of development that needs to be done on various aspects of the whole 
system before obtaining an easy to use all-inclusive system.
2.7 Assay development using ATP Bioluminescence
Both the Bioprobe and the LI luminometer were investigated in the initial development 
stage and details of the proposed development work using the both the Bioprobe and 
reagent system and the LI and reagents follow in Chapter 4. However, before looking at 
this work it is important to identify and discuss the potential difficulties that are 
associated with using ATP bioluminescence as the basis for a rapid test system.
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2.7,1 A TP extraction
Although ATP bioluminescence is one of the most sensitive and rapid methods available 
for the enumeration of bacteria (Lundin 2000) it is necessary to follow a series of steps in 
order to determine how many bacteria are present within a clinical sample. These steps 
involve the extraction and degradation of ATP from the non-microbial cells, followed by 
the independent extraction of ATP from the microbial cells.
For the in vitro ATP bioluminescence reaction to occur ATP must be extracted from the 
cell. This ATP extraction must take place within milli-seconds, because ATP has a rapid 
turnover inside the cell. In addition, some intracellular enzymes may try to use the free 
ATP for repair of the ruptured cell wall, therefore, the extractant needs to have chaotropic 
properties which allow inactivation of these intracellular enzymes (Lundin et a l 1994).
In many cases and especially with clinical samples, microbial ATP needs to be 
distinguished from non-microbial ATP. As yeast and mammalian cells have ATP 
concentrations of up to 1000 times higher than bacterial cells, it is important that there is 
no contamination of the final sample with non-microbial ATP. To overcome this 
situation extractants have been developed which selectively extract ATP from non- 
microbial cells but do not affect the microbial cells.
a) Extraction and degradation o f ATP from somatic or non-microbial cells 
Somatic or non-microbial cells can generally be lysed quite easily. Exposure to a non- 
ionic detergent such as Triton X-100 for a period of up to 1 minute is usually sufficient to 
lyse most somatic cells (Lundin and Thore 1975). However, when clumps of cells or 
tissues exist, the Triton X-100 may not fully penetrate the mass and some ATP may still 
remain within the structures (Stanley 1989).
Once the non-microbial cell has been lysed and the intracellular ATP released it needs to 
be removed from the solution where the intact microbial cells remain. It is important that 
this contaminating ATP is degraded before the microbial ATP is released since 
contaminating ATP often makes up over 99% of the total ATP present (Schram and 
Witzenburg 1989, Stanley 1989).
Removal of unwanted ATP can be carried out by addition of an ATP dephosphorylating 
enzyme, such as apyrase (Stanley 1989). Apyrase (EC 3.6.1.5) is basically an adenosine
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5’-triphosphatase (ATPase), which is naturally present in living cells where it regulates 
the levels of ATP within the cell. When apyrase is added to an ATP containing solution it 
begins to degrade the ATP into ADP, as shown in Equation 1 in Section 2.4.3.
There are, however, problems associated with using apyrase to degrade the non-microbial 
ATP (Stanley 1989). If insufficient apyrase is used, the removal of the non-microbial 
ATP may take longer, resulting in unwanted non-microbial ATP remaining to 
contaminate the sample. Conversely, the addition of a high concentration of apyrase 
could lead to the rapid removal of the non-microbial ATP, but this excess apyrase will be 
present to degrade the microbial ATP subsequent to its extraction from the cell.
In many situations a relatively high concentration of apyrase is added and after a specific 
period of time, during which the ATP is degraded, an inhibitor is added to denature the 
apyrase. Unfortunately, the use of such inhibitors can lead to the simultaneous inhibition 
of the luciferase enzyme. Therefore, an effective and selective inhibitor of apyrase is 
required that does not have an adverse affect on luciferase (Stanley 1989).
Alternatives to apyrase have been sought. Many of these are also ATP dephosphorylating 
enzymes (Sakakibara et a l 1997) such as adenosine triphosphatase (EC 3.6.1.3) and 
hexokinase (EC 2.7.1.1). These enzymes have been used individually and in combination 
with various other enzymes, such as AMP deaminase (EC 3.4.5.6), adenosine deaminase 
(EC 3.5.4.4) and alkaline phosphatase (EC 3.1.3.1). Sakakibara et a l (1997) 
demonstrated that a combination of apyrase and adenosine phosphate deaminase (EC 
3.5.4.17) was extremely effective in removal of non-microbial background ATP from a 
culture broth.
In order to degrade further the background ATP present in blood samples, apyrase has 
also been used in combination with Percoll density gradients (Molin et a l 1983, Nilsson 
et a l 1989). This involves a centrifugation step to separate blood cell debris from 
bacteria.
I
b) Extraction o f ATP from microbial cells
In order to lyse microbial cells, a more vigorous extractant is required, because microbial 
cell walls and membranes are much more robust than somatic cells. It is important that 
this extractant is both aggressive enough to release ATP from a broad range o f 
microorganisms and has the capability to inactivate intracellular enzymes that would
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normally breakdown the ATP (Stanley 1989). Three criteria that an extractant or 
microbial cell lysis agent needs to fulfil, are listed below (Lundin et a l 1994, Meighan et 
al 1994).
1. Complete release of the entire ATP pool fi*om the cell,
2. Complete, irreversible and immediate inactivation of all ATP converting
enzymes,
3. No analytical interference firom the extractant with the ATP assay.
The problem is, however, that criteria 2 and 3 are contradictory in that a chemical that 
would inactivate all ATP converting enzyme would intrinsically inactivate luciferase 
(Meighan er fl/. 1994).
A number of different types of extractants have been described (Hoffiier et a l 1999, 
Stanley 1989). Some of the more popular extractants include trichloroacetic acid (TCA) 
and dimethyl sulphoxide (DMSO), but these adversely affect the luciferase assay. The 
types of microbial ATP extractants have been divided into four groups (Stanley 1989) 
and these are shown in Table 2.5 along with the problems that are associated with each. 
TCA is thought to be the most reliable extractant and, at a final concentration of 2.5% 
(w/v), it is used as a reference extraction method (Lundin 2000).
In addition to the type of extractant it is also important to determine how long the
microbial cell should be exposed to the extractant. Selan et a l (1992) observed that
higher RLUs values were detected when a stock of Ps. aeruginosa was exposed to a 
commercial ATP extractant for 30 seconds rather than 10 seconds.
As many of the extractants in Table 2.5 are potent inhibitors of luciferase, their 
application to this technology is difficult. Nevertheless, a number of ways to limit their 
effects on the luciferin-luciferase reaction have been assessed. Traditionally, the 
inhibition has been overcome by diluting the extract prior to assay with the luciferase 
(Lundin et a l 1994), but this leads to a great loss in sensitivity. An alternative has been 
to use neutralising agents, which bind the chemicals leading to a neutralisation of the 
whole solution. Lundin et a l (1994) described the use of a-cyclodextrin to neutralise the 
effects of dodecyl trimethyl ammonium bromide (DTAB). Cyclodextrins are “doughnut 
shaped” molecules made up of 6 to 8 glucose molecules with a hydrophobic interior.
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Lundin et al. (1994) found that the addition of a-cyclodextrin to a solution containing 
microbial ATP extracted by DTAB, led to complete neutralisation of the DTAB and 
therefore no subsequent interference, or inhibition of the luciferase based ATP assay. 
However, it is noted that cyclodextrins also form complexes with o-luciferin and this 
needs to be considered when optimising the system (Lundin 2000). Therefore, during 
development, the cyclodextrin should only be present in a small excess over the DTAB.
2,7.2 Measurement o f A TP
a) Assay conditions
Once the non-microbial ATP has been extracted and degraded and the microbial ATP has 
been released, the concentration of microbial ATP can be determined. When a luciferin- 
luciferase reagent is added to the sample an almost immediate reaction will take place, as 
in Equation 4 in Section 2.4.3, with light being produced. The quantum yield is 0.88, 
therefore, almost one photon of light is emitted per ATP molecule (Lundin 2000). The 
assay can be calibrated using a known amount of ATP standard where no more than 1% 
of the final volume should be added. However, volumes of <10pl are generally avoided 
(as these are less accurate to measure). Thus, in addition to an RLU value being obtained, 
the amount of ATP can be expressed as moles of ATP. This is important so that samples 
can be compared and it compensates for variations such as those listed below (Lundin 
2000).
• Luminometer to luminometer variations (even between the same model), as well as 
deterioration in the sensitivity of a single luminometer over time.
• Batch to batch variations between the same luciferin-luciferase reagent.
• The inhibition from sample components. It has been noted that biological samples 
can contain substances that are inhibitory to the luciferase reaction. In addition, 
emitted light can be partially quenched by cellular debris or proteins in the sample to 
give a falsely low RLU value.
• Inhibition of the luciferase reaction by the compounds used to extract the ATP from 
the microbial cells (concentration dependent).
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It is also important that the ATP standard should not exceed the upper end of the linear 
range of the luminometer, which is generally set at <1 pM final ATP concentration in the 
reaction tube.
The most sensitive luciferin-luciferase reagents allow the detection of approximately 10’ 
moles (or 1 Attamole) of ATP (Lundin 2000). This is equivalent to the ATP present in 
half of one bacterial cell. However, this is not practical, as there are issues with cross 
contamination of equipment and consumables at these levels.
There are a number of variables that can affect the luciferase reaction. These include the 
D-luciferin -  which should be as pure as possible, excess magnesium ions and the type, 
concentration and pH of the buffer used. The optimal buffer usually contains 50 or 100 
mM Tris and 0.5 to 2mM EDTA all adjusted to 7.75 with acetic acid (Nichols et al. 1981, 
Webster a/. 1980).
b) ATP reagents
Three specific types of ATP reagent have been described by Lundin (1997, 2000). 
Further details on each of these are displayed in Table 2.6.
1. The stable light-emitting reagent has a very low decay rate and is useful for ATP 
monitoring. Measurements can be taken at leisure as there is a stable light emitted 
over time. However, its detection limit is not adequate for low numbers of bacteria.
2. The slow decay reagent has a higher decay rate (10% / minute). This is useful in that 
this type of reagent can be formulated to degrade its own ATP background during 
preparation. The detection limit is higher than in the stable light-emitting reagent and 
it is useful for detecting low levels of bacteria ATP.
3. The flash reagents have very high decay rates and consequently have a very sensitive 
detection limit. They are useful in the detection of very low levels of ATP (1 amol) 
but injector systems are required to add the reagents whilst the sample is in the 
luminometer and ATP free containers are required to avoid issues of contamination.
2  7.5 Correlation between ATP concentration and CFU/ml
Another issue that needs to be remembered is that often ATP cut-off limits for positive 
assay generally correspond to higher cell numbers than would be expected from cut-off
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limit in terms of CFU/ml (Lundin 2000). The reasons for this can be due to incomplete 
removal of non-microbial ATP or that the average CFU originates from more than one 
bacterial cell. This has been observed in bacteriuria testing, however few patients with 
urinary tract infections produce samples with bacterial levels close to the cut-off limits 
(Lundin 2000).
2.7.4 Crucial areas in the development process
Figure 2.7 illustrates critical steps that have been identified and needed to be addressed in 
order to develop a successful technique based on ATP bioluminescence. The first major 
complication was that a sample retrieved by the FASEB would possibly contain both 
microbial and non-microbial cells, therefore it was necessary to determine how to 
effectively lyse non-microbial cells and remove their ATP whilst leaving the microbial 
cells intact. Secondly, it was necessary to lyse the microbial cells and simultaneously 
inhibition all ATP degrading enzymes so that the released ATP was not degraded. In the 
final step the released microbial ATP needed to be quantified so that the level of 
microbial colonisation could be determined.
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STEP ONE
Determine how to effectively lyse non-microbial cells so that their intracellular ATP is 
exposed. Then determine how to remove (degrade) this ATP so that intact microbial 
cells (containing their ATP) remain
STEP TWO
Lyse the microbial cells so that their ATP is released and simultaneously inhibit all 
ATP degrading enzymes
STEP THREE
Detect the microbial ATP using appropriate reagents and a luminometer
Figure 2.7 A flow chart showing the major steps that need to be followed in order to develop a 
system based on ATP bioluminescence.
CHAPTER THREE 
Methods & Materials
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3.1 General introduction
This chapter details the materials and methods that were used in the laboratory. Details of 
all the materials used are given; these include enzymes, commercially available reagents, 
laboratory-formulated reagents and buffers, as well as the equipment and consumables. 
Information is also given on the samples used and the approvals gained in order to obtain 
these clinical samples. General methods for reagent formulation are also detailed as well 
as methods for operating various equipment. Finally methods that were development as 
part of this study are detailed, including the extraction and detection of microbial ATP 
from the clinical samples.
3.2 Materials
3.2.1 Chemicals
Table 3.1 lists all the chemicals that were formulated. All were dissolved in sterile 
distilled water to form stock solutions. The storage conditions and the supplier details are 
also listed in the table.
3.2.2 Enzymes
a) Apyrase (lOOU/ml)
Apyrase (EC 3.6.1.5) was purchased from Sigma Aldrich, UK, as a partially purified 
lyophilised powder containing adenosine 5’-triphosphatase and adenosine 5’- 
diphosphatase. Grade III apyrase (catalogue number A7646) was used in batches of 2000 
Units per vial. The contents of the vial were dissolved in 5ml of sterile distilled water and 
then filtered through a 0.22pm, 25mm syringe filter (Syrtec, USA). The filter was then 
flushed with 15ml of sterile distilled water to give a 20ml solution containing 100 
Units/ml apyrase. This stock was then aliquoted (1ml each) into micro-centrifiige tubes 
and these were stored at -20°C until required.
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b) 5 - adenylic acid deaminase (20 Units/ml)
One vial of 5’ - adenylic acid deaminase (EC 3.5.4.6) from Aspergillus Species contains 
1000 Units. This was supplied in diatomaceous earth (total weight of 9.4g) by Sigma 
Aldrich, UK. To prepare a solution containing 100 Units/ml, 940mg was removed and 
suspended in 3ml of water. The resultant suspension was vortex-mixed (30 seconds) and 
then filtered through a 0.22pm, 25mm syringe filter (Syrtec, USA). This filter was then 
flushed with 2ml of sterile distilled water giving 5’ - adenylic acid deaminase at a final 
concentration of 20 Units/ml. This solution was stored at 2-8 °C until required.
c) Hexokinase (1000 units/ml)
Hexokinase (Sigma Aldrich, UK) was supplied in a vial containing 1000 Units and this 
was reconstituted in 1ml of sterile distilled water. This solution was stored at 2-8 °C until 
required.
3,2.3 Commercially available reagents
a) Reagents used in conjunction with the Bioprobe luminometer
The Isostat isolator reagent (Oxoid, UK) was supplied in pre-aliquoted (700pl) tubes. 
This reagent was developed by Dorn and Smith (1978), and it contains the lytic agent 
saponin, which lyses red and white blood cells. It also contains anti-foaming and anti- 
coagulating agents and when used as intended, blood is added to the tube to give a final 
volume of approximately 10ml.
Hughes-Whitlock Limited supplied the ATPase, the Luciferin-Luciferase reagent with 
diluent buffer and the Bacterial Lysis Agent. The exact constituents and formulation of 
these reagents are unknown, as they were supplied as part of a commercial kit. All three 
of the reagents were dispensed firom plastic reagent bottles, with tips that deliver 50pl 
(±5 pi) of liquid per drop.
The Luciferin-Luciferase reagent (Hughes-Whitlock Limited, UK) was supplied as a 
fi*eeze-dried solid and it was reconstituted in a single vial of the diluent buffer when 
required. As a powder it has a shelf-life of two years. When reconstituted, it is useful for
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1 days if stored between 2°C and 8°C. In all investigations involving the Hughes- 
Whitlock Bioprobe the “High Sensitivity” Luciferin -Luciferase kit was used.
The ATPase was supplied as a standard reagent and it was found that increasing volumes 
were required to achieve high levels of ATP degradation. On request, Hughes Whitlock 
supplied a 10 times concentrated ATPase, which was subsequently used in the method 
development. Due to the manufacturer’s confidentiality concerns the contents and 
concentrations of both of these reagents were unknown but they were assumed to contain 
apyrase and MgClz.
The Bacterial Lysis Agent (Hughes-Whitlock Limited, UK) has a shelf-life of two years 
if stored at between 2°C and 8°C and was used in the liquid form in which it was 
supplied.
b) Reagents used in conjunction with the L I luminometer
The contents of the ATP Kit SL (Biothema AB, Sweden) are shown in Table 3.2. The 
formulation of the reagents within this kit is unknown (see the SL kit instructions for use 
in Appendix 2). When required, the SL reagent was removed from the freezer and 
brought up to room temperature. It was then reconstituted in a single vial of “Diluent C”. 
In its lyophilised form the SL reagent has a shelf-life of two years when frozen. When 
reconstituted it remains effective for 7 days if stored between 2°C and 8°C. Each reagent 
was dispensed using ATP-free pipette tips.
Biothema AB also supplied the HS reagent as a lyophilised reagent containing D- 
luciferin and luciferase. The HS reagent contains higher concentrations of both D- 
luciferin and luciferase, resulting in a more sensitive measurement of ATP level. One vial 
of HS reagent was reconstituted in a single vial of “Diluent E” and the shelf-life is 
similar to that of the SL reagent.
The ATP standards of choice for use in conjunction with the HS reagent are vials 
containing 5ml of 10'  ^ moles/L ATP or 5ml of 10'  ^ moles/L ATP (Biothema AB, 
Sweden).
Bactolyse (LumiTech, UK) is a mixture of cationic detergents in an aqueous buffer. This 
was supplied in a 50ml bottle from which it was dispensed in 50pl drops. It has a shelf-
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life of 2 years when stored between 2-8°C. A nucleotide-releasing agent (LumiTech, UK) 
was also supplied in a 50ml bottle and dispensed in 50pl drops. The shelf-life is again 2 
years when stored between 2-8°C.
3.2.4 ATP degradation reagent
The ATP degradation reagent was made up freshly each day using the components listed 
in Table 3.3. By adding each component to 6.57ml of sterile distilled water a final 
volume of 10ml was achieved. This 10ml solution was then filtered through a 0.22pm, 
25mm syringe filter, which was subsequently flushed with 4m 1 of sterile distilled water 
giving a final volume of 14ml and the final component concentrations shown in Table 
3.3. In situations, where greater than 14ml of the ATP degradation reagent were required, 
the volume of each of the components was doubled to give 28ml final volume.
3.2.5 Staphytect Plus kit
Staphytect Plus (Oxoid, UK) is a latex agglutination test for the differentiation of S. 
aureus by detection of a clumping factor. The Staphytect Plus kit contains blue latex 
particles coated with porcine fibrinogen and specific antibodies raised against capsular 
polysaccharides of S. aureus. It also contains a control reagent, which contains blue 
unsensitised latex particles and reaction cards, which provide a surface on which to carry 
out the assay. Positive {S. aureus strain ATCC 25923) and negative {S. epidermidis strain 
ATCC 12228) controls, supplied by Oxoid UK, were also used.
3.2.6 Microbank beads
Microbank beads (Pro-Lab Diagnostics, USA) were used to store microorganisms (below 
-20°C) for extended periods. These porous beads are acid washed and allow 
microorganisms to adhere readily to their surface. The beads (approximately 25 in total) 
are contained within a cryovial full of cryo-preservative.
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Table 3.2 Components of the Biothema ATP Kit SL.
Component Description Vials / 
bottles
SL reagent Lyophilised reagent containing D-luciferin and luciferase 4 vials
Diluent 0 ATP-free distilied water used to reconstitute the lyophilised 
D-luciferin and luciferase
4 vials of 
10ml each
ATP standard 10'^  moles/L of ATP* 4 vials of 
5mleach
Tris-EDTA
buffer
O.imol/L Tris (hydroxymethyl) aminomethane, 2mmol/L 
EDTA and adjusted to pH 7.75 with acetic acid
4 bottles of 
50ml each
*  In many cases 10‘® moles/L of ATP has been used instead of 10'® moles/L of ATP. This was a dilution (1:10) of the 10'® 
moles/L of ATP in sterile distilled water. This was because the linearity of the L1 luminometer is better within this range 
(Lundin 2000).
Table 3.3 Components of the ATP degradation reagent as formulated for this study.
Component Volume added Final
Concentration
Triton X-100 (1 % w/v) 1.4ml 0.1%
Apyrase (100Units/ml) 1.4ml 10Units/ml
Magnesium chloride (Imol/L) 280ul 0.02mol/L
5 -adenylic acid deaminase (20Units/ml) 350ul 0.5Units/ml
Sterile distilled water 6.57ml N/a
Sterile distilled water (used in recovery from filter) 4ml N/a
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3.2,7 Other solutions, buffers and media
a) Sterile distilled water
Distilled water was autoclaved at 121°C for 15 minutes, then stored in airtight 500ml 
bottles at room temperature prior to use. Once a bottle was opened for use the remaining 
contents were discarded after one day as the water was deemed to be no longer sterile.
b) Tris buffer (0.5 Mol/L)
Trizma HCl (Sigma Aldrich, UK) (10.64g) was added to Trizma Base (Sigma Aldrich, 
UK) (3.94g) and then dissolved in 200ml of sterile distilled water. This solution (pH 7.8) 
was stored at room temperature for up to one month prior to use.
c) Phosphate buffered water (PBW)
One phosphate tablet (Sigma Aldrich, UK), was dissolved in 500ml of distilled water and 
sterilised (autoclaved) at 121 °C for 15 minutes.
d) Blood agar plates (7%)
Blood Agar Base No.2 (Oxoid, UK) (40g), was dissolved in 1 litre of distilled water and 
then autoclaved at 121°C for 15 minutes. After cooling to just under 50°C, 70ml of 
defibrinated horse blood (Oxoid, UK) was gently stirred in. The solution (approximately 
25ml per plate) was immediately poured into sterile plastic petri dishes (Sterlin, UK). 
These blood agar plates were then left to set overnight before being stored at 2-8°C (for 
up to one month) until required.
e) Brain Heart Infusion Broth (BHI broth)
BHI Broth (Oxoid, UK) (18.5g) was added to 500ml of distilled water. This was 
thoroughly mixed and dispensed into glass vials (approximately 20ml each). These glass 
vials were then sealed and autoclaved at 121 °C for 15 minutes. The vials were left to cool 
and stored at room temperature until required.
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3.2.8 Consum ables
a) Syringe filter units
A  number of syringe filter units were evaluated for use in this study. The filters ranged in 
diameter fi*om 13mm to 25mm. The pore size of the filters was either, 0.2pm or 0.45 pm. 
The filters were supplied by Syrtec, USA; Millipore, USA; Sartorius, USA and Gehnan, 
UK.
b) Syringes
Single use 1ml, 2ml and 5ml Steripak plastic syringes (Becton Dickinson, Ireland) were 
used.
c) ATP-free pipette tips
Other groups have noted that there are potential ATP contamination problem resulting 
from the use of normal autoclaved pipette tips (Lundin 2000). As a result special “ATP- 
free” (Biopur) tips (Eppendorf, UK) were used to transfer the luciferin-luciferase 
reagents to the luminometer. These particular pipette tips were supplied in tip boxes each 
containing 96 tips and were guaranteed to have an ATP level of less than 10"^  ^ Mol/L 
ATP.
d) Micro-centrifuge tubes
To avoid potential contamination special ATP-free micro-centrifuge tubes (Eppendorf, 
UK) were used when the sample was mixed with the luciferin-luciferase reagent. These 
were supplied in boxes of 50 and were guaranteed to have an ATP level of less than 10'^  ^
Mol/L ATP.
e) Silver sample dishes (coupons)
These silver coloured sample trays, known as “coupons”, were supplied by Hughes 
Whitlock for use in conjunction with the Bioprobe luminometer.
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3.2.9 Microbial and non-microbial samples
a) Human blood
Whole blood provides a rich source of a somatic ATP (background ATP). By using 
blood, the efficacy of the reagents and method in releasing and degrading such ATP 
could be determined.
In order to get fresh blood samples the Campus Surgery at the University of Surrey was 
approached. Approval was obtained for the duty nurse to remove up 10ml of blood from 
healthy volunteers as required. The sampling of blood is described in Section 3.4.1.
b) CVC tips removed from catheterised patients
Due to ethical constraints it was not possible to sample the CVCs whilst they remained in 
situ within the patient. Therefore sampling of the CVC tip was carried out in the 
laboratory after the CVC was removed.
Generally, CVCs are removed from hospitalised patients, if  CRS was suspected, or if the 
use of the access device is no longer required. After removal of a CVC that is suspected 
as infected, the tip is severed from the rest of the CVC and sent to the hospital 
microbiology laboratory for analysis. This analysis involved application of the technique 
developed by Maki et al (1977) and the tip is discarded. After overnight culture any 
growth was documented. Organisms were identified using conventional microbiology 
techniques where growth was observed.
The Medical Microbiology Department in St George’s Hospital, London was approached 
to collect the CVC tips for investigation in this study. Approval was granted from St 
George’s Hospital for the personnel in the Medical Microbiology Department to collect 
CVC tips for this study as long as the following restrictions were adhered to:
• No clinical information would be given except for the data filled out on the report 
sheets supplied (see Appendix 3).
• In no way should the sample be traced to the patient, therefore a label (see Appendix 
3) was supplied to cover existing information already on the sample tube.
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These restrictions created a major constraint within the study in that it was not possible to 
get further information on the underlying condition of the patient, as well as the regime 
of treatment. Therefore it was unknown whether antibiotics were infused through the 
CVC lumen. Moreover, there was no information on how may of the patients actually 
had an episode of CRBSI.
After the “Maki” technique was carried out by the laboratory staff the CVC tips were 
stored in individual plastic containers at 4°C until collection, in batches of 15 to 20, for 
use in this study. In addition to collecting the CVC tips, accompanying information was 
supplied on data sheets (Appendix 3). This additional information included the date of 
CVC removal, the results of the Maki roll investigation and the microorganism isolated if 
there was any growth.
It should be noted that even-though a wide variety of CVC tips were collected, such as 
those from long-term CVCs (Hickman and PermCaths) and short-term CVCs, only the 
tips taken firom Arrow catheters (Figure 1.1) were analysed in this study.
c) Microorganisms
One ampoule of S. epidermidis (NCTC 11047) was cultured and colonies stored using 
the Microbank beads at -20°C. Other microorganisms that were used in this study were 
an environmental isolate of E. coli (Dr K. Powell personal communication) and clinical 
isolates of CNS and S. aureus cultured from CVCs and stored using the Microbank beads 
at -20°C.
3.3 Equipment used
3.3.1 Luminometers
The detection of relative light units (RLUs) that are emitted fi*om the sample involved a 
combination of either the Bioprobe luminometer (Hughes-Whitlock Ltd, UK) and its 
specific reagents or the LI luminometer (Mediators, Austria) and Biothema AB reagents. 
More details on each of these luminometers was given in Section 2.4.3.
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3.3,2 Other instrumentation
The other instruments used in this study are listed in Table 3.4.
3.4 General methods
This section details the methods that were common to all phases of this study. They 
include basic sample preparation for both stock solutions of microorganisms and 
dilutions of blood samples as well as the sampling of CVC tips.
3.4.1 Blood collection
Peripheral blood (10ml) was drawn each day from healthy human volunteers. Blood that 
was required for clotting experiments was drawn into a red-capped Vacutainer tube 
(Becton Dickinson, UK) containing no additives. Blood for routine work (where the 
blood was required un-clotted) was drawn into a Vacutainer tube containing lithium- 
heparin gel (green capped) only.
In addition, blood (10ml) was drawn through the CVC in the hospital wards by the 
hospital staff. The method used was similar to that described by Wing et al (1979).
3.4.2 Platelet rich plasma
Blood was freshly drawn from a healthy individual into a red capped Vacutainer tube 
(Becton Dickinson, UK) with no exposure to EDTA or heparin. It was then immediately 
transferred into a sterile glass tube where it was allowed to clot. After one hour the tube 
was gently mixed by inverting twice and 1ml of the supernatant removed -  leaving the 
blood clot in the tube. This supernatant (plasma) was red and white cell-depleted, but was 
a rich source of platelets, therefore it was termed “platelet-rich plasma” for the purposes 
of this study.
3.4.3 Serial dilutions of bacteria
a) Dilution o f overnight culture
One colony was picked from a blood agar plate using a sterile loop and put into a glass 
vial containing 20ml nutrient broth. After incubation (overnight) at 37°C, lOOpl of the
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“overnight culture” was taken and added to 900gl of sterile PBS to give a ten-fold 
dilution of the stock. Serial dilutions were then continued for a further five transfers so 
that a dilution of 10'^ was achieved.
b) Washing cells by centrifugation
One colony was picked from a blood agar plate using a sterile loop and put into a glass 
vial containing 20ml nutrient broth. After incubation (overnight) at 37°C, 1ml of the 
“overnight culture” was transferred into a centrifuge tube and centrifuged at 2500 rpm for 
5 minutes. The supernatant was then removed from this to leave a pellet, which was 
reconstituted in 1ml of PBW. The centrifugation process was repeated a further two 
times so that a final volume of 1ml of “washed” microorganisms was obtained.
3.4.4 Sampling and culture o f a CVC
Although the FASEB is intended for use while catheters are in-situ, it may also be used 
in the laboratory {in-vitro) to sample CVC tips that have already been removed from 
patients (Koch et al. 2002) or CVCs that have been colonised in vitro (Worthington et a l 
(2002b).
A new FASEB was taken and removed from its plastic sheath, then cut to a length of 
approximately 10cm. The CVC tip was held using forceps and the FASEB advanced into 
the lumen, unless more than one lumen was sampled. Generally the longest (distal) 
lumen was brushed. The FASEB was inserted all the way through the lumen before being 
removed and placed in a test tube.
Once the sample was retrieved it was placed in a tube. The solution containing the 
FASEB acquired sample (generally a final volume of 1ml) was vortex-mixed for 1 
minute and then lOOpl was removed and spread on a blood agar plate. This was 
incubated overnight at 37°C and the number of colonies estimated the next day.
3.4.5 Volume of sample removed using the FASEB
Fresh heparinised blood (1ml) was weighed and then a FASEB was dipped into the 
blood. The brush was then removed and the blood remaining subsequently weighed 
again. The difference in the two weights was recorded as the volume attached to the 
brush. This was repeated a ftirther nine times and the mean value calculated.
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3.4.6 Using Microbank beads for storage of microorganisms
a) Preparation for storage
Approximately 3 to 5 colonies were taken from a fresh culture of organisms (on a blood 
agar plate). These were used to inoculate the cyropreservation fluid, which surrounds the 
beads in the cryovial. The lid was closed on the cyrovial and the vial inverted five times. 
All the excess cryopreservation fluid was removed, using a sterile pipette, to leave the 
vial containing the beads with the microorganisms attached. The vial was closed tightly 
and stored below -20°C.
b) Recovery o f microorganisms
The cryovial was opened and a bead removed using sterile forceps. The vial was then 
returned to the freezer as quickly as possible. The bead was dropped into a vial 
containing 20ml of nutrient broth. This was then cultured at 37°C overnight. An aliquot 
of this was taken to inoculate another 20ml of nutrient broth.
3.4.7 Using the Staphytect Plus kit
The Staphytect Plus kit (Oxoid, UK) was brought to room temperature. One drop of the 
test latex was dropped onto one of the circles on the reaction card. One drop of control 
latex was dropped on to another circle. Using a loop, up to five colonies were removed 
from a blood agar plate and added to the test latex in the circle. This was repeated for the 
control latex. In both cases the latex was spread all over the circle. The card was then 
gently swirled (for up to 1 minute) so that there was mixing within the contents of each 
circle.
The presence of S. aureus was indicated by agglutination of the blue latex particles in the 
test circle and absence of agglutination in the control circle. If no agglutination occurred 
then the contents of the blue test circle remained a smooth blue suspension.
3.4.8 Determination of the “hold-up volume” of a syringe filter
Distilled water (1ml) was drawn into a plastic syringe, which was subsequently weighed 
as were a micro-centrifuge tube and a syringe filter. The water was then flushed through 
the filter and the filtrate collected in the micro-centrifuge tube. All three were re-weighed
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before air (1ml) was then flushed through the filter and any liquid displaced firom the 
filter was collected. All three were again re-weighed a further five times and the average 
volumes were recorded for both hold-up volume before air-purging and after air-purging.
3.4.9 Determination of the A TP content o f a syringe filter
The ATP was released by passing lOOpl of TCA (10%) through each filter and flushing 
this with Tris-EDTA (2ml). The ATP concentration was then determined using 50pl 
extract in the SL reaction. This was repeated three times using separate filter units.
3.4.10 Environmental conditions and reagent storage
Unless otherwise stated all experiments were carried out at room temperature. This was 
defined as between 20°C and 25°C. The room temperature was regularly recorded using 
a min./max. thermometer in the laboratory and experiments were not carried out if  the 
temperature was outside these limits.
All work that was carried out in conjunction the luminometers was conducted in the area 
of the laboratory that was the furthest from the window. This limited the amount of 
sunlight that would be exposed to the photo-detector of the luminometer. In addition, on 
days of particularly bright sunlight, the blinds were drawn to block out as much of light 
as possible.
All luciferin-luciferase reagents and other light sensitive reagents were stored in light 
proof containers in the refrigerator.
3.5 Methods used in conjunction with the Bioprobe luminometer
3.5.1 Determination of RLUs using the Bioprobe luminometer
The sample (either on one of the silver coupons or inside a whole syringe filter unit) was 
placed onto the stainless steel base plate. The luminometer part of the Bioprobe was then 
placed onto the steel base and gently pressed down (Figure 2.6). A vacuum automatically 
sealed the space between the instrument and the bottom (steel plate), creating a “light- 
tight” environment where the detector measures only light emitted from the sample. The 
luminometer then detected the number of photons of light emitted and expressed these as 
RLUs on the LED display (measuring over a 10 second period). A second reading was
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taken by gently pressing down on the Bioprobe to repeat the measuring process. The 
luminometer portion was then lifted off and the sample removed and discarded.
3.5.2 Samples contained within syringe filters
Using a syringe, 500pl of “treated” sample (sample that has been exposed to reagents that 
degrade contaminating ATP) was filtered through a 25mm (diameter) 0.45pm Millipore 
filter. This filter was then immediately flushed with 5ml of phosphate buffered water. 
Luciferin-Luciferase reagent (50pl) was added to the filter using a sterile 1ml syringe. 
The filter was immediately placed on the steel base-plate and the RLUs determined as in 
Section 3.5.1. Then using a new syringe, lOOpl of bacterial extractant was added to the 
filter and the RLUs determined again. One further measurement was taken immediately 
before the filter was discarded.
In addition, 100 pi of the remaining 500pi of sample was spread onto a blood agar plate 
and incubated overnight at 37°C.
3.5.3 Samples on the silver coupons
The serial dilution (lOOpl) of a particular microorganism was placed on a coupon and the 
Luciferin-Luciferase reagent (50pl) added. The dish was gently shaken and placed on the 
reading area of the Bioprobe where the RLUs were subsequently determined to give the 
background ATP level. Bacterial extractant (50pl) was added and the RLUs determined 
again.
The active concentration of the bacterial lysis agent was 25% (v/v) of the original 
supplied concentration. The Luciferin-Luciferase reagent was also used at 25% (v/v) of 
the original concentration. This is due to dilution of the final concentration of each 
reagent as they are added sequentially to the dish; for example, the bacterial extractant 
(50pl) was added to give a final volume of solution of 200pl on the dish.
3.5.4 Preliminary work with 1 Ox ATPase
The S. aureus serial dilution (lOOpl) was placed on a coupon and the lOx ATPase added 
(50pl). This was then followed by the Luciferin-Luciferase reagent (50pl) and 
subsequently read using the Bioprobe (background). Bacterial extractant (50pl) was then
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added and the filter read again. In controls where ATPase was not added, PBW was 
added instead to account for dilution effects.
The lOx ATPase (50 pi) was requested fi"om the manufacturer so that dilution effects 
resulting from the addition of normal apyrase (500pl) could be avoided.
5.5.5 Analysis o f blood samples which have been exposed to A TPase
A 1ml solution containing Isostat isolator reagent (1:50) and lOx ATPase (1:20) in PBW 
had fresh heparinised blood added to give a final blood concentration of 1.5%. The tube 
was vortex-mixed for 30 seconds before being incubated for 60 minutes. Using a 1ml 
plastic syringe, 500pl of sample was removed and filtered through a 25mm (diameter) 
0.45pm Millipore filter. This was flushed, using a 5ml plastic syringe, containing 5ml of 
PBW and the ATP level determined as before.
3.5.6 Method used to evaluate clinical samples
Nine blood samples were taken through the CVC of patients who were receiving total 
parenteral nutrition (TPN) through the CVC. These were all out-patients and all samples 
were collected on the same day. They were stored at 4°C overnight prior to assay. Each 
sample was taken and 15pl added to 1ml of Isostat isolator reagent (0.0014% (v/v)) to 
give a final concentration of 1:66.7). The tubes were vortex-mixed for one minute before 
lOX ATPase was then (final concentration 1:10 v/v) added and the tube vortex-mixed for 
5 seconds. Using a 1ml plastic syringe, 500pl of sample was removed and filtered 
through a 25mm diameter, 0.45pm pore size Millipore filter. Following a flush with 5ml 
of PBW, one drop (50pl) of luciferin-luciferase reagent was added to the filter using a 
1ml syringe. The whole filter was immediately placed in the Bioprobe and the RLUs 
determined. Two drops of bacterial extractant (lOOpl) were then added to the filter and 
the filter RLUs determined again with a further reading immediately taken to show 
whether luminescence was occurring. Additionally all nine samples were spread onto 
blood agar plates and incubated overnight at 37°C.
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3.6 Methods used in conjunction with the LI luminometer
3.6.1 Determination of RLUs using the Mediators LI luminometer
When measuring the ATP concentration of a sample in the Mediators LI, two methods 
were used depending upon which luciferin-luciferase regent was selected.
a) Determination o f ATP concentration using the SL kit
Various volumes (between 700pl and 790pl) of Tris-EDTA buffer (Biothema AB, 
Sweden) were transferred to clean ATP-ffee Eppendorf centrifuge tubes. Each tube was 
placed in the Mediators LI luminometer reading chamber and the SL reagent (200pl) 
added and the RLUs determined over a ten-second period. The sample drawer was then 
re-opened (see Figure 2.5) and the sample (between lOpl and lOOpl) added to give a final 
volume of 1ml. Again the RLU values were automatically determined when the drawer 
was re-closed. The drawer was opened for a third time and ATP standard (lOpl) added. 
The RLUs were again determined and recorded.
b) Determination o f ATP concentration using the HS reagent
The HS reagent (400pl) was transferred to a clean ATP-ffee Eppendorf centrifuge tube, 
which was then placed in the Mediators LI. Following this “blank RLU level” 
determination, between 50pl and 500pl of the vortex-mixed sample was added and the 
RLUs determined again. The volume of sample measured depends upon the extractant 
used; TCA was added in small amounts (<100pl) and DTAB extracts were added in
larger amounts (<500pl). Following this lOpl of an ATP standard was added and the
RLUs determined and recorded.
c) Determination o f ATP concentration
To determine the concentration of ATP in a sample, equation 5 was used:
(Sam ple - Blank) X  Concentration of Standard X  Extraction volume
(Standard - Sam ple) Sam ple volume (5)
where the sample, standard and blank values are reported as RLU. The concentration of 
the standard is usually IpMol/L and the extraction volume is 1.1ml for the DTAB
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method and 2.8ml for the TCA method, and the sample volume measured is between 
lOpl and lOOpl for the TCA method and up to 400pl for the DTAB method.
3.6,2 Method development
a) Concentration o f Triton X-100 required to lyse somatic cells
Various concentrations of Triton X-100 (0 to 4% final concentration) were added to a 
solution containing apyrase (lOU/ml) in excess magnesium ions. After a 30 minute 
incubation to degrade the released ATP, TCA (final concentration 2.5%) was added to 
inactivate the apyrase and release any further ATP. The subsequent ATP level of each 
solution was determined using SL method.
b) Filter flush volume
A solution containing heparinised blood (1:50) in ATP degradation reagent was left for 
60 minutes at room temperature. Aliquots (SOOpl) were filtered through each of four 
25mm diameter (0.2pm) syringe filters. These were then flushed with either 2.5ml, 5ml,
7.5ml or 10ml sterile water before 300pl of TCA (10%) was added and then flushed
using 2.5ml sterile water. The ATP concentrations were then determined using the SL 
method. This was repeated a ftirther three times.
c) Incubation period required for the ATP degradation reagent
ATP was added to the ATP degradation reagent to give a final ATP concentration of 
IpMol/L in a 5ml solution. This solution was vortex-mixed for 5 seconds and after a 2 
minute incubation 550pl was removed and added to 10% TCA (185pl) to stop the ATP 
degradation reagent reaction with ATP. Another 800pl was removed and filtered through 
a 25mm, 0.22pm syringe filter.
This was repeated at intervals of 5, 10, 20, 30, 60 and 120 minutes and these exposed 
immediately to TCA and filtered in the same way. Each sample that was filtered was 
subsequently flushed through with sterile water (7.5ml) and 10% TCA (300pl) added. 
The ATP in each was assayed using the SL reaction.
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d) Incubation time required fo r  TCA
Serial dilutions of stocks of E. coli, S. epidermidis, and C  albicans (to 10’^ ) were 
exposed to a final TCA concentration of 2.5% for either a 1, 2, 3, 5 or 10 minute period. 
At the end of each incubation a sample was immediately taken and the concentration of 
ATP quantified using the SL method. Each was left for one hour and the concentration of 
ATP determined again (control).
This was repeated using the 25mm diameter, 0.2pm pore size syringe filters. The 
organisms were added to the filter and 300pl of TCA (10%) added to each filter for the 
same incubation periods before being flushed from the filter with 2.5ml Tris-EDTA and 
quantified using the SL reaction.
3.63 Methods used specifically with TCA
a) Detection o f microbial serial dilutions in a pure system (TCA extracted)
A ten-fold dilution of the microorganism stock was made from a stock to 10'^. Then 
750pl of each microorganism dilution was added to 10% TCA (250pl) and following a 
vortex-mix for 5 seconds, each of these was left to stand for 20 minutes at room 
temperature. The extract (between 20pl and 50pl) was removed and transferred to an 
ATP-ffee micro-centrifuge tube (Eppendorf, UK) containing Tris-EDTA buffer (between 
750pl and 780pl) and SL reagent (200pl). The RLUs were determined using the SL 
method. In order to determine the number of organisms in each dilution, lOOpl of the 10'  ^
dilution was spread on a blood agar plate (in triplicate) and the readings were compared 
after 24 hours.
The above was also repeated using 20pl of extract in HS reagent (400pl), in conjunction 
with lOpl of lOOnMol/L.
b) Degradation o f ATP from an ATP standard
Various concentrations of ATP standard were exposed to the ATP degradation reagent 
for approximately 20 minutes (room temperature). 150pl of each was removed and added 
to 50pl TCA (10%). Further solutions were set up as above using 1ml of distilled water 
instead of the ATP degradation reagent.
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The ATP bioluminescence assay (SL reagent) was carried out using 20pl of extract 
removed from each of the tubes.
c) Effect o f TCA on S. epidermidis (NCTC11047)
Various concentrations of TCA were added to serial dilutions of a stock of S. epidermidis 
(NCTC 11047) to achieve final TCA concentrations of between 0 and 2%. These were 
left to incubate for 10 minutes at room temperature and the ATP concentration 
determined using the SL method.
d) Effect o f TCA on E. coli
Various concentrations of TCA were added to serial dilutions of a stock of E. coli to 
achieve final TCA concentrations of between 0 and 2%. These were left to incubate for 
10 minutes at room temperature and the ATP concentration determined using the SL 
method.
e) Effect o f TCA on apyrase and 5 ’-adenylic acid deaminase 
Tubes containing 500pl of one of the following were set up:
• MgCl2 (0.0IM) and apyrase (lOU/ml)
• MgCl2 (O.OIM) and 5’-adenylic acid deaminase (0.7U/ml)
• MgCl2 (O.OIM) and apyrase (lOU/ml) and 5’-adenylic acid deaminase (0.7U/ml)
TCA was added to each to achieve various concentrations (0 to 1.2%). These were
vortex-mixed and then left for 10 minutes at room temperature. A final concentration of 
5pmol/L ATP standard was added to each. Again these were left for 10 minutes before 
TCA (10%) was added to each to achieve a final concentration of 4% TCA (to stop the 
reaction). Water was then added to correct the volumes before the bioluminescence assay 
was carried out using the SL reagent.
f)  Buffering ability o f Tris on TCA
Various concentrations of TCA were added to give a final TCA concentration of 2.5% 
(w/v) in final Tris concentrations of O.lmol/L to O.4mol/L. The pH of each was then 
determined. This was repeated using lower concentrations of TCA (0-2.5% ).
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3.6.4 Methods using DTAB
a) Detection o f microbial serial dilutions in a pure system (DTAB extracted)
A ten-fold dilution of the microorganism stock was made to 10' .^ Then 50pl of each of 
these was then transferred to an Eppendorf micro-centrifuge tube (ATP-free) and 0.2% 
DTAB (50pl) added. After a vortex-mix for 5 seconds, each of these was left to stand for 
20 minutes at room temperature. Sterile distilled water (400pi) was then added to each to 
give a final volume of 500pl. In addition, lOOpl of the 10'  ^ dilution was spread on a 
blood agar plate (in triplicate).
The DTAB extract was vortex-mixed for two seconds before 400pl of the Biothema HS 
reagent was added to the Eppendorf micro-centrifuge tube. The number of RLUs was 
determined using the Mediators LI luminometer (settings are a 10 second delay and a 5 
second read time). A subsequent reading was taken and then lOpl of lOOnMol/L standard 
was added to the solution and again the ATP level (RLUs) determined. The readings 
were compared with the plate culture results from the blood agar plates after 24 hour 
incubation.
b) Detection limit o f the DTAB extraction (six clinical isolates)
Clinical isolates were recovered from CVC tips (St George’s Hospital, London, UK) and 
stored using the “Microbead” (Prolab, USA) system. When required, stock cultures were 
grown in nutrient broth and then the broth cultures were serially diluted. The HS reagent 
detection system was used to determine how sensitive the ATP bioluminescence method 
was in detecting low levels of each of the microorganisms. 50pl of the 5 x 10'  ^/ml stock 
was added to 50pl of DTAB (2%). After vortex-mixing for 5 seconds, each of the 
extracts was left to stand for 20 minutes before sterile distilled water (400pl) was then 
added to each giving a final volume of 500pl. The RLU level was determined using the 
HS reagent.
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3.6.5 Formulation of ATP-free a-Cyclodextrin (2.5%w/v)
a) Formulation o f 10% a-Cyclodextrin
a-Cyclodextrin (Sigma C4642) (500mg) was taken and dissolved in 5ml of sterile 
distilled water. 4ml of this preparation was added to 4ml of vigorously shaken “washed” 
Q Sepharose (slurry). The suspension was vortex-mixed for ten seconds and then allowed 
to sediment (15 minutes). The supernatant (6mls) was removed and added to 6mls of 
shaken “washed” Q-Sepharose. Again the suspension was vortex-mixed for ten seconds 
and then allowed to sediment (15 minutes). The supernatant was then aliquoted and 
stored.
b) Washing the Q Sepharose
Washing of the Q Sepharose Fast Flow (Amersham Pharmacia Biotech AB) is necessary 
as it is suspended in a solution containing 40% ethanol. This ethanol needs to be removed 
as it interferes with the HS reagent.
The Q Sepharose was vigorously shaken and approximately 20ml poured off. After 
allowing the slurry to sediment (15 minutes) 6ml of the ethanol supernatant was removed 
and replaced with 6ml of sterile distilled water. The suspension was vortex-mixed for ten 
seconds and then allowed to sediment (15 minutes). A ftirther 8ml was removed and 
replaced with 8ml water. After vortex-mixing and sedimentation this was repeated using 
a ftirther 8ml of water.
3.6.6 Methods used to determine A TP levels on CVC tips
Figure 3.2 illustrates the details of how the FASEB-retrieved samples were tested using 
either a TCA- or DTAB-based method. In both cases the FASEB -retrieved sample was 
added to 1ml of the ATP degradation reagent. This was vortex-mixed for 60 seconds 
before being left to incubate for 60 minutes at room temperature. Following incubation, 
lOOpl was removed fi*om the solution and spread on a blood agar plate. These plates were 
incubated at 37°C overnight. After this initial step the treatment of each sample differed 
and this is described below.
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a) Evaluation o f the '‘TCA method”
Using a sterile 1ml syringe 800|xl of the solution was filtered through a 0.2gm pore size, 
25mm diameter Syrtec filter. The filtrate was discarded and the filter was immediately 
washed by flushing through 7.5ml of sterile distilled water (3 x 2.5ml washes). 10% TCA 
(300pl) was then added to the syringe filter via another sterile 1ml syringe. This time the 
filtrate was collected in a sterile ATP-fi*ee plastic container. After two minutes, 2.5ml 
sterile water was flushed through the filter from syringe and the filtrate collected in the 
same container, giving a final volume of 2.8ml. Seventy-five microlitres of this extract 
was then used in the HS reaction and readings were compared with the plate culture 
results from the blood agar plates after 24 hours.
Using the equation in Section 3.6.1(c) the concentration of ATP in the sample was 
determined. In this case 2.8ml was extracted and flushed to form the sample. However 
only 75 pi of the sample was actually used in the reaction. This equates to approximately 
2.7% of the extracted sample and 2.1% of the original sample.
b) Evaluation o f the DTAB method
Using a sterile 1ml syringe 800pl of the solution was filtered through a 0.2um pore size, 
13mm Nalgene filter. The filtrate was discarded and the filter was immediately washed 
by flushing through 2.5ml of sterile distilled water. 2% DTAB (lOOpl) was then added to 
the top of the syringe filter using a pipette. The DTAB was allowed to slowly 
(approximately 10 minutes) fall through the filter membrane and the filtrate collected in a 
sterile (ATP-free) plastic container. Sterile distilled water (1ml) was flushed through the 
filter from syringe and the filtrate collected in the same container, giving a final volume 
of 1.1ml.
The DTAB extract was vortex-mixed for 5 seconds before 400pl was added to lOOpl of 
2.5% a-cyclodextrin solution in an ATP-free Eppendorf micro-centrifuge tube. This was 
vortex-mixed for 10 seconds and left to stand for 2 minutes before the background ATP 
level (RLUs) was determined. 400pl of the HS reagent was added to the same micro­
centrifuge tube and the ATP level (RLUs) determined, twice.
Using equation 5 in section 3.6.1(c) the concentration of ATP in the sample was 
determined. Here llOOpl were extracted as sample and 400pl of the sample was used in
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the reaction. This equates to approximately 35% of the extracted sample, which is 28% of 
the total sample. Readings were compared with the plate culture results from the blood 
agar plates after 24 hours incubation.
3.7 Cut-off limits and assay performance
The sensitivity and specificity of the technique based upon the ATP bioluminescence 
were determined as shown in Equations 6 and 7:
Sensitivity (%) = (a / (a+c)) x 100 (6)
Specificity (%)= (d / (b+d)) x 100 (7)
Where: a True positive
b False positive
c False negative
d True negative
This was based on the assumption that >100CFU/ml from a FASEB-retrieved sample 
was positive and <100CFU/ml from a FASEB-retrieved sample was negative (Kite et al. 
1997).
fri addition the PV^ and the P V  were determined using Equations 8 and 9.
PV" (%) = (a / (a+b)) X 100 (8)
PV (%) = (d / (c+d)) X 100 (9)
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Transfer FASEB retrieved sample into 1ml of the "ATP degradation reagent", 
vortex-mix (60 seconds) followed by an incubation (60 minutes) at room temperature
Remove 100pl and spread 
on a blood agar plate
TCA extraction method DTAB extraction method
Filter SOOpI of the solution through a 0.2um, 
25mm filter and then flush 7.5ml of sterile 
water (3 x 2.5ml) through the filter
I
Add SOOpI of 10% TCA to the syringe filter whilst 
placed on a sterile (ATP-free) plastic container
1
After a 2 minute incubation flush 2.5ml 
Sterile water through the filter whilst collecting 
the filtrate in the sterile plastic container
Filter SOOpI of the solution through a 0.2um, 
13mm filter and then flush 2.5ml of sterile 
water through the filter
I
Add lOOpI of 2% DTAB to the syringe filter whilst 
placed on a sterile (ATP-free) plastic container
i
After a 2 minute incubation flush 1.0ml 
sterile water through the filter whilst collecting 
the filtrate in the sterile plastic container
i
Vortex-mix the DTAB extract (5 seconds) before 
removing 400pl and adding it to lOOpI of 2.5% a- 
cyclodextrin
i
Vortex-mix this TCA-extracted filtrate for two 
seconds before removing either 75pl for addition 
to 400pl HS reagent, or lOOpI for addition to 900pl 
of SL (in Tris EDTA buffer).
Vortex-mixed this solution (10 seconds) then leave 
to stand for 2 minutes before adding 40Gpl of the 
Biothema HS reagent
The number of RLU’s are then determined using the LI 
(settings here are a 10 second delay and a 5 second read time)
I
Add lOpll of lOnMol/L standard to the solution and determine the RLU value. 
Use this value to determined the concentration of ATP in the sample (mol/L)
1
Compare this concentration of ATP with the CPU count from the blood agar plates
Figure 3.1 Protocols used when evaluating FASEB-retrieved samples (DTAB and TCA 
methods) in conjunction with the LI luminometer at room temperature.
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Structure of the results section
The results section of this thesis is made up of three chapters (Chapters 4, 5 and 6). This 
approach was selected because three specific sections of research were carried out.
Initial research was conducted using two luminometers, the Bioprobe in conjunction with 
its reagent system and the LI with the recommended Biothema AB reagents. Details of 
this preliminary research is reported in Chapter 4, where the off-the-shelf system 
(Bioprobe) was found to be unsuitable as few parameters could be varied and therefore 
optimisation of the technique was difficult. Chapter 5 details research carried out using 
the tube luminometer (LI) and a combination of commercial reagents and laboratory- 
developed reagents. A method was developed and evaluated using clinical samples, 
however improvements were identified to improve the performance of the technique. In 
Chapter 6 the further development and optimisation of the technique evaluated in Chapter 
5, is reported. This work was mainly centred around a new microbial lysis agent, 
resulting in the development of a modified technique, which was evaluated using clinical 
samples and the results analysed to determine the potential usefulness of the assay.
Display of results
Results are displayed as bar graphs, or occasionally as line graphs, showing the mean ± 
the standard deviation (SD) of a series of four experiments. Values plotted are either the 
original RLU values or in cases where a standard was used, as the ATP concentration (in 
mol/L). In cases where a small change in ATP level is displayed, results are displayed as 
a percentage of a control.
CHAPTER FOUR
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4.1 Background
In Chapter 2 ATP bioluminescence was identified as a useful technology that could 
potentially form the basis of a rapid test system for the detection of catheter-associated 
infection. Two luminometers were chosen for further evaluation: the Bioprobe 
luminometer and its associated reagent system (Hughes-Whitlock, UK) and the LI 
luminometer (Mediators, Austria) in conjunction with the recommended Biothema AB 
luciferase reagents.
The objective of this section was to determine which one of these two ATP 
bioluminescence detection systems is most appropriate for further use in this study. 
Experiments based on both for the systems are reported in this chapter. Initially the 
sensitivity of the systems were determined, with subsequent investigations involving the 
development of strategies to remove non-microbial contaminating ATP firom the sample, 
before the release and detection of microbial ATP.
4.2 The Bioprobe and associated reagents
The Bioprobe is supplied as an off-the-shelf instrument with the manufacturer also 
supplying all the reagents that are necessary for determining ATP levels. Therefore, 
reagents such as the bacterial lysis agent and the ATPase have been optimised, by the 
manufacturer, for use with the luciferase-based reagents.
In this section preliminary experiments were conducted to determine how sensitive the 
system is and if  further optimisation of the reagents were necessary.
4.2.1 Release and detection of microbial A TP
A bacterial lysis agent (Hughes Whitlock, UK) was used to lyse microorganisms so that 
intracellular ATP could be released. The manufacturers suggested that a final 
concentration l:5(v/v) of the supplied concentration would be adequate to lyse most 
bacteria and yeast species. This was confirmed when serial dilutions (to 10'^) of stocks of 
S. aureus, E. coli and C. albicans were exposed to various final concentrations of the 
bacterial lysis agent (1:5 to 1:2.5) and subsequent spread plate incubations reported <1 
CFU/ml present.
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A lucerin-luciferase reagent (Hughes Whitlock, UK) was used to detect and quantify the 
ATP that was released. The luciferin-luciferase reagent was used at a concentration of 1:5 
(v/v) of that supplied, as suggested by the manufacturers.
4.2.2 Sensitivity
The sensitivity of the Hughes-Whitlock reagents and Bioprobe luminometer was 
determined using the bioluminescence assay method described in Section 3.5. Figures
4.1, 4.2 and 4.3 show the detection limit for each of the three serial dilutions of stock 
microorganisms. In Figure 4.1 it can be seen that for S. aureus there is only good 
differentiation between the contaminating and microbial ATP at a level equivalent to 
10,000 CFU/ml. Figure 4.2 displays a level of between 100,000 and 1,000,000 CFUs for 
a serial dilution of E. coli and in Figure 4.3 there is good differentiation for C. albicans at 
the 1000 CFU/ml level.
In each of Figures 4.1, 4.2 and 4.3 it was observed that the limit of detection is dependent 
upon the level of background ATP present within the sample. This non-specific, 
contaminating ATP is naturally present within the broth and is only reduced through 
dilution of the broth; thus the higher the concentration of organisms then the higher the 
concentration of contaminating ATP.
In an attempt to reduce this level of contaminating ATP, the stock cultures were 
“washed” in PBW using a centrifugation method described in Section 3.4.3. However, 
this was found to be ineffective because even though the concentration of contaminating 
ATP was reduced, the ATP released from the microorganisms was much lower than 
expected. This was presumably due to the level of stress the microorganisms were put 
under during the centrifugation process, which led to depletion of their intracellular ATP.
4.2.3 Removal of contaminating ATP
In Section 4.2 it was observed that relatively high levels of contaminating ATP remain in 
the sample. In order to improve on sensitivity and specificity this contaminating ATP 
needs to be removed. To do this an ATPase (Hughes Whitlock, UK) was evaluated.
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Figure 4.1 Relative light units detected before (blue) and after (yellow) lysis of a serial dilution of S.
aureus. Each bar represents the mean ± SD of four experiments.
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Figure 4.2 Relative light units detected before (blue) and after (yellow) lysis of a serial dilution of E.
coli. Each bar represents the mean ± SD of four experiments.
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Figure 4.3 Relative light units detected before (blue) and after (yellow) lysis of a serial dilution of C.
albicans. Each bar represents the mean ± SD of four experiments.
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a) ATPase
The manufacturer suggested that the ATPase should be used at a concentration of 1:10 
(v/v) of that supplied. However, it was found that concentrations of 1:2 (v/v) were 
necessary to degrade the high levels of contaminating ATP present in serial dilutions of 
broth cultures. This created a problem in that adding more ATPase to an aliquot of a 
solution containing microorganisms resulted in a large dilution of the sample leading to 
the requirement for larger volumes of bacterial lysis reagent and luciferase reagents.
After consultation with the manufacturer, a ten times more concentrated ATPase (Hughes 
Whitlock, UK) was then obtained and Figure 4.4 shows that a 10% (v/v) final 
concentration of this lOx ATPase was much more effective at degrading the 
contaminating ATP. It can be clearly seen that the level of contaminating ATP is reduced 
to a low background level that is independent of the concentration of S. aureus. It can 
also be observed that the detection limit for S. aureus has improved from that observed in 
Figure 4.1 and is now <10,000 CFU/ml.
b) Release and degradation ofATP from somatic cells
In order to remove contaminating ATP from a sample it is less than adequate to simply 
add ATPase. A solution containing somatic cells, such as red blood cells and platelets, 
will require cell lysis so that all the intracellular ATP is released for subsequent 
degradation by the lOx ATPase.
Fresh heparinised blood was used as a source of non-microbial ATP. Preliminary 
experiments used a 1:66.7 (v/v) final concentration in 1ml. This particular volume was 
chosen because the FASEB collects between 10 and 15mg of material from a CVC and if 
this were dissolved in 1ml it would also give a concentration of approximately 1.5%.
The Isostat isolator reagent (Oxoid, UK) described in Section 3.2.3, was chosen as a 
possible somatic cell lysis agent. This particular reagent is routinely used in clinical 
microbiology laboratories for the lysis of red and white blood cells, prior to microbial 
cell concentration by centrifugation. Investigations were carried out to determine if this 
reagent could effectively lyse somatic cells. Various concentrations of the isolator
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Figure 4.4 Relative light units detected in serial dilutions of S. aureus. Each bar represents the mean 
± SD of four experiments where RLU values were determined before ATPase was added, 
after ATPase (10% v/v) was added and after bacterial lysis agent was added.
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reagent (0 to 0.02% v/v) were used in combination with lOx ATPase to degrade the 
released ATP. Subsequent addition of bacterial lysis agent lysed any intact cells and the 
remaining ATP was subsequently assayed.
Figure 4.5 shows that the optimum concentration at which somatic cell lysis occurs is 
between a final concentration of 0.001 and 0.002 % of the isolator reagent.
The isolator reagent is supplied in a tube containing 700pl of liquid. Its final working 
concentration is 7.0% (v/v) when blood is added to make a final volume of 10ml. A 
concentration of 2% of the 7% working solution was found to give optimum cell lysis. 
Therefore 0.0014% (v/v) isolator reagent in PBW was used in further experiments.
4,2.4 Filtration o f  sample
In section 4.2.3 it was observed that the use of the isolator reagent (0.0014% v/v) in 
combination with ATPase (10%) effectively releases and degrades the ATP released 
from a heparinised blood sample (l:66.7v/v). However, the level of ATP remaining is 
still relatively high and this reduces the potential sensitivity and specificity of the assay. 
To lower the concentration of ATP remaining, syringe filtration was evaluated in 
combination with the isolator reagent.
a) Filter characteristics
Two standard 25mm diameter syringe filters (Millipore, USA) were chosen for 
evaluation. One had a pore size of 0.2pm whilst the other has a pore size of 0.45 pm. The 
25mm diameter gives a relatively large surface area for the sample to spread over, with 
the result that any microorganisms that are present could collect on the filter membrane 
without causing a blockage of the membrane pores.
Serial dilutions (to 10’^ ) of stock solution of S. aureus, E. coli and C. albicans were 
passed through each of the two syringe filters and it was determined after subsequent 
culture of the filtrate that no microorganisms passed through either the 0.2pm or 0.45 pm 
filters. However, it was observed that increasing physical force was required to pass a 
solution containing the high concentrations of microorganisms through the 0.2pm filter. 
This was presumably due to microorganisms blocking the smaller pores of the 0.2pm 
filter. It was also determined that both had a hold-up volume of approximately 400pl and 
a post-air-purge hold-up volume of 220pl.
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Figure 4.5 Effect of a combination of lOx ATPase and various concentrations of isolator reagent on 
the ATP concentration remaining in fresh heparinised blood (1:66.7 v/v). Each bar 
represents the mean ± SD of four experiments. The control was the ATP concentration 
observed in a blood sample that was not exposed to isolator reagent.
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b) Determination o f microbial ATP concentration
The manufacturer of the Bioprobe luminometer suggested that ATP from the sample 
contained within a syringe filter could be determined if  the luciferase was added to the 
filter and the whole unit placed in the reading area of the luminometer, where the RLUs 
would be determined through the filter. In order to do this however, an appropriate 
volume of the luciferase reagent needs to be added. Therefore, it is important to take into 
account the hold-up volume in the syringe filter as any luciferase added to the filter will 
be diluted by liquid already present.
In Section 4.2.1 it was observed that RLUs could be determined by adding 50pl of 
luciferase to the sample to achieve a final luciferase concentration of 1:5 (v/v). As the 
hold-up volume here is ~220pl a decision was made to again use 50|xl of luciferase as 
this would give a final concentration of just under 1:5 (v/v) luciferin-luciferase.
c) Volume o f bacteriallysis agent required
A similar situation exists with the bacterial lysis agent where once the microorganisms 
are isolated onto the filter membrane, it is necessary to lyse them so that the ATP is 
released. Previous experiments on the silver coupons demonstrated that the bacterial lysis 
agent could be added to a large volume of sample as long as a final concentration of >1.5 
(v/v) was achieved.
Although 50pl should be adequate, an evaluation was conducted to determine if bacterial 
lysis agent (lOOpl) should be added to the filter in order to achieve complete lysis. Figure
4.6 illustrates that there is little difference between the addition of 50pl or lOOpl (to 
achieve a final concentrations of 18.5% and 31.1% v/v respectively) of bacterial lysis 
agent to various concentrations of E. coli in terms of the final RLU signal.
d) Sample volume added to filter
A sample volume of 500pl was passed through each filter. This represented 50% of the 
original sample. It was observed that addition of sample volumes of >500pl led to 
increased pressure being exerted on the filter, which may be due to the filter pores getting 
blocked.
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Figure 4.6 The RLU values detected from a serial dilution of E. coli, where the ATP is extracted 
using either 50gl or lOOgl (18.5% or 31.1%) of bacterial lysis agent. Each bar represents 
the mean ± SD of four experiments.
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e) Flush volume
After the sample has been added to the filter it needs to be flushed through the filter, 
otherwise it will remain there forming part of the hold-up volume. Various volumes (1- 
10ml) of PBW where flushed through both the 0.2pm and 0.45pm filters. It was found 
that at least 5ml of PBW was required to remove any material that could be seen with the 
naked eye on the syringe filter membrane.
J) Analysis o f blood samples taken through CVCs
The basic extraction method was challenged with blood samples drawn through the 
CVCs of nine home TPN patients in an outpatient clinic (Leeds General Infirmary). An 
aliquot of each of the blood samples was added to the isolator reagent and lOx apyrase 
added to give final concentrations of blood (1:66.7) and apyrase (1:10). These then had 
their ATP assayed as in Section 3.5 and the RLU values are reported for each in Table
4.1.
In seven of the nine samples an RLU value of greater than the background was observed. 
This suggested that these seven samples had significant levels of microorganisms. 
However, when these RLU values were compared to the CPUs obtained in plate culture it 
was observed that eight of the nine samples grew no colonies. Sample number four did 
grow 50 colonies but it was one of the two samples that had an RLU value lower than its 
background.
4.3 The LI and Biothema AB reagents
The LI luminometer, supplied by Mediators, is a stand-alone instrument. Mediators do 
not supply reagents for use with this luminometer, however, representatives from 
Mediators did recommend the Biothema AB luciferin-based reagents. Unfortunately, 
these only comprise just the luciferase and luciferin reagents, with associated buffers. 
Through conversations with Mediators and Biothema recommendations for microbial 
lysis agents were chosen (Lundin 2000, Lundin 2000 personal communication) and these 
were evaluated.
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4.3.1 Detection limit o f SL and HS reagents
Using serial dilutions of an overnight stock of S. epidermidis (NCTC 11047) the 
detection limit of the ATP bioluminescence assay using the Mediators LI luminometer 
was determined in combination with two types of luciferin-luciferase reagent (HS and 
SL) supplied by Biothema AB, and a TCA based extraction method.
Figure 4.7 shows the calibration curves determined using each of the two reagent 
systems, where 20pl of extract is measured in both. In each case the plotted values are 
the mean for four replicates of the S. epidermidis serial dilution. The CFU values were 
determined using a mean of triplicate spread plate CFU values (10^ to 10’^  dilutions).
The CFU values represent the number of cells that are present within the reaction tube, 
which is approximately 1.5% of the original sample.
Figure 4.7 demonstrates that the HS reagent is the more sensitive of the two reagents 
with its detection limit in the 10 to 100 CFU region. As for the SL reagent there is poor 
differentiation at the 10 to 100 CFU level but it does improve between 100 and 1000 
CFU. However, the RLU levels report with the SL reagent are much lower than those 
observed with the HS reagent.
4.3.2 Lysis of the microbial cells and release of ATP - TCA
As stated in Section 2.7, the use of TCA is a standard method to lyse microbial cells, and 
by which all other microbial lysis agents are compared. Its chaotropic properties at a final 
concentration of 2.5% w/v are well documented (Lundin 2000).
a) Effect o f TCA on S. epidermidis (NCTC 11047) and E. coli 
After exposure of a known concentration of S. epidermidis (5.5 x 10  ^ cells) to various 
concentrations of TCA, it was observed that a final TCA concentration of > 0.1% led to 
complete lysis of all S. epidermidis cells. Similar results were observed with E. coli cells, 
where complete lysis of all the cells occurred with TCA (0.25%).
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Figure 4.7 A standard curve showing the relationship between the RLUs and S. epidermidis cells
(CFU) using the SL and HS reagents (Biothema AB, Sweden). Each point represents the
mean ± SD of four experiments.
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b) Effect o f TCA concentration on the luciferin-luciferase reaction (SL Reagent)
The instructions for use supplied with the SL kit by Biothema AB (Appendix 2) 
suggested that the sample volume added to the Tris-EDTA buffer and SL reagent should 
not be such that it leads to >50% inhibition of the light emission. In Figure 4.8 it is 
demonstrated that if the sample contains a final concentration of approximately 0.1% 
TCA, then there is 50% inhibition of the signal that would normally be observed when no 
TCA is present (control). In this case if the extracted sample has a final concentration of 
2.5% TCA, only 20pl can be removed and measured in a 1ml reaction containing SL 
reagent buffered in Tris-EDTA.
c) Effect o f TCA on the HS reagent
Increasing the TCA concentration lowers the RLU signal from the HS and standard 
reaction. Figure 4.9 shows the gradual decrease in RLU values as the concentration of 
TCA is increased from 0 and 0.2%. It can be seen that at a final concentration of 0.2% 
TCA approximately 60% of the control signal is observed.
d) Effect o f various concentrations o f Tris buffer on TCA
In order to suppress the inhibitory effects of the TCA on the luciferase reagent an attempt 
was made to buffer the TCA. It was observed that TCA (<0.25% w/v) had a pH of 7.8 in 
0.5mol/L Tris and that TCA concentrations of <0.1% have a pH of 7.8 in O.lmol/L Tris. 
However, at the final working concentration of TCA (2.5%) that are likely to be observed 
in this study. Tris (0.5 mol/L) was unable to buffer the TCA and the pH remained at 1.7.
Moreover, as Figure 4.10 illustrates, increasing the concentration of Tris from O.lmoFL
to 0.4mol/L also attenuates the RLU signal from the HS and standard. Therefore, if  TCA 
is used then the most effective strategy for maintaining an optimum pH of 7.75 for the 
luciferase to fimction, is to reduce the TCA concentration through dilution of the sample 
in Tris-EDTA buffer.
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Figure 4.8 Effect of TCA on the signal emitted by the SL reagent and an ATP standard in Tris-
EDTA buffer. Each bar represents the mean ± SD of four experiments.
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Figure 4.9 Effect of TCA on the signal emitted by the HS reagent and an ATP standard in Tris- 
EDTA buffer. Each bar represents the mean ± SD of four experiments. Note that six 
concentrations were originally selected (between 0 and 0.125%(v/v)) as in the SL work 
above in section 4.3.2b, however an extra three concentrations (0.15, 0.175 and 
0.20%(v/v)) were required investigated as <60% had not been achieved at 0.15%(v/v).
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Figure 4.10 Effect of Tris concentration in the buffer used in the reaction between the HS reagent and
an ATP standard. Each bar represents the mean ± SD of four experiments.
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4.3.3 Lysis of the microbial cells and release o f ATP- Bactolyse
a) Concentration required for bacterial cell lysis
The use of a commercially available microbial cell lysis agent called “Bactolyse” 
(Lumitech, UK) was evaluated (Section 3.2.3), Preliminary investigations using serial 
dilutions of stocks of E. coli, S. epidermidis and C. albicans (10^ to 10'^) in Bactolyse 
(concentration of 50% (v/v) of that supplied) demonstrated that Bactolyse does indeed 
lyse microbial cells as none of the stocks reported any CPUs after subsequent plate 
culture.
b) Effects o f Bactolyse on luciferase
Figure 4.11 demonstrates that using increased volumes of Bactolyse extracted sample, 
subsequently leading to an increase in the concentration of Bactolyse in the final reaction 
tube, reduces the signal emitted from the standard - SL reaction. This is a similar effect as 
observed with TCA in Section 4.3.2, where the microbial lysis agents are inhibiting the 
luciferase reaction in a concentration-dependent manner. In this case the use of Bactolyse 
is of no real advantage over TCA. Moreover Bactolyse is a commercially available 
reagent of unknown formulation and this too makes it unattractive for further evaluation 
in this study. Moreover the chaotropic properties of the Bactolyse were investigated and 
it was observed that Bactolyse, at its supplied concentration, had little inhibitory effect on 
the activity of apyrase (1 to 20 Units/ml) in excess MgCb (>0.02 Mol/L).
4.3.4 Lysis of the microbial cells and release of ATP -  Triton X-100
Triton X-100 is a detergent that has been evaluated with clinical samples (Lundin et al. 
1975). Its potential usefulness in this investigation was evaluated using blood cells 
obtained from freshly drawn blood samples.
a) Concentration required to lyse somatic cells
Using fresh heparinised blood (1:100) the optimum concentration of Triton X-100 
required for lysis of non-microbial cells was determined. It was observed that a final 
concentration of between 0.1 and 0.2% Triton X-100 was required for the highest level of
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Figure 4.11 Effects of various concentrations of Bactolyse-extracted sample on the signal produced 
by the SL reagent (9.5% v/v) and an ATP standard. The control does not contain any 
Bactolyse-extracted sample (just Tris-EDTA, SL and ATP standard). Each bar represents 
the mean ± SD o f four experiments.
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cell lysis. This is illustrated in Figure 4.12 where the concentrations of ATP remaining 
after lysis of blood cells with various concentrations of Triton X-100 (0.02 to 0.8% v/v) 
are shown. Post-lysis, apyrase (lOU/ml) was added to degrade the ATP and TCA (2.5% 
final concentration) added to inhibit the apyrase and lyse any remaining cells. The graph 
shows that low concentrations of Triton X-100 (<0.1% v/v) do not result in high levels of 
somatic cell lysis, therefore a higher concentration is required. However, concentrations 
of Triton X-100 (>0.2% v/v) also give poor cell lysis. As a result a concentration of 0.1% 
Triton X-100 was adopted for use in this study.
b) Effect o f Triton X-100 on microbial cells
Triton X-100 (0 to 2%) was found to have no adverse effects on stock serial dilutions
(10"  ^to 10"^ ) of S. aureus and E. coli (in triplicate) after the organisms were exposed (30
minutes) to the Triton X-100 prior to overnight culture. The data is not shown here but 
there was basically no difference in CFU counts between organisms exposed to Triton X- 
100 and controls in PBW.
4,3,5 Degradation of released ATP- apyrase
ATP released from non-microbial cells can be degraded using enzymatic or physical 
means. The use of ATP degrading enzymes, such as apyrase, is popular (Sakakibara et al. 
1997) and investigations using such enzymes are detailed below.
a) Grade Selection
Preliminary experiments involved apyrase grade I (A-6132, Sigma, UK), which is 
partially purified with a low adenosine 5’-triphosphatase (ATPase) activity and variable 
adenosine 5’-diphosphatase (ADPase) activity. This particular grade was found to be of 
little use as very high concentrations (-100 U/ml) were required for effective ATP 
degradation. Experiments using apyrase grade I (<20 U/ml final concentration) were 
found to be ineffective at reducing the relatively high concentrations of ATP released 
from fresh heparinised blood cells (1:50).
Following this initial work a grade III apyrase (A-7646, Sigma, UK) was chosen for use 
in this study. It is partially purified with ten times higher ATPase activity than the grade I 
apyrase and it too has variable ADPase activity.
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Figure 4.12 The concentration of ATP remaining in blood cells (diluted 1:100) after lysis with various 
concentrations of Triton X-100 and subsequent treatment with apyrase and TCA. Each 
point represents the mean ± SD o f four experiments.
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b) Preparation o f apyrase stock
It became necessary to filter the reconstituted apyrase prior to storage and / or use, as the 
level of contaminating ATP in the reconstituted solution was high (>50 pmol/L). The 
method that was elucidated to prepare ATP free apyrase solutions (lOOU/ml) is detailed 
in Section 3.2.2. This method involves the filtration and washing of a highly concentrated 
solution of apyrase through a 0.22pm, 25mm syringe filter.
c) Effective apyrase (grade III) and magnesium ion concentration
In order for apyrase to function properly, the presence of a divalent metal ion, such as 
magnesium, is required. Preliminary experiments to determine a suitable apyrase 
concentration for the degradation of ATP were carried out in excess magnesium chloride 
(0.05 mol/L) using sterile distilled water. The optimum working concentration for 
apyrase was found to be in the range of 5 to 20 U/ml. Figure 4.13 shows that after a 10 
minute incubation in excess magnesium ions, apyrase (lOU/ml) will degrade a high level 
of ATP to leave <600 pmoFL of ATP remaining.
Further investigations using apyrase (lOU/ml) in the presence of various concentrations 
of magnesium chloride (0 to 0.2moFL) are shown in Figure 4.14. Here it can be seen that 
there is little difference in the activity of the apyrase (lOU/ml) in the presence of >0.02 
mol/L magnesium chloride. This led to the selection of a magnesium ion concentration of
0.02 moFL for use in all future experiments involving apyrase (lOU/ml).
Additionally, it was demonstrated that magnesium chloride (0.02moFL), in the presence 
of apyrase (lOU/ml), had no adverse affects on the ATP content of S. epidermidis and E. 
coli or the function of 0.1% Triton X-100.
d) Apyrase in combination with magnesium chloride and Triton X-100
The effect of a combination of apyrase (lOU/ml), magnesium chloride (0.02 moFL) and 
Triton X-100 (0.1% v/v) on a standard level of pure ATP as well as ATP released from 
blood cells was investigated with the results shown in Table 4.2. It was demonstrated that 
incubation of fresh heparinised blood (1:50) in a solution containing apyrase (lOU/ml), 
magnesium chloride (0.02 moFL) and Triton X-100 (0.1% v/v) gave similar levels of
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Figure 4.13 Effect of various concentrations of apyrase (grade III) on the degradation of a known
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Chapter Four Pa2e 163
100
O)C
1!
II
;
10
0.01 0.02 0.04 0.06 0.08 0.1
Magnesium chloride concentration (Mol/L)
0.2
Figure 4.14 Effect of various concentrations of magnesium chloride on the activity of apyrase 
(lOU/ml). The control contains apyrase (grade I I I )  only. Each bar represents the mean ± 
SD of four experiments.
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Table 4.2 Effect o f a combination o f apyrase (lOU/ml), magnesium chloride (0,02 Mol/L) and 
Triton X-100 (0.1% v/v) on ATP concentrations (n/Mol/L) from ATP standards and from 
ATP released from blood cells. Results shown are the mean o f four (±SD) four separate 
experiments.
Sample Sequential addition * 
nMol/L (SD)
Simultaneous 
incubation nMoi/L (SD)
A TP standard (50nmol/L) 0.54 (0 .13) 0.59 (0 .19)
Heparinised blood (1 ;50) 9.61 (1 .57) 9 .28  (0 .99)
Platelet rich plasma (1 :50) 5.1 (0 .68) 5.6 (1 .17)
Sample exposed to Triton X-100 for 10 minutes before apyrase and added.
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degradation as incubation of fresh heparinised blood (1:50) in a solution containing 
Triton X-1 GO, followed by the sequential addition of apyrase. It was also observed that 
this combination of chemicals had no adverse effect on serial dilutions of E. coli and S. 
epidermidis.
4.4 The LI system versus the Bioprobe system
When using the Bioprobe system to lyse blood cells and degrade the released ATP, it was 
observed that the Isostat isolator reagent in combination with the ATPase was partially 
effective. However, a relatively high level of contaminating non-microbial ATP still 
remained within each sample. The addition of filtration to the method was evaluated, but 
in Section 4.2.4(f) it was observed that the results obtained using the Bioprobe system 
were of no clinical benefit and therefore the method based on this instrument and 
reagents was of no clinical use. In order to detect microbial ATP, all non-microbial ATP 
needs to be removed from the sample. This sample preparation is crucial, with ATP from 
white and red blood cells as well as platelets needing to be extracted and removed. If this 
is not achieved, contaminating ATP would form a significant proportion of the sample 
and therefore the ATP released from the microbial cells would be lost in this 
contaminating background ATP.
The major reason for the poor performance of the Bioprobe and associated reagents is 
that they constitute an “off-the-shelf’ system and it was difficult to vary the 
concentrations of component reagents and, therefore, effectively vary parameters during 
the development phase. In addition, the fact that some of the component chemicals that 
make up reagents are unknown further complicates the situation. Figure 2.7 in Section 
2.7 illustrated the three main obstacles that needed to be overcome in order to develop a 
method based upon ATP Bioluminescence. The first two steps cannot adequately be dealt 
with without knowing the constituent components of the reagents used to lyse cells and 
degrade ATP.
By using the LI luminometer in combination with Biothema luciferase reagents and 
other chemicals it was possible to vary parameters much more freely. Background RLU 
levels could be reduced using a combination of chemicals as shown in Table 4.2.
Thus the LI luminometer, Biothema reagents and various chemicals were selected for 
use in further development. The main reasons for this selection are summarised below:
Chavter Four__________________________________  Pa^e 166
1. The concentrations of components such as apyrase, Triton X-100 and TCA can be 
easily varied, so that optimisation of a method is more straightforward.
2. The luciferase reagents supplied by Biothema worked well with the LI luminometer. 
In addition the Biothema reagents include an ATP standard which means that ATP 
concentrations can be determined from the detected RLU values are designed
3. The LI luminometer is more sensitive than the Bioprobe in that low levels of ATP 
can be detected.
Further investigation and optimisation of the technique based upon the Mediators LI is 
required so that a sample containing intact microbial cells with no non-microbial ATP 
could be obtained. This further development is described in Chapter 5, where the 
Mediators LI luminometer and luciferin-luciferase based kits supplied by Biothema AB 
(Sweden) are exclusively used. Chapter 5 also details the development of a reagent and 
method, based on a number of enzymes and physical techniques, which could be used to 
remove non-microbial ATP and release microbial ATP for detection and quantification.
CHAPTER FIVE
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5.1 Background
In Chapter 4 it was reported that the use of an off-the-shelf luminometer (the Bioprobe) 
and reagent system was of no clinical benefit. However, the Mediators LI luminometer 
used in conjunction with laboratory-formulated reagents did provide a system that could 
potentially degrade substantial levels of background ATP prior to extraction and 
detection of microbial ATP. Further development using the Mediators LI luminometer 
and luciferin-luciferase based kits supplied by Biothema, was carried out and is described 
in this chapter. This includes the development of a reagent and method that could be used 
to remove non-microbial ATP and release microbial ATP for detection and 
quantification.
5.2 Optimisation of the LI-based method
5.2,1 Improving the level o f degradation
In Section 4.3 it was determined that apyrase alone was ineffective at removing high 
levels of contaminating ATP. The possibility of using alternative enzymes or a 
combination of enzymes to improve the level of ATP degradation was investigated. Two 
enzymes were identified as potentially beneficial: adenosine phosphate deaminase and 
5’- adenylic acid deaminase. The combination of adenosine phosphate deaminase and 
apyrase has previously been investigated by Sakakibara et ah (1997) where 
contaminating ATP concentration was successfully degraded to -IpMoFL. This level 
was set as a target in the present study, but unfortunately a source for adenosine 
phosphate deaminase could not be found in the UK and shipping costs from Japan were 
extremely high. Therefore, the usefulness of this enzyme was not investigated. However, 
5’- adenylic acid deaminase (A1907, Sigma, UK) was obtained. This enzyme breaks 
down 5’-AMP to 5’-IMP (Inosine monophosphate) through a deamination reaction. Its 
usefulness in combination with apyrase in magnesium ions (0.02moFL) was evaluated.
a) Apyrase in combination with 5 adenylic acid deaminase
The effect of 5’ adenylic acid deaminase (concentrations of O.lU/ml to lOU/ml) in 
conjunction with apyrase (lOU/ml), magnesium chloride (0.02 moFL) and Triton X-100 
(0.1% v/v) on the ATP concentration of platelet-rich plasma (1:50) is shown in Table 5.1.
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Table 5.1 Concentration o f ATP remaining after platelet-rich plasma (1:50) is exposed to various
concentrations o f 5’ adenylic acid deaminase in conjunction with apyrase (lOU/ml), 
magnesium chloride (0.02 Mol/L) and Triton X-100 (0.1% v/v). Values shown are the 
mean (±SD) o f four experiments.
Table 5.2
5 ’ a d e n y lic  a c id  d e a m in a s e  M ean  (±S D ) A T P c o n c e n tr a t io n  
c o n c e n tr a t io n  (U /m l) (pM ol/L)
Control * >10,000
0 4632 (166.1)
0.1 1547 (42.3)
0.2 964 (29.4)
0.5 5 8 2 (2 1 .8 )
1 5 9 6 (1 9 .7 )
5 573 (18.5)
10 6 1 8 (2 2 .9 )
* The control was the ATP concentration of the piateiet-rich plasma in Triton X-100 (0.1%) only.
Degradation o f various concentrations o f ATP by the ATP degradation reagent. Values 
shown are the mean o f four experiments.
A T P c o n c e n tr a t io n  
(nM ol/L)
A T P c o n c e n tr a t io n  % A T P  
(nM oi/L) a fte r  e x p o s u r e  r e m a in in g  
to  th e  A TP d e g r a d a t io n  
r e a g e n t
69.48 0.050 0.072
109.10 0.053 0 .048
195.42 0.053 0 .0 2 7
258.24 0.062 0.024
350.86 0.082 0 .023
558.87 0.057 0 .010
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In Figure 5.1 it can be seen that a high level of degradation occurs with the addition of > 
0.5U/ml 5’ adenylic acid deaminase.
Figure 5.1 demonstrates that the combination of 5’ adenylic acid deaminase (0.5U/ml and 
apyrase (lOU/ml) produces a higher level of degradation from a pure ATP sample than 
the use of either of these enzymes individually.
b) Effect o f magnesium concentration
Further experiments were conducted using heparinised blood (1:25) to determine the 
optimum magnesium ion concentration required when both 5’ adenylic acid deaminase 
and apyrase are present together. It was reported that there was little difference between 
results with 0.02mol/L (38,453 RLUs) and 0.2mol/L (37,237 RLUs). Therefore, the 
optimum magnesium ion concentration, when used with heparinised blood (<1:25), 
remains 0.02moFL magnesium chloride.
c) Effect o f 5 ’ adenylic acid deaminase on microorganisms
It was also observed that S. epidermidis cells were not affected by 5’ adenylic acid 
deaminase (up to 5U/ml), when exposed for 30 minutes prior to overnight culture.
5.2,2 Effectiveness o f the A TP-degrading reagent
In Section 5.2.1 the combination of 5’ adenylic acid deaminase (0.5U/ml), apyrase 
(lOU/ml), magnesium chloride (0.02 mol/L) and Triton X-100 (0.1% v/v) degraded high 
levels of ATP. Further experiments were carried out using these reagents in combination 
and for simplicity this combination of enzymes and chemicals was termed “ATP 
degradation reagent”.
Table 5.2 shows that when various concentrations of ATP standard are exposed to the 
ATP degradation reagent, >99% of the ATP is removed. Samples reporting between 
69.48 to 558.87 nmol/L were reduced to <0.1 nmoFL. Further experiments were carried 
out and in Table 5.3 platelet-rich plasma which had an ATP concentration of 60.32 
nmol/L, was degraded to 0.058 nmol/L after exposure to the ATP degradation reagent. 
Similar levels of degradation were evident with heparinised blood (393.56 nmoFL to 
0.584 nmoFL) although the concentration of ATP was initially higher - due to the more
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Figure 5.1 Effect of various enzyme combinations within a solution containing magnesium chloride 
(0.02 mo EL) and Triton X-100 (0.1% v/v) on the degradation o f a known concentration 
of ATP. Each bar represents the mean (±SD) of four experiments.
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homogeneous distribution of white and red blood cells, in addition to platelets. From this 
it was evident that in samples with a high number of blood cells there will be a problem 
degrading contaminating ATP.
The ATP degradation reagent was shown to have no adverse affects on the ATP content 
of serial dilutions of S. epidermidis, C. albicans and E. colt when exposed for 30 
minutes prior to overnight culture.
5.2.3 Further improvements to the A TP degradation reagent
hi Sections 5.2.2 it was demonstrated that the ATP degradation reagent improved upon 
the release and degradation of ATP associated with non-microbial cells without adversely 
affecting the microbial cells. The formulation of this working reagent is shown in Table
3.3 in Chapter 3. However, despite this level of degradation, somatic ATP concentrations 
could still be higher than the concentrations of ATP, which would be present in some 
CVC samples. Therefore, other enzymes and techniques were investigated in order to 
achieve the highest level of ATP degradation that is possible.
a) Hexokinase
Exposure of fresh heparinised blood (dilutions from 1:16.7 to 1:50) to the ATP 
degradation reagent in the presence of hexokinase (1 to lOU/ml) did not lead to an 
increase in the level of ATP degradation aheady observed.
b) Incubation periods
An attempt was made to improve the level of degradation by increasing the time that the 
sample was exposed to the ATP degradation reagent at room temperature. Figure 5.2 
illustrates the effects of various incubation times and it was observed that a minimum of 
10 minutes was required to achieve a high level of degradation. However, as optimal 
degradation of ATP occurred between a 30 to 60 minute incubation period, a 60-minute 
incubation period at room temperature was chosen as the most appropriate for sample 
exposure to the ATP degradation reagent. Further experiments using this incubation 
period but conducted at 30°C and 37°C did not improve upon the level of ATP 
degradation.
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Figure 5.2 Determination o f the optimum incubation time required for the ATP degradation reagent 
to degrade ATP from an ATP standard. Each point represents the mean ± SD o f four 
experiments.
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5.2,4 Inhibition of the ATP-degrading enzymes
In Section 4.3 the concentration of TCA required to lyse microorganisms was determined 
to be 0.25%. Further experiments were conducted to determine if this concentration of 
TCA would be adequate to simultaneously inhibit the ATP-degrading enzymes that are 
released from the microbial cells and those that are present due to the ATP degradation 
reagent.
a) Effect o f TCA on ATP-degrading enzymes
In Table 5.4 it can be seen that as the concentration of TCA exposed to a particular ATP- 
degrading enzyme is reduced, there is a reduction in the signal given out by the SL 
reaction with the sample. TCA concentration of >0.8% is required to inhibit both apyrase 
(lOU/ml) in excess MgClz and 5’-adenylic acid deaminase (0.5U/ml), individually and in 
combination with each other. At levels of <0.8% TCA the apyrase and 5’-adenylic acid 
deaminase were not inhibited and these enzymes were subsequently capable of degrading 
ATP.
Therefore the concentration of TCA required for inhibition of the ATP-degrading 
enzymes (1%) is much higher than that required for microbial cell lysis (0.25%). This 
creates an issue in that the high concentration of TCA would also affect the luciferase 
enzyme. Alternative strategies to inhibit the enzymes were investigated so that this high 
final TCA concentration would not he necessary and the adverse effects on the luciferase 
would be avoided.
b) Effect o f heat on apyrase and 5 '-adenylic acid deaminase
Individually and as part of the ATP degradation reagent, it was demonstrated that apyrase 
(10 U/ml) and 5’-adenylic acid deaminase (0.5U/ml) are still active at temperatures 
<60®C, but inactivated at 70”C. Experiments were carried out by adding the sample to 
sterile distilled water at the selected temperature (for example 70°C). Unfortunately, due 
to evaporation, a volume of at least 5ml of water was required so that adequate inhibition 
could take place. This dilution effect of boiling buffers was found to be too great and it 
created issues with the sensitivity of the assay, therefore boiling buffers were not 
explored further.
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c) Effect o f Suramin and Thimerosal on apyrase
The possible inhibitory effect of Suramin [8-(3-benzoamido-4-methylbenzamido) 
naphalene-1,3,5,-trisulfonic acid] was investigated and it was observed that 
concentrations of 0.02mg/ml Suramin had no effect on the activity of apyrase (lOU/ml) 
in excess MgCl2. In similar experiments concentrations of up to lO'"^  mol/L Thimerosal 
had little effect on apyrase (lOU/ml) in excess MgClz.
Additionally, it was observed that the SL reagent reaction with an ATP standard 
(lOOnmol/L) was affected by Suramin concentrations of >0.00015mg/ml.
No alternative to TCA was found therefore it was used as an inhibitor of the ATP- 
degrading enzymes as well as a microbial cell lysis agent.
Although it was observed that TCA (1.0%) was adequate for degrading enzymes and 
microbial cell lysis it was decided that it was still necessary to use TCA (2.5%) as 
recommended by Lundin (2000). This is because the effectiveness of TCA (1.0%) has 
not been investigated with all microbial species that may be encountered.
5.3 Filtration
In Section 5.2 it was reported that high levels of ATP could be released and degraded 
from non-microbial cells using the developed ATP degradation reagent. It was also 
observed that this reagent does not affect S. epidermidis, C. albicans and E. coli and it is 
inhibited by TCA. However, there is still a significant level of contaminating ATP 
(-0.2%) remaining and this has potentially detrimental effects on the sensitivity of the 
assay. In order to improve on the removal of this contaminating ATP, the potential 
benefits of combining ATP-degrading enzymes with syringe filtration was evaluated.
5.3.1 Syringe filter selection
Syringe filters used in combination with the ATP degradation reagent provide a possible 
solution to the ineffectiveness of the degradation process observed thus far. A number of 
different syringe filters were evaluated and results are shown in Table 5.5. Three 0.45pm 
pore size syringe filters were evaluated and the Sartorius syringe filter was found to be 
contaminated with ATP (>5pmol/L). Both the Millipore and the Gelman filters, however 
were basically ATP free (<lpmol/L). The two 0.2pm filters were also ATP free but the
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Millipore (0.2pm) filter was difficult to use as pressure would build up when fluid was 
passed through it. There were no such problems with the Syrtec (0.2pm) 25mm syringe 
filter and consequently it was chosen for further evaluation.
Serial dilutions (to 10’^ ) of stocks of all E. coli, S. epidermidis, S. aureus and C. albicans 
were passed through each of the two syringe filters and it was determined after 
subsequent culture of the filtrate that no microorganisms passed through either the 0.2pm 
or 0.45 pm filters.
The following Sections detail the assay development using a combination of the ATP 
degradation reagent with 25mm diameter, 0.2pm pore size Syrtec syringe filters.
In order to improve upon the levels of degradation already observed in Section 5.2, 
various physical parameters were evaluated. These included the determination of the 
length of incubation period required at the point the sample is introduced to the ATP 
degradation reagent and the point where TCA is added to the syringe filter.
5.3.2 TCA optimisation
Three specific areas of optimisation were identified with regard to the use of TCA to 
extract ATP from microorganisms that are trapped in a syringe filter. These are described 
below, in three separate Sections, although much of the work overlapped.
a) Incubation period
Studies carried out to determine how fast TCA lyses microbial cells and inactivates ATP- 
degrading enzymes demonstrated that at a final concentration of TCA (2.5%) lysis and 
degradation are complete within one minute. Further experiments carried out using 
25mm diameter, 0.2pm pore size syringe filters indicated that less than two minutes was 
required for the TCA (final concentration >2.5%) to penetrate all areas o f the filter 
membrane and lyse all the microbial cells.
b) Volume o f TCA to be added
TCA needs to be added at a higher concentration so that a final concentration of 2.5% 
can be achieved. With syringe filters it is slightly more complicated in that the true 
volume of liquid in the syringe post-washing is difficult to determine. Therefore in order 
to achieve a final concentration of TCA (2.5%) within the syringe filter unit a number of
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factors needed to be taken into consideration. The assumption is that the hold up volume 
within the Syrtec syringe filter is 420pl and the post-air-purge hold up volume is 260pl 
(see Table 5.5 for further details). As a final concentration of 2.5% is required it is 
necessary to add a higher concentration of TCA in order to compensate for the liquid 
already retained in the filter. It is assumed therefore that there is 420pi of liquid in the 
filter and the addition of 140pl of TCA (10%) will give a final TCA concentration of 
2.5%. However, as can be seen in Table 5.6 this was not the case. The optimum volume 
of TCA (10%) which was necessary in this group of experiments was between 250 to 
350pl, which in a “closed system” should give a final concentration of >3.5% TCA. 
However, this is not closed and liquid is being lost through the bottom of the filter 
housing as liquid is introduced at the top. It is possible therefore that much of the 10% 
TCA flows straight through the filter and does not mix quickly enough with the residual 
liquid in the filter. As a result of this work it was decided that a minimum of 300pl of 
10% TCA should be added to the filter in future experiments.
c) Retrieving ATP after TCA extraction
After the appropriate concentration of TCA has been added to a syringe filter, the 
released ATP needs to be collected for assay. The simplest way to perform this is to flush 
the TCA-extracted ATP from the filter. Experiments were carried out to determine how 
much sterile water or Tris-EDTA was required to extract the highest ratio of ATP. As 
stated above there is already 420pl of TCA-extracted ATP in the Syrtec filter. If this was 
air-purged then approximately 160pl (<40% of sample) could be collected as the 
remaining TCA-extracted sample would remain within the syringe filter, absorbed in the 
membrane as part of the 260pl “post-air-purge hold up volume”. In order to get a higher 
recovery it was necessary to flush a high volume of liquid through the filter. A volume of 
2.5ml was selected because it resulted in a final TCA concentration of just over 1% in the 
final extract. The use of lOOpl of this sample in the bioluminescence reaction (SL) meant 
that there was a final TCA concentration of 0.107% in the bioluminescence reaction 
involving the SL reagent in Tris-EDTA buffer. This is based upon the observations in 
Section 4.3.2, where 0.1% TCA gives 50% inhibition of the signal that is normally 
observed when no TCA is present.
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Table 5.6 Volume o f TCA (10%) that needs to be added to a 25mm diameter syringe filter in order 
to extract the highest concentration o f ATP firom a S. epidermidis stock solution. Values 
shown are the mean (±SD) o f four experiments.
TCA (10%) volumes 
added (pi)
Assumed final TCA 
concentration in syringe 
filter (% v/v) *
Mean (±SD) ATP 
concentration (pmol/L)
100 1.92 756.32 (71.2)
120 2.22 825.14(65.4)
150 2.63 840.25 (62.9)
200 3.23 923.63 (81.4)
250 3.73 1126.47(124.6)
300 4.17 1234.87 (131.8)
350 4.55 1248.12(130.7)
400 4.88 1054.16(129.7)
Assumes a closed system and Is based on the volume added plus the hold up volume of the filter (420pl)
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5.3.3 ATP degradation reagent optimisation
a) Incubation o f sample with the ATP degradation reagent
In Section 5.2.3(b) experiments were conducted to determine the effect of having various
incubation times for the reaction between the sample and the ATP degradation reagent. In 
Figure 5.3 this data is displayed again but also on this graph is the effect of filtration after 
the incubation. Similar trends were observed between the filtered and unfiltered samples, 
and as expected, lower concentrations of contaminating ATP remained in the filtered 
samples. Using the data in Figure 5.3 it was determined that optimal degradation of ATP 
using this combination of reagents occurred at 60 minutes.
b) Volume o f sample to be filtered
The sample is added to 1ml of the ATP degradation reagent. For the purposes of 
sensitivity it is necessary to assay as much of this sample as possible. However, in 
addition to the bioluminescence assay, some of the sample needs to be cultured. It was 
therefore decided that SOOjxl of the sample should be filtered and finally be assayed 
whilst lOOpl of the sample be used in plate culture.
c) Filter flush volume after sample addition
It was important to flush the syringe filter after addition of the solution containing sample 
and ATP-degrading enzymes, to remove cellular debris that could clog the filter or lead 
to quenching of the hioluminescence signal and to remove any remaining ATP-degrading 
enzymes that might be non-specifically bound to the filter.
Studies were carried out to determine how useful it would be to wash with a solution 
(2.5ml) containing one of each of the following: Triton X-100 (0.02%), a 1:10 dilution of 
the ATP degradation reagent, Tris-EDTA or sterile water. It was observed that there was 
no difference between each, with the result that sterile water was selected for use in the 
step.
In further work it was demonstrated that exposing heparinised blood (1:50) to the ATP 
degradation reagent, followed by filtration through a 25mm diameter (0.2pm) syringe 
filter and then flushing with various volumes of sterile water, led to the detection of
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Figure 5.3 Determination o f the optimum incubation period required for the ATP degradation 
reagent to degrade ATP from an ATP standard (1 pmol/L). Each point represents the 
mean ± SD o f four experiments, with the pink points representing samples that have been 
filtered after ATP degradation and the blue points have not been filtered.
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various concentrations of ATP after TCA extraction. Figure 5.4 illustrates that a flush 
volume of greater than 5ml was required in situations where heparinised blood (1:50) 
was used. Further experiments suggested that when a higher concentration of blood 
(1:10) was used a flush volume of at least 7.5ml was required. Therefore, 7.5ml flush 
volumes were adopted for use in conjunction with 25mm diameter (0.2pm) syringe 
filters.
5.3.4 Evaluation of method
Even with the addition of a filtration step contaminating ATP still remained. The possible 
usefulness of hexokinase (<10U/ml) was investigated again and as in Section 5.2.3(a), 
the addition of hexokinase (2.25U/ml) to the ATP degradation reagent in combination 
with filtration had no additional effect on the level of ATP degradation (Table 5.7).
Further experiments with hexokinase (2 to 20U/ml) did not enhance the degradation of 
ATP from platelet-rich plasma (1:100 dilution), when used in combination with the ATP 
degradation reagent and filtration.
In Table 5.8, the combination of apyrase and 5’ adenylic acid deaminase with filtration 
achieved the highest level of degradation (5pmol/L). Levels of >500pmol/L remained 
after apyrase (lOU/ml) and Triton X-100 in the presence of magnesium ions had been 
used to degrade the ATP. The use of filtration improves the technique, with levels of 
<20pMol/L observed. When 5’adenylic acid deaminase is added to the apyrase (lOU/ml) 
and Triton X-100 the level of ATP degradation improves in both filtered and unfiltered 
samples. The use of 5’adenylic acid deaminase in the absence of apyrase was not as 
effective as was the use of hexokinase on its own.
5.3.5 Volume of sample measured in the luciferase reaction
a) Effect o f TCA extractant volume on the SL reagent
When SOOpl of TCA (10%) is added to the filter and subsequently flushed with Tris- 
EDTA buffer (2.5ml) to give a final volume of 2.8ml, the final TCA concentration is 
1.07%. Based on the observations in Section 4.3.2, a final concentration of approximately 
0.1% TCA gives 50% inhibition of the signal that would normally be observed when no
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Figure 5.4 Effect on the concentration of ATP remaining on syringe filters (25mm, 0.2qm) after
flushing with various volumes of sterile water prior to extraction with TCA. Each bar
represents the mean ± SD of four experiments.
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TCA is present. Therefore, lOOpl of the TCA (1.07%) extract was used as the sample in 
the bioluminescence reaction involving the SL reagent in Tris-EDTA buffer (total 
volume 1ml), as this gives a final TCA concentration of 0.107%.
b) Effect o f TCA extractant volume on the HS reagent
Using the HS reagent the final volume of the bioluminescence reaction contains 400pl of 
HS reagent plus the sample volume. In Section 4.3.2 it was observed that a final TCA 
concentration of 0.2% reduced the signal to -60% of normal. As there are 400pl of HS 
this equates to the addition of <100pl of the TCA (1.07%) extract.
Using a laboratory-prepared extract it was observed that volumes of sample of <20pl 
reported lower than expected RLU values. Predictably, there are problems with the 
addition of >100pl of sample, as this leads to a concentration-dependent inhibition of the 
luciferase observed through the RLUs produced by the luciferase-ATP standard reaction. 
Values shown in Table 5.8 demonstrate that a final TCA concentration of 0.051% to 
0.357% gave a reduction in signal of 40% of the control. Based on these results, it was 
decided that a sample volume of 75 pi would be the most appropriate for addition to the 
400pl of HS reagent. However, 75pl is still only 2.68% (75/2800 x 100) of the original 
extracted volume, which in turn is 2.14% of the original sample ((75/2800) x (800/1000) 
X  100).
5.4 Analysis of CVC tip samples
The method developed and described in the Sections 5.1 through to 5.3 was challenged 
with FASEB samples retrieved fi*om CVC tips that were removed from catheterised 
hospital patients. The methodology used has been described in detail in Section 3.6.6 of 
Chapter Three.
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5.4.1 Evaluation of clinical samples using the bioluminescence assay 
A total of 114 Arrow Triple lumen, 7Fr, 20cm CVCs (as shown in Figure 1.1) were 
removed from patients in a local hospital (St George’s Hospital, London). The tips were 
cut from the remainder of the CVC and each tip was subjected to semi-quantitative 
extraluminal culture using the method described by Maki et a l (1977). The results of the 
Maki technique were reported in CFUs and where a sample was too numerous to count 
(TNTC) an estimation of the number of cells was made (for example >500). Each of the 
114 tips were subsequently stored at 2-8°C until the internal lumen of the tip was 
sampled using the FASEB. The CVC tips were collected in batches each week from the 
hospital and this resulted in a variation in time between CVC removal and examination 
of the internal lumen. A portion of the FASEB-retrieved sample was cultured to 
determine the number of organisms present inside the CVC, whilst the remainder of this 
sample was taken and used in the bioluminescence assay. All 114 were exposed to the 
ATP degradation reagent and filtration through a 0.2pm 25mm syringe filter. The ATP 
concentration was determined in 65 samples using the SL reagent (Table 5.9) and in the 
remaining 49 samples using the HS reagent (Table 5.10). These tables also display the 
identity of microorganisms that were isolated from the samples, as well as the RLUs and 
the ATP concentration obtained from the FASEB samples. Initially, organisms were not 
identified in the FASEB cultures of the first 65 samples (Table 5.9).
From Tables 5.9 and 5.10 it can be seen that there are FASEB-retrieved samples that 
reported no growth and others that reported low to high levels of colonisation with 
various species of microorganisms. Sixteen (24.6%) samples reported no growth in Table 
5.9 and 10 (20.4%) in Table 5.10.
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5.4.2 Correlation between ATP concentration and CFU
An attempt was made to determine if there was any correlation between the ATP 
concentrations measured for each of the FASEB samples and the CFU/ml reported from 
culture of the same FASEB sample (Figures 5.5 and 5.6). In both graphs the “no growth” 
samples have been converted to “1” to allow logarithmic plot.
A strong correlation was not evident in the case of the samples detected using the SL 
reagent (Figure 5.5). However there was evidence that samples which reported 1000 
CFU/ml or less reported ATP concentrations of approximately 1000 pMol/L or less.
A slightly better correlation was observed in the samples detected using the HS reagent 
(Figure 5.6). Samples which reported 1000 CFU/ml or more reported ATP concentrations 
of approximately 100 pMol/L or greater. This suggested that the application of cut-off 
values might be useful.
5.4.3 Cut-off limit based on CFU/ml values
To investigate further the possibility of applying a cut-off limit in terms of the CFU/ml, 
graphs were plotted which categorised samples by whether they had greater or less than 
lOOCFU/ml or lOOOCFU/ml. The cut-off of 1000 CFU/ml was selected because of work 
carried out by Brun-Buisson et al. (1987) and Cleri et a l (1980) on quantitative tip 
culture, and the cut-off of 100 CFU/ml based on a study by Kite et al. (1997) on the 
FASEB.
a) SL reagent
Figures 5.7 and 5.8 illustrate the cut-off points at >1000 CFU/ml and >100 CFU/ml 
respectively for ATP concentrations determined using the SL reagent.
In Figure 5.7, thirteen (20%) of the 65 CVC tips have colony counts of >1000 CFU/ml. 
The mean ATP concentration for samples reporting <1000 CFU/ml is 208.25 pMol/L 
(range 1.98 to 1397.0 pMol/L) and the mean ATP concentration for a sample with >1000 
CFU/ml is 83547.34 pMol/L (range 2.39 to 1040000 pMol/L). Nine (69.2%) of the 13 
samples reporting >1000 CFU/ml gave values that overlap with the ATP concentrations 
of the samples that reported <1000 CFU/ml. Thus there is poor distinction between 
positive and negative results based on this cut-off.
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Figure 5.5 Correlation between the ATP concentrations measured for each o f the FASEB samples 
using the SL reagent and the CFU/ml reported from culture o f the same FASEB sample 
(n=65). The “no growth” samples have been converted to “1” to allow logarithmic plot.
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Figure 5.6 Correlation between the ATP concentrations measured for each of the FASEB samples
using the HS reagent and the CFU/ml reported from culture of the same FASEB sample
(n=49). The “no growth” samples have been converted to “1” to allow logarithmic plot.
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In Figure 5.8, 41 (63.1%) of the 65 CVC tips have colony counts of >100 CFU/ml. The 
mean ATP concentration for samples reporting <100 CFU/ml is 289.81 pMol/L (range 
1.98 to 1397.0 pMol/L) and the mean ATP concentration for a samples with >100 
CFU/ml is 26503.83 pMol/L (range 2.39 to 1040000 pMoFL). 37 (90.2%) of the 41 
samples reporting >100 CFU/ml gave values that overlap with the ATP concentrations of 
the samples that reported <100 CFU/ml. Again poor distinction was observed between 
positive and negative results as defined by this 100 CFU/ml cut-off.
b) HS reagent
Figures 5.9 and 5.10 illustrate the cut-off points at >1000 CFU/ml and >100 CFU/ml 
respectively for ATP concentrations determined using the HS reagent.
In Figure 5.9, 14 (28.6%) of the 49 CVC tips have colony counts of >1000 CFU/ml. The 
mean ATP concentration for samples reporting <1000 CFU/ml is 220.67 pMol/L (range
4.86 to 1484.37 pMoFL) and the mean ATP concentration for a sample with >1000 
CFU/ml is 4618.10 pMol/L (range 8.98 to 15610.72 pMoFL). 6 (42.9%) of the 14 
samples reporting >1000 CFU/ml gave values that overlap with the ATP concentrations 
of the samples that reported <1000 CFU/ml.
In Figure 5.10, 26 (53.1%) of the 49 CVC tips have colony counts of >100 CFU/ml. The 
mean ATP concentration for samples reporting <100 CFU/ml is 238.77 pMol/L (range
4.86 to 1484.37 pMol/L) and the mean ATP concentration for a sample with >100 
CFU/ml is 2572.50 pMol/L (range 8.98 to 15610.72 pMol/L). 18 (69.2%) of the 26 
samples reporting >100 CFU gave values that overlap with the ATP concentrations of the 
samples that reported <100 CFU/ml. Again there is poor distinction between positive and 
negative results for both the 100 and 1000 CFU/ml cut-off limits.
c) Cut-off selection
Distinction observed between positive and negative results is poor but it seems to be 
slightly better with samples assayed with the HS reagent than with the SL reagent. 
Basing a CFU count on 100 CFU/ml gives high levels of overlap between samples 
measured with the SL (90.2%) and HS (69.2%) reagents. Using >1000 CFU/ml the levels 
of overlap between samples measured with the SL (69.2%) and HS (42.9%) are 
improved, but still do not provide a test of clinical utility.
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Figure 5,7 The ATP concentrations (pMol/L) determined using the SL reagent in CVC tips that have
recorded >1000CFUs or <1000 CFUs in culture using the FASEB technique (n=65).
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Figure 5.8 The ATP concentrations (pMoPL) determined using the SL reagent in CVC tips that have
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Figure 5.9 The ATP concentrations (pMol/L) determined using the HS reagent in CVC tips that have
recorded >1000 CFUs or <1000 CFUs in culture using the FASEB technique (n=49).
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Figure 5.10 The ATP concentrations (pMoPL) determined using the HS reagent in CVC tips that have
recorded >100 CFUs or <100 CFUs in culture using the FASEB technique (n=49).
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The poor differentiation between positive and negative samples based on these cut of 
values may be due to the small percentage of the extracted sample (<5%) that is used in 
the final ATP determination. This creates a great sensitivity problem as 95% of the 
sample is not measured. The amount of sample that is eluted from the filter is 2.8ml and 
as 75pl and lOOpl were used in the HS and SL reactions respectively then only 2.7% and 
3.6% of the sample is measured. However, as 800pl of the original sample is filtered then 
this equates to 2.2% and 2.9% respectively of the original sample.
5.4.4 Cut-off based on ATP concentration
Kite et al. (1997) defined significant counts after culture of a FASEB-retrieved sample as 
>100 CFU/ml. This was used as the level of significance for cultured samples in this 
study. The sensitivity and specificity of the bioluminescence assay to detect positive 
catheter tip samples (>100CFU/ml) as a function of the ATP limit defining a positive 
FASEB sample was determined. The sensitivity and specificity of the SL reagent to 
detect positive FASEB samples at various ATP concentration cut-off (pMol/L) levels is 
displayed in Figure 5.11. The FASEB samples detected using the HS reagent are 
displayed in Figure 5.12.
If for example a cut-off limit of 10 pMol/L was chosen the bioluminescence assay using 
the SL reagent detected 20 (83.3%) of the positive CVC tips (sensitivity) and 37 of the 
samples were classified as false positive to give a specificity of 9.8%. In Figure 5.11 it 
can been seen that if  the cut-off limit was increased the sensitivity decreases but the 
specificity increases. This is observed when at a cut-off limit of 100 pMol/L the 
bioluminescence assay detected 9 (37.5%) of the positive CVC tips and 12 of the samples 
were classified as false positive to give a specificity of 70.7%.
By using the HS reagent (Figure 5.12) it was observed that at a cut-off limit of 100 
pMol/L the bioluminescence assay detected 16 (61.5%) of the positive CVC tips and 12 
samples were classified as false positive to give a specificity of 47.8%.
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Figure 5.11 The sensitivity and specificity of the bioluminescence assay to detect positive catheter 
samples (>100CFU/ml) as a function of the ATP limit defining a positive catheter sample 
using FASEB culture as the reference method. This graph is based upon 65 FASEB 
samples detected using the SL reagent
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Figure 5.12 The sensitivity and specificity of the bioluminescence assay to detect positive catheter 
samples (>100CFU/ml) as a function of the ATP limit defining a positive catheter sample 
using FASEB culture as the reference method. This graph is based upon 49 FASEB 
samples detected using the HS reagent
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5,4.5 Strategies to improve the cut-off based on ATP concentration
In order to improve clinical utility and introduce a greater separation between positive 
and negative samples, three additional factors were identified and investigated, with 
results reported in Chapter Six. These were, use of an alternative microbial cell lysis 
agent that is more specific than TCA, ways to increase the volume of sample, measured 
in the luciferase reaction and improvement in the separation of microbial and non- 
microbial ATP.
CHAPTER SIX
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6.1 Bacl^round and rationale
In Chapter 5 it was observed that an assay based on syringe filtration and TCA extraction 
was inadequate, as there was poor differentiation between positive and negative samples. 
One of the reasons for this poor definition was that less than 5% of the TCA-extracted 
ATP sample was used in the bioluminescence assay. To improve upon the sensitivity 
level, the extracted ATP should form a larger part of the final sample. This chapter 
details the introduction and use of 13mm diameter syringe filters instead of the 25mm 
diameter syringe filters used in experiments reported in Chapter Five. The application of 
DTAB as an alternative lysis agent to TCA is also reported here. Finally as in Chapter 
Five the modified methodology was challenged with CVC tips that have been removed 
from catheterised hospital patients.
6.2 Application of 13mm diameter syringe filters
6.2.1 Syringe filter selection
In Chapter 5, a final volume of 2.8ml was extracted from the 2.5mm diameter syringe 
filters to provide a TCA-extracted ATP sample. The addition of 2.5ml of sterile water is 
necessary to extract the majority of ATP from the filter (Section 5.3). Further work was 
carried out to determine if the use of a syringe filter with a diameter of 13mm diameter 
and 0.2pm pore size (Nalgene, USA) would lower the volume of liquid required to flush 
the ATP and thus increase the concentration of ATP in the final sample.
6.2.2 Characteristics o f the 13mm diameter Syringe filter
The 13mm diameter syringe filter had a hold-up volume of 210pl and a post-air-purge 
hold-up volume is 50pl and it was observed that each filter had a low ATP content 
(<10pmol/L). It was demonstrated that the syringe filter successfully trapped all E. colt, 
S. epidermidis, and C. albicans cells contained within solutions that were flushed through 
the filter, as there were no colonies present after culture of the filtrate.
6.2.3 Method development
This section details the assay development using a combination of the ATP degradation 
reagent with 13mm diameter, 0.2pm pore size Nalgene syringe filters.
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a) Volume o f sample to be filtered
As with the 25mm diameter, 0.2pm pore size syringe filters, 800pl of the solution 
containing sample in ATP degradation reagent was added to the filter before being 
flushed with 5ml of liquid. Previously 7.5ml had been used in conjunction with 25mm 
diameter syringe filters.
b) TCA optimisation
As these syringe filters are smaller than the 25mm diameter filters used in Chapter 5 it 
was necessary to carry out some optimisation of the assay.
Again TCA needed to be added so that a final concentration of >2.5% was achieved. As 
the hold-up volume is 210pl, a volume of at least 70pl of TCA (10%) was thought to be 
necessary. However, as can be seen in Table 6.1 this was not the case as the optimum 
volume of TCA (10%) which was necessary was lOOpl.
Addition of the lOOpl of TCA (10%) left 210pl of TCA-extracted ATP remaining within 
the syringe filter. In the 25mm filters a volume of 2.5ml was used to flush the TCA- 
extracted TCA from the filter. Based upon this it was decided to add a volume of 1.5ml 
to the 13mm diameter filters in order to flush out the TCA-extracted ATP and give a final 
volume of 1.6ml, and a final TCA concentration of <0.65% (v/v).
c) Volume o f sample measured in the HS reagent
Based on the observations in Section 5.3.1, a final concentration of approximately 0.2% 
TCA gives approximately 50% inhibition of the HS reagent signal that would normally 
be observed when no TCA is present. Therefore, 75 pi of the TCA (0.65%) extract was 
used as the sample in the bioluminescence reaction involving the HS reagent (total 
volume 475pi), as this gives a final TCA concentration of 0.1% (v/v).
6,2.4 Evaluation of the method using CVC tips
The method that has been developed and described in the Sections 6.1 through to 6.2.3 
was used to determine if microbial ATP could be detected in CVC tips removed from 
catheterised hospital patients. A total of 6 CVC were removed and treated as already
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Table 6.1 Volume o f TCA (10%) that needs to be added to a 13mm diameter, 0.2pm pore size
syringe filter in order to extract the highest concentration of ATP from a S. aureus stock 
solution. Values shown are the mean o f four experiments.
TC A  (10% ) volumes added  
(Ml)
Assumed final TC A  
concentration in syringe 
filter (%  v/v) *
A TP  concentration (pmol/L)
50 1.92 352 .57
60 2.22 407.11
70 2.50 418 .35
80 2.76 442 .35
90 3.00 458 .79
100 3.23 4 87 .63
150 4 .17 398 .54
Assumes a closed system and Is based on the volume added plus the hold-up volume of the filter (210pl)
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outlined in Section 5.4. All six were exposed to the ATP degradation reagent and 
filtration through a 0.2pm pore size 13mm syringe filter; the ATP concentration was 
determined using the HS reagent.
Table 6.2 shows results from CVC tips tested using the HS reagent. However the 
sensitivity is poor, resulting in poor differentiation between positive and negative results. 
Again there is still a low volume of TCA-extracted sample (<4.7%) used in the final 
assay and perhaps an alternative microbial cell lysis agent to replace TCA may be 
appropriate as this could lead to a higher volume of the sample being used.
6.3 An alternative microbial ATP extractant to TCA
Alternative microbial cell extractants have been reported in a Chapter 2 where it was 
detailed that all microbial cell extractants intrinsically inhibit the luciferase enzyme. A 
way around this problem is to use an extractant that can be neutralised after it has 
irreversibly inhibited the ATP degrading enzymes. An example is the chemical DTAB, 
which can be neutralised by a-cyclodextrin (Lundin et al. 1994). Experiments involving 
the development of a method using this extractant are described below.
6.3.1 Concentration of DTAB necessary to extract microbial ATP
DTAB is less inhibitory to the HS reagent than TCA when used at similar concentrations 
(1.0-1.5%). In addition DTAB (0.01-0.5%) has a pH of 5.2, unlike TCA, which has a pH 
of 1.5.
A stock culture of S. epidermidis (approximately 10^  cells/ml) was exposed to various 
concentrations of DTAB (0 to 0.1%). A final concentration of 0.5% TCA was used as a 
control to show 100% lysis. The detection of RLUs involved the SL reagent system in 
combination with the LI luminometer. Figure 6.1 demonstrates that at concentrations of 
>0.01% DTAB, the percentage of ATP released is similar to that of the control.
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These results were further verified by culture of each extract using the spread plate 
technique. This showed that there are S. epidermidis colonies present at the 0.005% 
(>1000 CFU/ml) and the 0.01% (15 CFU/ml) concentrations of DTAB. However at 
concentrations of >0.01% DTAB there are no colonies. This would suggest that all of the 
S. epidermidis have been lysed. Therefore a DTAB concentration of greater than 0.01% 
is required to ensure complete lysis of a solution of S. epidermidis (NCTC 11047).
A similar investigation, with a stock solution of E. coli, showed that at concentrations of 
<0.02% DTAB there were E. coli colonies present after culture. However at 
concentrations of >0.02% DTAB there were no colonies present. Therefore a DTAB 
concentration of >0.02% DTAB is required to ensure complete lysis of a solution of E. 
coli.
Using a final concentration of 0.02% DTAB in a serial dilution to 10'  ^ in 1ml of S. 
epidermidis (NCTC 11047) the detection limit of the HS reagent was found to be 188 S. 
epidermidis in a final volume of 900pl. RLU readings were compared with the CFU 
counts obtained for each dilution and these are plotted on Figure 6.2. The RLU values 
plotted are taken from one experiment that showed similar results to that of four 
replicates. Here 100% of the DTAB-extracted sample is measured.
6.3.2 Effect o f  DTAB on apyrase and MgCl2
Using the HS reagent system (Biothema AB) in combination with the Mediators LI 
luminometer, the effects of various concentrations of DTAB (0 to 1%) on the activity of 
apyrase (10 Units/ml) in the presence of MgCli (0.02M) was investigated. Apyrase (10 
Units/ml) in the presence of the excess MgCli is completely inhibited by > 0.4% DTAB. 
This level of inhibition is similar to that of the control, that is, the RLUs emitted by a 
standard that has not been exposed to the combination of apyrase and MgCb- Figure 6.3 
shows the percentage inhibition at each concentration compared to the control.
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Figure 6.1 Effects of various concentrations of DTAB on the release of ATP from a stock culture of  
S. epidermidis. The control has a final concentration of 0.5% TCA only and it is assumed 
that 100% lysis has occurred using this concentration of TCA. Each bar is the mean±SD 
of four experiments.
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Figure 6.2 A standard curve showing the relationship between the RLUs and the number of cells of 
S. epidermidis using the HS reagent system (Biothema AB) in combination with the 
Mediators LI luminometer after extraction with DTAB. Each point is the mean±SD o f  
four experiments.
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Figure 6.3 Effect of various concentrations of DTAB on the activity of apyrase (10 units/ml) in an
excess of magnesium chloride (0.02mol/L). Each bar is the mean±SD of four
experiments.
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6.3.3 Effect of DTAB on the ATP degradation reagent
Using the HS reagent system in combination with the Mediators LI luminometer, it was 
demonstrated that the activity of the ATP degradation reagent (containing apyrase (10 
Units/ml), 5’-adenylic acid deaminase (0.2U/ml), 0.02M MgCL and Triton X-100 
(0.1%w/v)) was completely inhibited by > 0.8% DTAB. This level of inhibition is similar 
to that of the control. The percentage inhibition of various concentrations of DTAB (0 to 
1%) is shown in Figure 6.4.
Results show that a minimum of 0.8% DTAB is required to effectively extract the 
microbial ATP from a microbial cell and inhibit the ATP degrading enzymes.
6.3.4 Detection limit of assay using the DTAB extraction method
Five clinical isolates from colonised CVC tips were cultured. Serial dilutions (to 5 x 10“ )^ 
were made from each stock of isolate. Serial dilutions of each stock were also cultured 
and a count (CFU/ml) determined for the original stock solution. The sensitivity of the 
ATP bioluminescence assay (HS reagent method) was determined for each. Table 6.3 
shows that levels of <500 organisms could be detected in four of the five samples. The 
organisms were identified using Gram staining and the Oxoid Staphytect Plus assay for 
staphylococci.
In a further study, ATP was quantified at all the serial dilutions so that calibration curves 
could be determined. Figures 6.5, 6.6 and 6.7 show the calibration curves that can be 
obtained by lysing various microorganisms with DTAB (0.01%) and detecting the RLU 
emitted from each at the various dilutions using the HS reagent. The CFU values are 
based upon culture results of lOOpl of the 10'  ^ dilution, which was carried out in 
triplicate, in each case.
Based on these results, the sensitivity of the assay (when measuring 100% of the sample) 
is < 500 CFU/ml for the staphylococci, but it is >1,000 CFU/ml for E coli.
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Figure 6.4 The effect of various concentrations of DTAB on the activity of the ATP degradation
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Figure 6.5 A calibration curve showing the detection limit of the DTAB (0.1%)-extracted ATP from
the S. epidermidis cells. Each point is the mean±SD of four experiments.
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Figure 6.6 A calibration curve showing the detection limit of the DTAB (0.1%)-extracted ATP from
the E. coli cells. Each point is the mean±SD of four experiments.
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Figure 6.7 A calibration curve showing the detection limit of the DTAB (0.1%)-extracted ATP from
the MRSA cells. Each point is the mean±SD of four experiments.
Chapter Six_______________________________________ _^_______________________________ Page 223
6.3,5 Effect o f DTAB on lucferin-luciferase reaction with ATP
The effect of increasing the concentration of DTAB on the reaction between the HS 
reagent and an ATP standard was investigated. Figure 6.8 shows the effect of cumulative 
additions of DTAB and water was added as a control so that dilution effects were 
minimised. From the graph, it can be seen that the addition of increasing concentrations 
of DTAB does lead to an inhibition of the HS induced signal (RLUs) and this is a 
concern as the relatively dilute solution of DTAB (0.057%) leads to a great reduction in 
the signal.
When TCA was used, as reported in Section 6.2, the final concentration of TCA was 
diluted by the volume of sterile water flushed through the filter. However, as a 
concentration of DTAB (0.8%) is necessary to lyse the cells and inhibit the enzymes, 
then a 1:10 dilution of the extract will only give a concentration of 0.08%, which 
according to these results will still be inhibitory to the HS reagent.
6.4 Neutralisation of the inhibitory effects of DTAB
6.4.1 a-cyclodextrin
In Section 6.3 it was observed that the reaction between the HS reagent and an ATP 
standard was inhibited in the presence of DTAB (0.057%). In Chapter 2 a-cyclodextrin 
was introduced as a possible agent to neutralise the effects of DTAB. The use of a- 
cyclodextrin was investigated in this study and in some preliminary studies it was 
observed that the inhibitory effects of DTAB were reversed in the presence of a- 
cyclodextrin (0.5%).
Further studies showed that DTAB (0.2%) was neutralised by a-cyclodextrin (0.75%). It 
was also observed that the use of concentrations of a-cyclodextrin of >0.75% leads to 
quenching of the light given off and the use of <0.75% leads to the DTAB-induced 
inhibition of the luciferase reaction.
6.4.2 Effect o f a-cyclodextrin on the DTAB (0.046%) induced inhibition
In Figure 6.8 it was observed that there was a dramatic effect on the signal given out by 
the HS reagent in the presence of DTAB (0.046%). Further work was conducted
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Figure 6.8 The effect of increasing the concentration of DTAB (0 to 0.057% w/v) on the reaction
between the HS reagent and the ATP standard (lO'^mol/L). Each point is the mean of four
experiments.
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where DTAB (0.046%) was exposed to various concentrations a-cyclodextrin (0 to 
0.76%). Figure 6.9 shows the effect of these various concentrations of a-cyclodextrin on 
the DTAB-induced inhibition of the HS plus standard reaction. It is clear that increasing 
the concentration of a-cyclodextrin leads to an attenuation of the DTAB-induced 
inhibition of the HS standard reaction. Therefore, in the presence of a-cyclodextrin the 
effect of DTAB is partially neutralised. The dramatic drop in RLU signal after the 
addition of the DTAB was due to the dilution effect of adding extra liquid.
6.4.3 Addition o f a-cyclodextrin to DTAB-extracted ATP
Figure 6.9 demonstrates that by increasing the concentration of a-cyclodextrin to 0.76% 
(w/v) there is better neutralisation of DTAB (0.046%). Further work was carried out 
using samples extracted from syringe filters using DTAB (2%). The manufacturer of the 
HS reagent claim that up to 600pl of liquid can be added to 400pl of the HS reagent. 
Therefore with this in mind, various volumes (lOOpl to 600pL) were evaluated. Optimum 
results were observed with a final volume of SOOpl of sample, which comprised of 400pl 
(36.4%) of the DTAB extract and lOOpl of a-cyclodextrin (2.5% w/v) to give a final a- 
cyclodextrin of 0.5% and a final DTAB concentration of <0.091%. Then this 500pl of 
sample was added to the HS reagent and the RLUs determined.
6.5 Removal of contaminating ATP from a-cyclodextrin
The a-cyclodextrin supplied by Sigma was found to contain a relatively high 
concentration of ATP. This had to be removed in order for the a-cyclodextrin to be of 
any use in this assay. The method that was developed involved the use of Q Sepharose 
Fast Flow (Amersham Pharmacia Biotech AB) and it is detailed in Section 3.6.5. During 
the development of this method it was found that the Q Sepharose needed to be washed, 
as it was supplied in ethanol. A washing procedure was also developed and this too is 
detailed in Section 3.6.5.
Analysis of the final ATP content of the resultant “ATP free” a-cyclodextrin showed that 
the RLU value reduced from levels of approximately 2,800 to <50 RLUs.
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Figure 6.9 Effect of various concentrations of a-cyclodextrin (0 to 0.76%) on the DTAB (0.046%)
induced inhibition of the HS - standard reaction. Each point is the mean (±SD) of four
experiments.
Chapter Six________________________________________________________________________ Pase 227
6.6 Detection of microbial ATP in CVC tips
The method developed and described in the Sections 6.1 to 6.3 was challenged with 
FASEB samples retrieved from CVC tips that were removed from catheterised hospital 
patients. The methodology used has been described in detail in Section 3.6.6 of Chapter 
3.
6,6.1 Analysis o f clinical samples
A total of 46 Arrow Triple lumen, 7Fr, 20cm CYCs were removed from patients in St 
George’s Hospital, London after they were suspected to be implicated in catheter- 
associated infection. After removal the tips were cut from the remainder of the CVC and 
each tip was subjected to semi-quantitative extraluminal culture using the method 
described by Maki et al. (1977). Each tip was then stored at 2-8°C until the internal 
lumen of the tip was sampled using the FASEB. The CVC tips were collected in batches 
from the hospital and this resulted in a variation in time between CVC removal and 
examination of the internal lumen. Of the 46 samples the range of sample storing time 
varied from 3 to 37 days (mean = 13.34 days).
The FASEB was used to sample the distal lumen of each of these CVC tips. A FASEB 
was also used to sample the intermediate lumen of one of the triple lumen CVCs (number 
44), thus giving 47 results from 46 CVCs.
The results in Table 6.4 are taken from 47 samples where the CFU values from cultures 
using both the Maki technique and FASEB-retrieved sample are displayed. The RLUs 
(determined using the HS reagent) and the ATP concentration obtained from the FASEB 
sample are also displayed. In addition the identity of microorganisms that were present 
have been listed. The ATP concentrations shown in Table 6.4 range from 0.47 to 9230.33 
pMol/L (mean 232.69, mean excluding the outlying result =37.09).
In determining the ATP concentration 400pl of a total of llOOpl extract was used as the 
final sample, which equates to 36.4% of the total extract. However as 800pl of the 
original FASEB-retrieved sample is filtered and subsequently extracted then the 
proportion of sample forming the final sample is 29.1% of the original sample.
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6.6.2 Correlation between internal and external colonisation.
From Table 6.4 it can be seen that in 17 (36.2%) cases the same predominant species of 
microorganism was detected using the Maki technique and the FASEB. Of these twelve 
samples grew >100 CFU/ml. A further six samples reported no growth using both the 
Maki technique and the FASEB technique. In the remaining 24 samples there was growth 
detected using one technique and not the other in 15 cases and 9 samples grew different 
predominant species using both techniques. Mixed growth was observed in 11 samples 
analysed using the Maki technique and 9 using the FASEB.
Table 6.5 details the predominant microorganisms identified using the Maki and FASEB 
techniques. It can be seen that CNS are the most common species isolated from both the 
intra-luminal and extra-luminal portions of the CVC tip (Table 6.5).
6.6.3 Correlation between ATP concentration and CFU/ml
It was observed that 6 samples reported no growth using the Maki technique and the 
FASEB technique. Moreover 5 (83.3%) of these reported ATP concentrations of <10 
pMol/L ATP. A further 6 samples reported growth of <100 CFU/ml using both 
techniques and 5 (83.3%) of these reported ATP concentrations of <50 pMol/L ATP. An 
attempt was made to determine if there was any correlation between the ATP 
concentrations measured for each of the FASEB samples and the CFU/ml reported from 
culture of the same FASEB sample (Figure 6.10). A strong correlation was not evident, 
however there was an indication that samples reporting <1000 CFU/ml generally 
reported ATP concentrations of approximately 200 pMol/L ATP or less.
6.6.4 Cut-off limits based on CFU counts
The utility of cut-off limits was investigated using the same cut-off criteria applied in 
Section 5.4. The mean ATP concentration for samples reporting <1000 CFU/ml was 
31.49 pMol/L ATP (range 0.47 to 364.32 pMol/L ATP) and the mean ATP concentration 
for samples with >1000 CFU/ml was 1082.22 pMol/L ATP (range 3.51 to 9230.33 
pMol/L ATP). It was observed that 9 (14.9%) of the CVC tips had colony counts of 
>1000 CFU/ml, however 8 (88.9%) of these reported ATP concentrations which
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Table 6.5 Microorganisms implicated in CVC colonisation as detected using either the technique 
developed by Maki et al. (1977) or the FASEB technique.
Microorganism
Number (%) detected using
Maki et al. 
technique (n=37)
In vitro FASEB 
technique (n=30)
No. % No. %
Coagulase negative staphylococci 23 62 2 16 53.3
S. aureus 5 13.5 2 6.7
Yeasts 2 5.4 4 13.3
Others 7 18.9 8 26.7
(Mixed growth) 11 N/a 9 N/a
Predominant microorganism in the case of mixed growth
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Figure 6.10 Correlation between the ATP concentrations measured for each of the FASEB samples
and the CFU/ml reported from culture of the same FASEB sample (n=47). The “no
growth” samples have been converted to “1” to allow logarithmic plot.
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overlapped with the ATP concentrations of the samples reporting <1000 CFU/ml (Figure 
6.11). In Figure 6.12, seventeen (36.2%) of the CVC tips had colony counts of >100 
CFU/ml and 15 (88.2%) reported ATP concentrations which overlapped with the ATP 
concentrations of the samples that reporting <100 CFU/ml. The mean ATP concentration 
for samples reporting <100 CFU/ml was 25.44 pMol/L ATP (range 0.47 to 230.9 pMol/L 
ATP) and the mean ATP concentration for samples with >100 CFU/ml was 598.43 
pMol/L ATP (range 1.00 to 9230.33 pMol/L ATP).
Basing a CFU count on 100 CFU/ml gives high levels of overlap between the samples 
(88.2%). There was no difference if a level of >1000 CFU/ml was chosen (88.9%). Thus 
there is poor distinction between positive and negative results as defined by this 100 CFU 
or 1000 CFU cut-off limits.
6.6.5 Cut-off based on A TP concentration
Thirty (63.8%) of the samples were reported as negative and 17 (36.2%) as positive, 
based upon a level of significance of >100 CFU/ml for cultured samples. The sensitivity 
and specificity of the bioluminescence assay to detect positive catheter tip samples (>100 
CFU/ml) as a function of the ATP limit defining a positive catheter sample is shown in 
Figure 6.13.
By taking a nominal cut-off limit of 10 pMol/L ATP as an example, it can be determined 
that the bioluminescence assay detected 12 (70.6%) of the positive CVC tips 
(sensitivity), yet 13 of the samples were classified as false positive, using this cut-off 
limit, to give a specificity of 56.7% (Figure 6.13). If the cut-off limit was increased then 
the sensitivity decreased but the specificity increased. Therefore, an increase in the cut­
off limit to 50 pMol/L ATP meant that 26 (86.7%) of the negative samples which had 
ATP concentrations of less than 50 pMol/L were true negatives. Indeed 16 (94.1%) of the 
samples that had no growth had an ATP concentration of <50 pMol/L ATP. Furthermore, 
8 (47.1%) of the samples that reported >100 CFU/ml had ATP concentrations in excess 
of 50 pMol/L ATP. However, 9 (52.9%) samples were reported as false negative using 
this cut-off limit.
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Figure 6.11 The ATP concentrations (pMol/L) determined using the HS reagent in CVC tips that have
recorded >1000 CPUs or <1000 CPUs in culture using the FASEB technique (n=47).
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Figure 6.12 The ATP concentrations (pMol/L) determined using the HS reagent in CVC tips that that
have recorded >100 CPUs or <100 CPUs in culture using the FASEB technique (n=47).
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Figure 6.13 The sensitivity and specificity of the bioluminescence assay to detect positive catheter tip 
samples (>100 CFU/ml) as a function o f the ATP limit defining a positive catheter 
sample using FASEB culture as the reference method. This is based on all 47 samples.
Chapter Six________________________________________________________________________ Pa2e 238
6.6.6 Positive and negative predictive value
In order to determine a suitable cut-off limit the predictive value of a positive result 
(PV^) and the predictive value of the negative result (PV) as a function of the ATP cut­
off limit for a positive CVC tip were determined (Figure 6.14).
At a concentration 1 pMol/L ATP the PV^ and PV  are 37.8% and 100% respectively. By 
increasing the cut-off limit of these predictive values (Figure 6.14) the PV^ was increased 
and the PV  decreased to give 100% and 65.2% respectively at a cut-off limit of 1000 
pMoFLATP.
6.6.7 Effect o f sample storage prior to analysis
Of the 47 samples that were analysed 18 (38.3%) were stored for 7 days or less prior to 
sampling by the FASEB technique (Table 6.6). The remainder of the tips were stored for 
between 8 and 37 days (mean duration was 18.8 days). Those tips stored for <7 days 
produced results with a higher specificity (81.8%) at a cut-off level of 20 pMoFL ATP 
than those tips stored for >7 days. However, the length of storage time had little effect on 
the sensitivity of the assay at this cut-off level of 20 pMol/L ATP.
6.6.8 Selection of a cut-off level
It is a requirement that this assay has a high predictive value for a negative result; that is 
the PV  should be as close to 100% as possible. By combining the results in Figure 6.13 
with those from Figure 6.14 it is possible to determine the optimal cut-off limit. A 
suitable cut-off limit would have to fall between 1 and 10 pMoFL ATP so that a PV  of 
>70% could be achieved. However the problem with a cut-off limit at this ATP 
concentration is that the specificity and PV^ of the method are low (<60%). Nevertheless, 
a low ATP concentration cut-off is necessary so that false negative results are avoided. 
At 10 pMoFL ATP cut-off limit 17 (56.7%) of the negative samples had ATP 
concentrations of less than 10 pMoFL ATP, but five (29.4%) false negatives results were 
also reported using this cut-off limit. As a consequence the cut-off limit for the assay 
would need to be set at an ATP concentration closer to 1 pMoFL ATP, which would 
ensure that all positive results are determined and as few false negative results as possible 
are achieved.
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Figure 6.14 The predictive values of positive and o f negative assay as a function of the ATP limit for 
a positive CVC sample using FASEB culture as the reference method (n=47).
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Table 6.6 Effect of sample storage at 2-8°C, for greater or less than seven days, on the sensitivity 
and specificity o f the bioluminescence assay using a cut-off level o f 20pMol/L ATP 
(n=47).
<7 days >7days
Number of tips (%) 18 (38.3%) 29 (61.7%)
Sensitivity 60% 57.9%
Specificity 42.9% 81.8%
CHAPTER SEVEN 
Discussion
Chapter Seven______________________________________________________________________Pase 241
Despite the many benefits that CVCs offer, complications arising from their use have 
been noted since their introduction (Collins 1991). It is now estimated that over 500,000 
cases of CRBSI occur annually in Western Europe and the USA (Crump and Collignon 
2000). This creates a tremendous burden on the healthcare system with the average 
excess cost per survivor estimated to be $28,690, which is partly due to an additional 6.5 
days required in ICU (Pittet 1994a, Pittet et al. 1994b).
Infections involving CVCs derive from a complex interaction between the host, the CVC 
and the microorganism (Mermal and Maki 1994, Raad 1998). There are no defined levels 
at which microorganisms may be said to contribute to infection or colonisation, however 
the occurrence of bacteraemia is less frequent than the level of observed device 
colonisation (Kite et al 1997, Raad 1998). Nevertheless, a high level of colonisation is 
generally thought to be a precursor to bacteraemia (Cleri et al 1980, Dittmer et al 1999, 
Kite et al 1997, Maki et al 1977).
In order to determine if a CVC is the source of an infection, common practice involves 
the removal of the CVC (Johnson and Oppenheim 1992, Maki et al 1977). However, 
such retrospective analysis results in the unnecessary removal of approximately 80% of 
CVCs as they are subsequently found not to be the source of the infection (Kite et al 
1997, Padberg et al 1981, Pettigrew et al 1985, Ryan et al 1974). The accurate 
diagnosis of a catheter-associated infection is a challenge in that clinical symptoms are 
often non-specific (Dobbins et al 1999, Elliott et al 1994a). Moreover, the results of 
microbiological investigations are often difficult to interpret (Elliott et al 2000, 
Worthington et al 2002a). Methods are available by which the CVC can be sampled 
whilst it remains in situ within the patient (Dobbins et al 1999, Siegman-Igra et al 
1997). However, clinicians are generally not in favour of leaving a suspected CVC in situ 
whilst waiting up to 24 hours for a culture result. Therefore, there is a requirement for a 
more rapid method of determining the microbial status of the CVC whilst it remains in 
situ.
Many of the rapid techniques that have been evaluated for use in the diagnosis of CRBSI 
have used blood aspirated through the CVC and have not required catheter removal (Blot 
et al. 1999, Gowardman et al. 1998, Kite et al. 1999, Kleiman et al. 1984, Moonens et al 
1994, Rogers and Oppenhiem 1998, Rushforth et al 1993, Tighe et a l 1996b, von Baum
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et al 1998, Worthington et al 2002a). However, none of these techniques has been 
adopted for routine use in the determination of the microbial status of a CVC. In a meta­
analysis by Siegman-Igra et al (1997) of sixteen methods used for the diagnosis of 
catheter-associated infection only three were rapid techniques and two of these (the Gram 
staining and the AOLC method) allowed the CVC to remain in situ.
The development of a technique that would aid in the rapid diagnosis of catheter- 
associated infections without CVC removal was attempted in this study. This chapter 
discusses the results of this investigation both in the context of the development of the 
technique and with reference to literature reviewed in Chapter 1. The development and 
evaluation processes are presented as well as major findings and the recommendations for 
future work.
Assay Development
The FASEB was used as the sampling device in this study. It has been shown to be the 
only device that can provide a sample from the inside of the CVC without the risk of 
contamination. Indeed, use of the FASEB in combination with conventional culture 
methods has been reported to have a higher sensitivity and specificity for the diagnosis of 
catheter-associated infections than traditional tip culture methods (Dobbins and Kite 
1999, Kite et al 1997, 1999). However, no studies have been conducted that have 
evaluated the feasibility of using a FASEB-retrieved sample in conjunction with a rapid 
test to aid in the diagnosis of catheter-associated infections. Perhaps Tighe et al. (1996b) 
came closest with the use of the FASEB to dislodge material from the catheter lumen 
prior to the aspiration of blood for use in the AOLC test.
Rapid detection of the presence of microorganisms in various clinical and non-clinical 
samples has been conducted using different types of detection technologies, such as 
particle counting (Medcrafr 1993, Stevens et al 1993), microscopy (Tighe et al 1996b) 
and ATP bioluminescence (Lundin et al 1989). In this study three such technology 
platforms were evaluated and using a scoring system, ATP bioluminescence was selected. 
One of the advantages of ATP bioluminescence was that it has a detection limit that 
allows measurement of as few as 100 microorganisms within a clinical sample (Lundin 
2000). Indeed ATP bioluminescence has been successfully used in conjunction with other
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clinical samples where the detection of relatively low numbers of microorganisms is 
necessary (Lundin 1989, Nilsson et al. 1989, Sakakibara et al. 1997, Thore et al. 1975).
Preliminary investigations into the possible application of ATP bioluminescence to a 
rapid test for the detection of microorganisms associated with CVCs involved the 
attempted development of a method using the Bioprobe luminometer and its dedicated 
reagent system. Contrary to the manufacturer’s claims that the detector was sensitive 
enough to detect the equivalent of between 100 and 1000 CFU/ml (Report 1995), it was 
demonstrated that the sensitivity of the ATP bioluminescence assay was inadequate for 
detecting microbial ATP at this level. This was most likely to be due to the distance from 
the sample to the photo-detector (-20mm), which would mean that not all the light is 
detected. In attempting to distinguish between contaminating and microbial ATP, a 
commercially available ATPase was evaluated and it was observed (Figure 4.4) that a 
relatively high concentration of the ATPase could reduce contaminating ATP levels prior 
to release and determination of the microbial ATP. Further development using an isolator 
reagent and syringe filtration in combination with the ATPase demonstrated that further 
release and degradation of ATP from fresh blood cells was possible. However, a 
relatively high concentration of ATP still remained to contaminate samples. This was 
demonstrated during an evaluation with nine blood samples drawn through the CVC 
where the RLU values obtained did not correlate with subsequent CFU/ml counts.
As the background RLU level could not be reduced using the combination of this off-the- 
shelf instrument and reagent system it was considered necessary to develop and formulate 
a reagent system that would facilitate a reduction in the background ATP level leading to 
the successful extraction and detection of microbial ATP. Figure 2.7 in Section 2.7 
illustrated the three main steps that needed to be overcome in order to develop an 
adequate method for detection of microorganisms based upon ATP bioluminescence. 
These steps involve the lysis and degradation of non-microbial ATP, followed by the 
lysis of microbial cells and the simultaneous inhibition of ATP converting enzymes and 
thirdly the detection of the released microbial ATP. In order to satisfy the Steps 1 and 2 
of Figure 2.7 the Mediators LI luminometer and recommended Biothema AB reagents 
were evaluated in conjunction with laboratory formulated reagents. This system was more 
appropriate than the Bioprobe system in that the sample could be contained within a tube
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that could be located close to the photo-detector during the bioluminescence reaction. 
Additionally, using the LI system in conjunction with laboratory formulated reagents it 
was observed that more of the contaminating, non-microbial ATP could be removed from 
the sample, thus leaving microbial ATP to be detected.
The development of a system based upon laboratory-formulated degradation reagents in 
conjunction with commercially available luciferase detection reagents and the LI 
luminometer was described in Chapter 5 after preliminary development was reported in 
Chapter 4. To fulfil the requirements of Step 1 of Figure 2.7, a combination of chemicals 
and enzymes were evaluated to determine if it would be possible to exclusively lyse non- 
microbial cells and degrade the released ATP, whilst leaving microbial cells intact. The 
use of Triton X-100 in the lysis of somatic cells has previously been documented (Lundin 
and Thore 1975). Triton X-100 (0.1%v/v) was found to be the optimum concentration for 
lysing somatic cells such as those in a fresh heparinised blood sample (Figure 4.12). 
Additionally the combination of Triton X-100 with apyrase in excess Mg^  ^ led to the 
release and degradation of >90.0% of the ATP in fresh heparinised blood samples and 
platelet-rich plasma. This was an improvement on the level of degradation previously 
reported by Molin et al. (1983) with blood samples, however Molin et al. used a grade I 
apyrase which contained a low ATPase activity. The grade m  apyrase used in the present 
study has ten times higher ATPase activity than the grade I apyrase, therefore more ATP 
is converted to ADP over a much shorter period of time. Nevertheless, with this level of 
degradation approximately 600 pMol/L of ATP is left remaining, which may be 
equivalent to as many as 300,000 bacterial cells (Lundin 2000). Further methods of 
degrading this remaining ATP were investigated. Sakakibara et al. (1997) have 
previously demonstrated high levels of non-microbial ATP degradation by using a 
combination of apyrase and adenosine phosphate deaminase to achieve a residual ATP 
concentration of 1 pMol/L. Unfortunately a source for adenosine phosphate deaminase 
could not be found for use in this study. However, it was possible to obtain 5’ adenylic 
acid deaminase, which like adenosine phosphate deaminase breaks down AMP to IMP. 
Using a combination of 5’ adenylic acid deaminase and apyrase in excess of Mg^^ with 
Triton X-100 (known in the present study as the ATP degradation reagent) led to the 
release and degradation of >99.0% of the ATP from platelet-rich plasma, to leave <250 
pMol/L ATP remaining (Figure 5.1). As the aim was to reduce the ATP concentration to
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approximately 1 pMol/L, a significant concentration of potentially contaminating ATP 
was still remaining. Further additional enzymatic alternatives were investigated with no 
additional success. Other strategies to aid in the removal of this residual ATP were 
investigated. Syringe filtration has been suggested by Lundin (2000) as a suitable method 
for isolating microbial cells and maximising their separation firom contaminating ATP. A 
washing technique involving syringe filters was developed and evaluated in this study. 
Syringe filters with a 25mm diameter and 0.22pm pore size were used in conjunction 
with platelet-rich plasma (1:50), which was pre-treated with the ATP degradation reagent. 
An improved level of ATP removal was observed which resulted in <0.2% of the original 
ATP concentration remaining (Table 5.3). This equated to ~ 50 pMol/L of ATP 
remaining firom platelet-rich plasma (1:50) and -500 pMol/L of ATP remaining from 
heparinised blood (1:50). By degrading this level of ATP firom such a rich source of fi*ee 
ATP, it was accepted that the criteria set in Step 1 of the fiow chart (Figure 2.7) were 
fulfilled. Additionally, this washing procedure was found to have no adverse effect on the 
microbial cells and their intracellular ATP concentration. This is in agreement with 
comments made by Lundin (2000) who prefers this type of washing and cell 
concentration to that of centrifugation, which can lead to non-physiological conditions 
that could result in depleted microbial ATP levels.
In order to release ATP from microbial cells and inhibit all ATP converting enzymes, so 
that the requirements of Step 2 in Figure 2.7 could be fulfilled, TCA was evaluated in 
conjunction with the syringe filter technique. Lysis of microbial cells trapped on the filter 
membrane was achieved by the addition of TCA to obtain a final concentration of >2.5%. 
This TCA concentration was suggested by Lundin (2000) and was found in the present 
study to be adequate for rapid cell lysis and simultaneous inhibition of all ATP degrading 
enzymes. It was observed that apyrase (10 Units/ml) and 5’-adenylic acid deaminase 
(0.5U/ml) were both inhibited by TCA (>0.8%).
The ATP released fi*om the microorganisms after lysis by TCA was collected by flushing 
the syringe filter with over five times the hold-up volume. This led to a significant 
dilution of the ATP pool in the sample, as the final volume was 2.8ml. Nevertheless, the 
TCA concentration was simultaneously diluted from 2.5% to just over 1.0%, therefore 
reducing its inhibitory effects on the luciferase reaction. Further optimisation of the assay
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led to the finding that no more than lOOgl of this TCA extracted sample could be 
measured in a final 1ml volume of the luciferin-luciferase reagent (SL) in Tris-EDTA. 
Indeed a similar situation was observed with the HS reaction where no more than 75 pi 
could be assayed in a final volume of 475pi. These observation were consistent with 
those identified by Lundin (1997) and in the previous development work carried out in 
this study (Figures 4.8 and 4.9) were a final concentration of 0.1% TCA gives a 50% 
inhibition of the luciferase reaction. At this level of inhibition the detection of RLUs is 
still possible as addition of an internal standard will compensate for the observed 
inhibition, however further inhibition leading to a signal of <50% of the maximum would 
lead to unreliable results (Lundin 1997, 2000).
The combination of the ATP degradation reagent in conjunction with a syringe filtration 
method and TCA was evaluated using 114 FASEB-retrieved samples and found to be of 
little clinical utility as there was little correlation between CFU and ATP concentration. 
The poor differentiation may be due, in part, to the small percentage of extracted sample 
(<5%) that is used in the final ATP determination. In all cases the volume of sample 
eluted from the filter was 2.8ml, however only 75pl and lOOpl were assayed in the HS 
and SL reactions respectively. Therefore only 2.7% and 3.6% of the sample is measured. 
However, as only 800pl of the original sample is filtered (with the remainder used in 
plate culture) this equates to just 2.2% and 2.9% respectively of the original sample. This 
creates a great sensitivity problem where >95% of the sample is not measured and low 
levels of microbial colonisation and infection will not be distinguishable from 
background levels of ATP. Unfortunately, this is one of the issues with chemicals used to 
lyse microbial cells and inhibit ATP converting enzymes. Other chemicals, which can be 
used as an alternative to TCA extraction have been reported in Section 2.7, but all have 
problems associated with their use (Table 2.4). Nevertheless, in this study the quaternary 
ammonium compound, DTAB, which is less hazardous than TCA (Lundin 2000) was 
investigated. By combining the DTAB extraction with 13mm diameter, 0.2pm pore size 
syringe filters - instead of 25mm diameter syringe filters - an improved method was 
developed. It was observed that DTAB (>0.8%) was adequate for rapid, simultaneous cell 
lysis and inhibition of all ATP degrading enzymes, thus fulfilling the requirements of 
Step 2 in Figure 2.7. Further development showed that just 1.0ml of sterile water was 
required to elute the ATP solution (extract) from the 13mm syringe filter.
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The advantage of using DTAB was observed when its inhibitory effects could be 
neutralised by a-cyclodextrin (Lundin et al. 1994). Further development of the assay led 
to optimum neutralisation of a final DTAB concentration (-0.08%) with a final 
concentration of 0.5% a-cyclodextrin. This is consistent with the findings of Lundin et al. 
(1994) who suggest that cyclodextrins should be present in a small excess over the 
quaternary ammonium compound.
Using a-cyclodextrin to neutralise the DTAB contained within the ATP extracted from 
the syringe filter in combination with the HS reagent led to 29.1% of the eluted sample 
being used in the assay. This was much improved upon the 2.7% observed when the TCA 
extract was used. This 10-fold increase in sample volume led to better assay performance 
when compared to the TCA extraction method.
Assay Evaluation
The DTAB extraction method was outlined in Figure 3.1 and was used to determine the 
microbial ATP content of 47 FASEB samples retrieved from CVC tips that were 
removed from hospitalised patients after a catheter-associated infection was suspected. In 
Table 6.4 the microorganisms isolated intraluminally and extraluminally were reported 
and these were consistent with those found in other studies (Dobbins et al. 1999, Fletcher 
and Bodenham 1999a). Organisms were isolated from the extraluminal surface of 37 
CVCs and from the internal lumen of 30 CVCs. CNS was the predominant 
microorganism isolated from both the internal and external lumens (Table 6.5) and this is 
again consistent with previous studies, as illustrated in Figure 1.10 in Chapter 1. The high 
percentage of CNS isolated from both surfaces of the CVC is in agreement with the 
findings of a study by Kite et al. (1997) who reported CNS in 83% of colonised CVCs. 
Six samples reported no growth using both the Maki technique and the FASEB 
technique. This suggests that these CVCs may have been inserted for a short period of 
time (<24 hours) because microbial colonisation of a CVC surface often occurs just 24 
hours after insertion (Raad 1998).
The results of FASEB culture were the basis for establishing true positive (>100 CFU/ml) 
and true negative (<100 CFU/ml) results for catheter colonisation (Kite et al. 1997). 
Unfortunately, in this study no clinical evaluation was carried out due to ethical
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restrictions. This meant that details on the underlying condition of the patient, the 
treatment being undertaken and whether antibiotics were infused through the CVC 
lumen, were all unknown. Therefore information on which CVCs actually were 
associated with bacteraemia or septicaemia was not available. This was a major 
constraint and it is recognised as so by the author. Further work in this area will require 
more patient information to be collected. Such information would be useful in 
understanding the selective pressures that certain biofilm-forming microorganisms may 
have been influenced by.
Using the DTAB extraction method, many of the samples reported ATP concentrations of 
>1 pMol/L. If it were assumed that one bacterial cell has an ATP concentration of 2 x 10' 
Mol/L (Lundin 2000) then 10'^  ^ Mol/L (or 1 pMol/L) would correspond to 500 
microorganisms in 1ml of sample. However, in 33 (70.2%) samples where <500 CFU/ml 
were observed >lpMol/L ATP was detected. Indeed within this study ATP concentrations 
are generally in the pMol/L to nMol/L region rather than the fMol/L to the pMol/L range, 
even-though 80.9% of samples reported less than 1000 CFU/ml after culture of the 
FASEB-retrieved sample. This finding is consistent with the observation by Lundin 
(2000) who suggests the ATP concentration can often correspond to higher cell numbers 
than would be expected from CFU/ml count. Moreover, Nilsson et al (1989) have 
reported a similar situation where ATP concentrations determined for microorganisms in 
aerobic blood cultures were much higher than the actual number of bacteria that appeared 
to be present. A possible explanation for this may be that the removal of non-microbial 
ATP fi*om the FASEB-retrieved sample was incomplete because the ATP degradation 
reagent was unable to access each individual somatic cell and/or unable to degrade all the 
ATP present (Nilsson et al 1989). A second possible explanation may be that a single 
CFU is not necessarily originating from one distinct cell (Lundin 2000). Indeed 
organisms such as staphylococci, exist in clusters and, therefore, a single CFU may 
equate to many cells. A third reason may have been that the DTAB (0.8%) may not have 
been at a high enough concentration to penetrate the glycocalyx of some of the biofihn- 
forming microorganisms. Future work in this area should allow enough sample for direct 
counting procedures such as microscopy so that more accurate counts can be obtained.
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Due to the difficulty in relating ATP concentration to the CFU count, the application of a 
cut-off based upon ATP concentration and using the 100 CFU/ml FASEB significance 
level was evaluated. Thirty (63.8%) of the CVCs that were removed on suspicion of 
causing infection were subsequently categorised as negative following culture of the 
FASEB-retrieved sample (<100 CFU/ml). These samples consisted of 17 CVC tips that 
gave no growth and 13 that were colonised with low numbers of microorganisms. This 
proportion of negative CVCs is similar to that seen in other studies (Dobbins et al. 1999). 
Of these 30 that would have been saved by FASEB culture, the ATP bioluminescence 
assay detected 26 (86.7%) if a cut-off limit of 50 pMol/L was applied between positive 
and negative results as determined by the ATP bioluminescence assay (Figure 6.13). 
However, only 8 (47.1%) of the samples that were reported positive by the FASEB 
culture method were detected at this cut-off limit. By using a lower cut-off limit of 10 
pMol/L, 17 (56.7%) of the negative samples were detected using the ATP 
bioluminescence assay. Nevertheless, 12 (70.6%) of the positive CVCs were detected at 
this cut-off limit. A further reduction of the cut-off limit to 1 pMol/L ATP would ensure 
that all positive results were determined as the sensitivity of the assay would be high 
(close to 100%) resulting in as few false negatives as possible being achieved. However, 
the specificity at a cut-off limit of 1 pMol/L ATP would be low (<10%) resulting in many 
positive results (both true positives and false positives) which would ultimately lead to 
unnecessary CVC removals. Nevertheless, a low ATP concentration cut-off may be 
necessary so that false negative results are avoided. A possible solution to this dilemma 
of reducing the level of false positives without increasing the level of false negatives 
would be to combine the ATP bioluminescence assay with subsequent confirmatory plate 
culture. This method has been successfully used by Nilsson et al. (1989) when 
distinguishing between positive and negative blood cultures. In their particular study ATP 
concentrations were categorised as positive, borderline or negative, with follow up 
culture only on the borderline samples. Using this strategy a high level of sensitivity and 
specificity was achieved (Nilsson et al. 1989). By employing this method in the present 
study it may be possible to identify ATP concentrations at which the FASEB-retrieved 
sample is positive, borderline or negative. In the case of positive samples the CVC would 
be removed immediately and in the case of a negative result the CVC would be allowed 
to remain in situ within the patient. For results that would fall into the borderline category
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the CVC would be left in situ but the patient would be monitored closely for any further 
symptoms of bacteraemia or septicaemia, before the confirmatory plate cultures are 
received. It would be envisaged, however that plate cultures would be carried out for all 
samples so that any microorganisms are identified and that appropriate antibiotic therapy 
or other clinical action is recommended.
hr the present study, it may be possible to classify results, in terms of ATP concentration, 
as negative (<10 pMol/L), borderline (10 pMol/L to 50 pMol/L) and positive (>50 
pMol/L). By classifying the results in this manner it was observed that 22 of the samples 
are negative and 12 are positive, with 13 (27.7%) borderline results. Of the 12 samples 
reporting an ATP concentration of >50 pMol/L ATP, four (33.3%) gave colony counts of 
<100 CFU/ml and are therefore false positive results. Five (22.7%) of the 22 negative 
results reported >100 CFU/ml and are false negative results. Of the 13 borderline results 
9 reported <100 CFU/ml after plate culture. Therefore of the 30 that had <100 CFU/ml by 
FASEB culture the ATP bioluminescence assay detected 17 (56.7%) immediately and a 
further 9 after the borderline results were cultured to give a total of 26 and a specificity of 
86.7%. Five of the CVCs were reported as false negative to give a specificity of 70.6%. 
Based upon this cut-off limit the PV^ of the assay is 75% and PV  of the assay is 83.9%.
Nine (19%) CVCs were identified incorrectly using the ATP bioluminescence assay and 
specified cut-off limits. There were four false positive results where the ATP 
concentration reported was high (>50 pMol/L) but <100 CFU/ml were cultured. CNS (10 
CFU/ml) was cultured from one sample, whilst the other had no growth and another had 
50 CFU/ml of an organism that was not identified. Yeast (20 CFU/ml) was cultured fi’om 
the fourth sample, where an ATP concentration of 230.9 pMol/L was also reported. The 
high ATP concentrations in these samples may be explained by one or a combination of 
the following:
1. The most likely explanation is that all the contaminating non-microbial ATP was not 
removed from the sample prior to addition of the DTAB. This could be due to 
possible clumping of non-microbial cells within the sample and the inability of the 
Triton X-100 and /or the ATP degrading enzymes to fully penetrate these cells and 
consequently ATP remained within cells and / or debris, until DTAB is added. 
Sonication may have added value in this situation, but it was not evaluated as part of
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this study. Future work should investigate the possible advantages of sonication for 
these types of sample.
2. There is also a possibility that microorganisms were present but could not be cultured. 
This has been observed before where Passerini et al. (1992) demonstrated that 76% 
(52/76) of catheters studied using SEM had bacterial cells present within the biofilm 
but only 32% of the catheters yielded significant numbers of bacteria when a proven 
scraping/sonication recovery method was employed. If this were the case then it is 
possible that the ATP bioluminescence assay is detecting viable microorganisms that 
cannot be cultured. Therefore the possible existence of SCVs cannot be ruled out as 
these would contain ATP which would be detected, but the SCV may be difficult to 
culture using conventional microbiological techniques (Bayston 1999, Krimmer et al. 
1999). Bayston (1999) suggests that ATP generation is reduced in these cells, 
however the actual ATP turnover may be lower but the ATP concentration remains 
the same (Lundin, personal communication 2001). More research in this field will 
determine if the measurement of ATP is appropriate in these clinical samples. This is 
because the samples may contain mature biofilms, which have inherently lower ATP 
concentrations than would normally, be observed in planktonic cells (Bayston 1999).
3. It may be the case that the CFUs are not originating from one distinct cell. Indeed, as 
stated before, organisms such as staphylococci, exist in clusters and, therefore, a 
single CFU may equate to many cells (Lundin 2000). One of the samples contained 
10 CFU/ml of CNS and it may be possible that more cells were present in clusters 
thus giving few CFU/ml. Further work that utilises total counting techniques 
(microscopy) would be useful for these samples.
4. In the case of the yeast sample these are much larger than bacterial cells and therefore 
have a greater volume of ATP. Consequently, a low number of yeast cells could give 
a relatively high concentration of ATP. Nevertheless, it is useful that ATP was 
detected in this sample as a CVC that is colonised by yeast, even at low levels, should 
be removed (Raad 1998, Wickham et al. 1992). Additionally some yeast are difficult 
to culture and therefore high ATP levels may be observed in cases where there are no 
growth.
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Of the 22 negatives that reported <10 pMol/L ATP, 5 (22.7%) reported >100 CFU/ml 
after culture. These are false negative results, where mixed growth was observed in three 
of the samples, colonies of CNS were observed in the fourth and an unidentified 
organism was reported in the fifth sample. A concern with these samples is that 
significant levels of yeast, S. aureus and coliforms were cultured, and often when these 
organisms colonise a CVC there is a much higher risk of the colonisation leading to 
infection (Kite et al. 1997). In contrast CNS frequently colonise CVCs, as has been 
observed in this study, but are less likely to be implicated in septicaemia. These 5 false 
negative results are more difficult to explain than the false positive results discussed 
above, because if viable cells are present in significant quantities then it would be 
expected that their intracellular ATP could be detectable. Possible reasons for this 
anomaly may be:
1. It is possible that the DTAB (>0.8%) was not concentrated enough to lyse the 
microorganisms that were present in these samples. Moreover, the DTAB may not 
have effectively broken down the glycocalyx that may have been present within these 
biofilm samples. A similar situation may have occurred here as has occurred with 
antimicrobial agents (Douglas 2003, Fletcher and Bodenham 1999a, Potera 1998, 
Vorachit et al. 1993) and a higher concentration of DTAB may be required. More 
work is necessary to determine if this concentration of DTAB is appropriate and 
effective in all possible FASEB-retrieved samples. The effectiveness of DTAB may 
be dependant on the maturity of the biofilm in addition to the species of 
microorganism involved in the colonisation of the CVC.
2. The signal generated during the ATP bioluminescence assay may have been quenched 
thus giving a low RLU value (Lundin 2000). This is unlikely, however, because an 
ATP standard was added at the end of each of the assays and there was no significant 
reduction observed in RLU count from the reaction between the bioluminescence 
reagents and the standard.
3. The ATP content of the microorganisms may have been affected by the components 
of the ATP degradation reagent. However, as the ATP degradation reagent was 
exposed to the whole sample and the fact that subsequent plate culture was possible 
would suggest that this is unlikely.
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4. The filtration process may have in some way affected the concentration of ATP by 
stressing the organisms. Beumer et al. (1992) has observed that microorganisms such 
as Campylobacter jejuni have reduced ATP levels in response to adverse 
environmental conditions and stress. More development is necessary to determine the 
effects on ATP level of flushing microorganisms through a filter membrane.
5. The ATP content of SCV cells may vary with the length of time the CVC is in place 
and the maturity of the biofihn, with older biofihn cells possibly containing lower 
levels of ATP (Bayston 1999). It was not noted whether the cells that were cultured 
were actually SCV that may have reverted back to the normal phenotype when 
cultured on the blood agar plate. Further work in the area of biofilms and the 
physiology of biofilm cells may provide further evidence on the ATP content of these 
cells.
Comparison o f present technique with other rapid techniques
Sensitivity and specificity
A sensitivity and specificity of 70.6% and 86.7% respectively, is comparable with studies 
that have sought to develop rapid techniques to detect catheter-associated infections. 
Elliott et al. (2000) reported a sensitivity and specificity of 75% and 90% respectively for 
an antibody assay test for diagnosis of CRI due to CNS. Further optimisation of this assay 
by Worthington et al. (2002a) resulted in an ELISA assay with a sensitivity of 70% and a 
specificity of 100%. However, a major disadvantage of this assay is the fact that only 
patients with catheter-associated infections caused by CNS can be diagnosed. This is 
because the antibody used in the detection system is specific for CNS. Therefore, based 
on Figure 1.10 in Chapter 1, this would suggest that infections caused by other organisms 
(up to 63%) would go undetected.
Other studies that have sought to develop rapid techniques have reported varying 
performance during evaluation. Five studies involving the AOLC method in conjunction 
with blood drawn through the CVC have been reported (Gowardman et al. 1998, Kite et 
al. 1999, Rushforth et al. 1993, Tighe et al. 1996b and von Baum et al. 1998). The study 
by Rushforth et al. (1993) suggested that the AOLC test had a high sensitivity and 
specificity (87% and 94% respectively) for the diagnosis of CRS using blood aspirated
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through the CVC. However, the success of the test in this neonatal population could not 
be translated in adult populations (Gowardman et al 1998, Tighe et al 1996b, von Baum 
et al 1998). Gowardman et al (1998) reported that all twelve CVCs associated with 
microorganisms that were confirmed as the cause of CRB SI were not detected using the 
ALOC method (false negative results). These included 5 species of CNS, one yeast and 
one S. aureus amongst others, von Baum et al (1998) demonstrated that the AOLC 
method was positive in 2 of 4 cases of CRB SI and the AOLC method detected organism 
is only 20% of all colonised catheters. Tighe et al (1996b) reported 15 false negative 
results, however a higher level of sensitivity was reported when the AOLC method was 
used in combination the FASEB. The combination of these techniques reduced the level 
of false negative result to three, where CNS was subsequently cultured from two CVC 
tips and Streptococcus pneumoniae from the other. Kite et al (1999) demonstrated a 
higher level of specificity (92%) and sensitivity (96%) of the AOLC method when used 
in combination with Gram staining. Nevertheless, in this study of 128 samples five 
results were reported as false positive and two as false negative. It was observed that 
three of the false positive samples contained yeast that could subsequently not be cultured 
and it was reported that these yeast cells had the morphological appearance of Malassezia 
spp, which would require specialist culture conditions (Kite et al 1999). The reason for 
differences in results within these studies may not only be due to the assay which was 
conducted but also the types of patients and duration of CVC placement. The studies by 
von Baum et al (1998) and Gowardman et al (1998) involved ICU patients, whereas 
Tighe et al (1996b) and Kite et al (1999) involved surgical patients and those receiving 
TPN. On the face of it, this may not seem to be an issue, however CVCs are generally in 
place for a longer period of time in the TPN patients than the ICU patients, therefore they 
are more likely to be colonised endoluminally (Cmich and Maki 2002b, Raad 1998). The 
mean duration of catheter placement in the Kite et al (1999) study was 16 days, whereas 
in the Gowardman et al (1998) study it was 6 days. Current thinking suggests that 
catheters in place for <10 days are less likely to be colonised on the internal lumen than 
CVCs in place for >10 days (Raad 1998). Therefore the results obtained by Gowardman 
et al (1998) may not be unexpected.
Unfortunately in the present study, the duration of catheterisation was unknown, however 
as the catheters were all Arrow triple lumen catheters, these are generally placed for
Chapter Seven______________________________________________________________________Pase 255
periods of no more than 10 to 30 days. This could lead to a situation where colonisation 
would be more likely on the outside rather than the inside of the CVC lumen. This was 
observed in this study where microorganisms were isolated from the extraluminal surface 
of 37 CVCs and from the internal lumen of 30 CVCs. In future work this will be 
important information that should to be collected as CVCs which have been inserted for 
<10 days may report more CFU extraluminally than endoluminally.
Other studies that do not involve microscopy, but do require blood aspirated from the 
CVC have reported varying results. A prospective study by Blot et al (1999) 
demonstrated that a cut-off DTTP value of 120 minutes had a 91% specificity and 94% 
sensitivity for the diagnosis of CRI. However, Rijnders et al (2001) found that the DTTP 
was not useful for diagnosis of CRBSI in a mixed medical-surgical ICU. Four false 
positives and 1 false negative were reported leading to a sensitivity of only 25%. These 
patients had short-term multi-lumen CVCs and the mean duration of catheter placement 
was 12 days. This again suggests that the duration of catheter placement is crucial to the 
success of any rapid test involving blood aspirated from the CVC. Additionally, Rijnders 
et al (2001) comments that 78 of the 100 patients were receiving antibiotics at the time 
of catheter removal. This is a possible reason for the fact that more patients had CRS 
without associated bacteraemia (5) than CRBSI (3). This too may have an effect of the 
efficacy of an assay based upon blood aspirated from the CVC. Therefore the sampling of 
planktonic cells may lead to false negative results especially if these cells have been 
exposed to bactericidal concentrations of a specific antibiotic. This again suggests that 
techniques which sample sessile organisms in a biofilm are more relevant to the detection 
of catheter-associated infection causing organisms (Wilcox et al 2001). Additionally, the 
ATP bioluminescence assay may be better applied to CVCs that are in place for >10 to 30 
days rather than CVCs in place for <10 days where extraluminal colonisation is more 
prevalent.
Total assay time
The ATP bioluminescence assay has a laboratoiy processing time to result of 
approximately 75 minutes from receipt of the FASEB-retrieved sample. This is much 
longer than the routine methods currently used in pathology laboratories (Cleri et al 
1980, Kite et al 1997, Maki et al 1977). However, these techniques require overnight
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culture before a result is obtained. The present technique compares well with other rapid 
techniques that do not require CVC removal. The technique described by Blot et al. 
(1999) requires a laboratory processing time of at least 2 hours and the techniques 
described by Elliott et al. (2000), Worthington et al. (2002a) and Tighe et al. (1996b) 
require 12 hours, 4 hours and 1 hour respectively. More rapid techniques such as the 
Gram stain and AOLC test described by Kite et al. (1999) can be completed in 
approximately 30 minutes. The 75 minutes required by the ATP bioluminescence assay 
could be reduced by testing multiple samples simultaneously (in practice up to six 
samples could be processed at one time). Additionally, through further optimisation of 
the assay it may be possible to reduce the total assay time. This may be achieved by using 
other ATP degrading enzymes either in combination with, or instead of, the current 
dephosphorylation enzymes, or the addition of chemicals that could disrupt fibrin and 
thrombus so that all somatic cells are exposed to the Triton X-100. The use of Percoll 
density gradients or indeed the customisation of columns used in DNA preparation work 
may aid the process.
The possibility of supplying a tube containing the ATP degradation reagent to the 
hospital ward should also be investigated. In this way a FASEB-retrieved sample could 
be added to this reagent and much of the initial 60 minute incubation currently required 
could be completed before the sample reaches the pathology laboratory. However this 
may be difficult to control if the incubation is temperature sensitive.
Ease o f use
The present assay is some-what labour intensive in comparison to the routine 
conventional methods currently used and the DTTP method described by (Blot et al. 
1998, 1999). However, many of the other rapid assays are labour intensive and require 
specialist training (Tighe et al. 1996b, Worthington et al. 2002a). Kite et al. (1999) 
comment that the Gram stain and AOLC technique is “easily leamf’, which suggests that 
specialist training is required and that it is a technique that may not be familiar to all “on 
call” staff who provide emergency cover outside the normal 9 to 5pm working day. 
Moreover, Gowardman et al. (1998) found the AOLC test to be labour-intensive and 
demanding on skilled personnel for accurate performance and interpretation. The assay 
based on ATP bioluminescence has a number of individual steps, which makes it slightly
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cumbersome, however through further development and optimisation it may be possible 
to merge certain steps so that less manipulations are required.
Cost o f assay
Although the application of ATP bioluminescence technology is relatively expensive 
(-£6,000 for the luminometer and approximately a further £2.00 per test thereafter) when 
compared with an average of £0.35 for conventional microbiology culture (Kite, personal 
communication 2002), it is similar in expense to the other rapid methods that have been 
evaluated for use in CRBSI detection. Techniques such as the DTTP method (Blot et al. 
1999), the ELISA method (Worthington et al. 2002a) and the AOLC method (Kite et al. 
1999, Tighe et al. 1996b) all require specialist equipment and if these are not readily 
available in the routine pathology laboratory then initial capital outlay could be as high as 
£30,000. The accuracy and cost-effectiveness of the DTTP method and the method based 
upon Gram stain and AOLC have been discussed by Farr (1999) in a commentary in the 
Lancet. Farr (1999) suggests that further studies be carried out by other investigators, 
within other clinical settings, before either method is recommended for use. Farr (1999) 
also suggests that of the two the DTTP method would be easier to set up as the 
continually monitoring blood-culture systems are used in most clinical microbiology 
laboratories. However, like the ELISA technique (Worthington et al. 2002a) the ATP 
bioluminescence assay would require specialist equipment and reagents, which could be 
expensive. Both are more suited to batch testing as control samples (positive and 
negative) may be needed. Additionally, the current assay requires various consumables, 
such as disposable syringes and syringe filters. These could again be removed through 
optimisation of the assay or through automation of some of the steps.
Overall performance
The ATP bioluminescence technique in combination with a FASEB-retrieved sample 
compares favourably with other rapid techniques that are currently available. Its 
sensitivity and specificity, of 70.6% and 86.7% respectively, are adequate, in comparison 
to some of the techniques that have been evaluated. However, further improvements are 
required in terms of ease-of-use, cost and total assay time. This technique has a number 
of advantages and disadvantages, with one of the major issues that needs to be addressed
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being the number of individual steps that are required in order to prepare the sample prior 
to ATP quantification.
Conclusions
As a result of this study a number of conclusions can be made. These have been separated
into those associated with assay development and those made as a result of the evaluation
of the developed method.
Assay Development
• The ATP degradation reagent, comprising of apyrase (grade m, 10 Units/ml), 5’ 
adenylic acid deaminase (0.5U/ml), Triton X-100 (0.1% v/v) in excess magnesium 
ions can be used to lyse blood cells and degrade up to 99% of ATP that is 
subsequently released.
• Use of the ATP degradation reagent in combination with syringe filtration increases 
the level of ATP removal firom blood cells in the sample to beyond 99%. The 
remaining ATP equates to approximately 50 pMol/L in platelet-rich plasma (1:50) 
samples and 500 pMol/L in heparinised blood (1:50) samples.
• The use of DTAB at a final concentration of >0.8% to extract ATP fi*om selected 
clinical isolates associated with catheter infections, was equally as effective as the 
standard TCA (2.5%) method recommended by Lundin (2000).
• Both TCA (2.5%) and DTAB (>0.8%) will irreversibly inhibit the activities of 
apyrase (10 Units/ml) and 5’-adenylic acid deaminase (0.5U/ml).
• Neutralisation of the final DTAB concentration (0.08%) was achieved with a final 
concentration of 0.5% a-cyclodextrin.
• The use of a-cyclodextrin in combination with DTAB increased the volume of 
microbial ATP extract that could be assayed by 10-fold, when compared with the 
TCA extraction method.
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• By using 13mm syringe filters the volume of buffer required elute microbial ATP 
from the filter is reduced from 2.5ml (required by 25mm filters) to 1.0ml.
• The Mediators LI luminometer was found to be a more appropriate luminometer 
than the Bioprobe for this application. This was mainly due to the close proximity of 
the sample to the photo-detector. The LI also had a sufficient linear range to allow 
the detection of low levels of microbial ATP in combination with the HS luciferase 
reagent.
Assay Evaluation
• The ATP bioluminescence technique (outlined in Figure 3.1 -  the DTAB extraction 
technique) in combination with a FASEB-retrieved sample compares favourably 
with other rapid techniques that are currently available, in terms of sensitivity, 
specificity, ease-of-use, cost and total assay time.
• By using the cut-off limits for negative (<10 pMol/L), borderline (10 pMol/L to 50 
pMol/L) and positive (>50 pMol/L) it was observed that the ATP bioluminescence 
assay has a sensitivity and specificity of 70.6% and 86.7% respectively, with a PV^ 
of 75% and a PV  of 83.9% for CVCs associated with significant colonisation (>100 
CFU/ml).
• Even though four false positive and five false negative results were reported, this 
assay based on the cut-off limits described provided accurate information on 26 
CVCs that were true negatives and 12 that were colonised (true positive results).
• The use of this ATP bioluminescence technique in combination with a FASEB- 
retrieved sample may assist in the rapid detection of CVCs associated with suspected 
bacteraemia in catheterised patients.
Overall Conclusions
This study indicates that ATP bioluminescence is a useful technique that may be used in 
conjunction with FASEB-retrieved samples to detect or eliminate catheter-associated 
infections without removing the CVC. It is the first time that ATP bioluminescence has
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been applied as a technique to the area of catheter-associated infection diagnosis. In 
addition, this is the first study, which has investigated directly whether a FASEB- 
retrieved sample can be used in combination with rapid detection technologies.
Other novel features that were successfully developed and may add to the literature 
aheady available in the field of ATP bioluminescence include, the development of the 
ATP degradation reagent and its use in combination with the 13mm syringe filters, which 
provided a novel approach to degrading high levels of contaminating ATP prior to 
microbial cell lysis. Degradation of relatively high concentrations of ATP in blood 
samples has been achieved in this study, with previous studies degrading much lower 
ATP concentrations in laboratory-spiked broth samples (Sakakibara et al 1997). 
Moreover, the application of a DTAB-based extraction method, instead of the TCA-based 
microbial cell extraction method, was successfully demonstrated and the subsequent 
neutralisation of DTAB by a-cyclodextrin was successfully achieved and applied to 
samples in this study. This again is a new approach that had not been applied to clinical 
samples.
Further work will be required to improve upon the sensitivity and specificity of the final 
proposed testing method (Figure 3.1- the DTAB extraction technique), with the main 
emphasis being on the sample preparation so that all contaminating ATP is degraded and 
all microbial cells are exposed to the microbial lysis agent prior to ATP quantification. 
Suggestions for further development and optimisation are detailed in the following 
section.
Further work
This study demonstrates that ATP bioluminescence is a useful technique for detecting 
low numbers of microbial cells. The application of this technique to a FASEB sample 
retrieved from a CVC tip that has been removed from a catheterised patient has also 
shown some potential but a number of issues have been raised. These issues are best 
discussed in reference to Figure 2.7 where the critical steps to method development 
where identified. The present study has demonstrated that Step 3 can be achieved through
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technology that aheady exists, however, a number of issues remain unresolved within 
Steps 1 and 2.
In Step 1, the goal was to lyse non-microbial cells and release their intracellular ATP for 
subsequent degradation without affecting the ATP concentration of the microbial cells. 
The combination of the ATP degradation reagent and syringe filtration was adequate to 
some degree but contaminating ATP remained. Further work is necessary to reduce and / 
or completely degrade this contaminating ATP. Some possible ways of doing this have 
been identified and are listed below.
• Use of micro-centrifuge filters instead of syringe filters, where more sample could be 
forced through the filter membrane in a controlled manner, and leaving intact cells 
imbedded in the membrane. However, the effect of the stress of the filtration process 
needs investigation.
• Use of Percoll® density gradients in conjunction with a centrifugation step to 
separate blood cell debris from microorganisms. Some work using this technique to 
degrade background ATP present in blood samples has been attempted in the past 
(Molin et al 1983, Nilsson et al 1989). Additionally, the application of techniques 
such as the use of DNA preparation columns should be investigated.
• Identification of other ATP-degrading enzymes which could be used in combination 
with, or instead of, the current constituents of the ATP degradation reagent, for 
example adenosine phosphate deaminase (Sakakibara et al 1997).
• The addition of chemicals or enzymes that could disrupt fibrin and thrombus so that 
all somatic and microbial cells are exposed and no clumps of cells exist. The use of 
sonication may be advantageous.
The aim in Step 2 was to develop a method for microbial cell lysis so that all the 
intracellular ATP is released and all ATP-degrading enzymes are simultaneously and 
irreversibly inhibited. In the present study two such compounds, namely TCA and DTAB 
were found to be useful in that, at an appropriate concentration, all microbial cells were 
lysed and the ATP-degrading enzymes were inhibited. However, as pointed out in Table 
2.5, these, like many microbial ATP extractants, are potent inhibitors of luciferase, thus 
they need to be diluted or neutralised prior to ATP detection. Further work here would be
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beneficial as the more extracted sample that can be used in the final ATP determination 
then the greater the sensitivity of the technique. Some possible improvements are detailed 
below.
• Investigate further if DTAB has the capability of releasing ATP from actual biofihn 
(that is, the capability of penetrating glycocalyx) rather than planktonic 
microorganisms.
• Optimise the reaction between a —cyclodextrin and DTAB.
• Determine if there are other compounds available that could be used to lyse 
microbial cells and simultaneously inhibit ATP degrading enzymes before being 
completely neutralised so as not to affect the luciferase reaction; for example another 
member of the cyclodextrin family (Lundin et al 1994).
• Use boiling buffers and allow most of the liquid to evaporate prior to ATP 
concentration determination, so that the effects of dilution are not a factor.
There is a possibility of improving the method through at least one of the points raised 
above or through a combination of the points, identified for both Steps 2 and 3 from 
Figure 2.7.
In addition to these, another area where improvements could be made is through the use 
of samples that are more representative of the internal lumen of a CVC. For example, 
attempting to grow a biofilm within a CVC in vitro and then using this as a standard 
sample. This could be more appropriate than using blood.
In summary, this work does indicate that ATP Bioluminescence technology can be used 
with this type of CVC sample. Further work will be required in some of the areas 
identified above, in order to improve sample preparation so that an adequate sample is 
obtained for accurate ATP concentration determination. A future evaluation should 
involve FASEB samples retrieved for patients whilst the CVC remains in situ so that the 
effects of variables such as CVC tip storage duration are avoided.
The Mediators LI luminometer was seen to be an extremely useful instrument, which had 
a good linear range and was sensitive at the low end. The detection reagents supplied by 
Biothema AB were also seen to be useful, with the HS reagent being more sensitive than
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the SL reagent. Both this instrument and the HS detection reagent are recommended for 
use in further development.
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Appendix 1
Scanning Electron Microscopy (SEM)
Scanning Electron Microscope
Samples were observed using a Hitachi S-4000 scanning electron microscope. 
Materials
Sodium cacodylate (IM)
A stock solution of sodium cacodylate (IM) (Sigma Aldrich, UK) was prepared and 
buffered to pH 7.2 using HCl (IM). This was stored at room temperature until 
required.
Solution containing glutaraldehyde (3% v/v) and Sodium cacodylate (O.IM)
A stock of glutaraldehyde (3% v/v) and sodium cacodylate (IM) was prepared by 
dissolving 10ml of glutaraldehyde (25%) (Sigma Aldrich, UK) in 65ml of sterile 
water and 8.33ml of the sodium cacodylate (IM).
Preparation of CVC tips
The CVC tips were selected and these were sectioned longitudinally and transversely 
using a sterilised double-edged razor blade (which was sterilised with alcohol).
The sections were then fixed in a solution containing glutaraldehyde (3% v/v) in 
sodium cacodylate (IM) for 3 hours. The samples were then exposed to the following 
series:
• Washed in sodium cacodylate (O.IM) ( 3x10  minutes),
• Washed in distilled water (3x10  minutes),
• Dehydrated in an ethanol series of 20%, 40%, 60%, 80%, 90% and 100% (v/v) 
ethanol for 10 minutes each.
The samples were then placed in acetone and stored at room temperature.
Further processing of the sample
The samples were removed from the acetone and mounted on aluminium stubs. These 
were then coated with gold using an Edwards sputter coating device (SI5OB). The 
samples were then observed using a Hitachi S-4000 scanning electron microscope at 
an accelerating voltage of 20.0kV. The software package was set up so that the scale 
bar was automatically placed on the image. The images were saved to zip disc on a 
Dell computer.
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BioThema AB
Strandvâgen 36 Phone +46 850151641
S-130 54 Dalaro Fax +46850150952
Sweden E-post: biothema@swipnet.se
VAT No. SE556303345401 Website: www.biothema.com
ATP Kit SL 144-041
Instructions for use 
Intended use
ATP Kit SL is intended for monitoring of adenosine triphosphate (ATP) over the range of lO '^  -10*^  mol/L. 
The low decay rate of the light emission (around 0.5 %/min) is <hie to a low consumption of ATP in the firefly 
luciferase reaction and a luciierase activity that is unchanged during the time of the measurement Under these 
circumstances measurement of the intensity of the light emission allows continoous monitoring of formation or 
degradation of ATP in enzymatic reactions or release of ATP fi%)m cells. Thus assa)% can he performed in much 
the same way as NAD(P)H is spectrr^ hotometricalty or fluorometrically monitored in a ss^  based on 
dehydrogenase reactions. Furthermore the stable li^ t makes ass^  even of a constant ATP level more 
convenient and reliable, particular  ^when using manual luminometers. If a higher sensitivity is required 
BioThema has two other reagents allowing the detection of 10*'^  mol and 10"'' mol, resp.. Please cf. our 
Website: www.biothema.com.
Assav principles
Firefly ludferase catalyses the following reaction: 
luciferase
ATP + D-Iuciferin + Qz ------> AMP + PPi + oxylucifetin + COz + light
The assay has been optimised to give a stable light at all ATP levels tqr to 10^  mol/L. The reagent contains D- 
ludferin, magnesium ions, PPi (inorganic pyrophosphate) and BSA (bovine serum albumin).
Kit contents
1. ATP Reagent SL. 4 vials of lyophilised reagent containing D-ludferin and ludforase.
2. Diluent C 10 mL. 4 vials containing ATP flee distilled water.
3. Tris-EDTA BuSer 50 mL. 4 bmtles containing 0.1 rnol/L Tris(hydro)ymethyl) aminomethane, 2 mmol/L 
EDTA and adjusted to pH 7.75 with acetic acid.
4. ATP Standard 5 mL. 4 vials containing 10'^  moIes/L of ATP.
The kit should be stored at -18 °C. However, during normal transport times the kit is not affected by ambient 
teirperature. If used within a week the kit may be stored at +4 °C. The kit and the individual componmits are 
labelled with expiry date assaming borage at-18 °C.
Reagent reconstitution
The ATP Reagent is reconstituted by adding the entire content of the Diluent C vial (10 mL) to the reagent 
vial. It is very important to avoid corrtamination. Please use a clean pair of tweezms to remove the rubber 
stoRxr firom the ATP Reagent vial. Pour the diluent ^ ntly into the reagent vial to dissolve the lyophilised 
reagent. Stfosequently pour the solution back into the Diluent C vial. Once reconstituted the reagent must be 
protected firom light. In reconstituted ATP Reagent the luciferase activity slowly dectys. However, calibrating 
the assays with ATP Standard makes it possible to use the ATP reagent fOTsevnal days at +4 °C or for 1 
month at -18 °C. Reagents should be allowed to attain room temperature before the assty (the qximum 
temperature for the luciferase reaction is around 25 °C.
Instrumentation
The stable light makes it possible to use manual single tube luminometers, automatic tube luminometers or 
microjHate luminontôers. The detection limit obviously depends on the liuninometer. With most luminometers 
10'' ^  moles of ATP can be detected.
Assav procedure using internal ATP Standard
In this procedure a known amount of ATP is added in the assay of each individual sample. This strongly 
increases the reliability of foe assay and makes it possible to express ATP results in moles rather than riu or 
other non-chemical units. The assay can also be performed using external ATP Standard. However, this is a 
less reliable procefone in most cases. Hease conâilt BioThema for advice, if you are considering using external 
ATP Standard.
A Tube luminometer
1. Add sample and Tris-EDTA Bufier to give a total volume of 0.8 mL in the cuvette.
2. Add 0.2 mL ATP Reagent SL.
3. Measure the light emission corresponding to sample ATP, Lmp.
4. Add 10 pL of ATP Standard.
5. Measure the light emission corresponding to sample plus standard ATP, Lmpfstd-
6. Calculate the sample ATP concentration in the cuvette fay the following equation:
ATPjmp” 10 X  Lmp/ ( LœpHld “ Lmp)
The factor 10*’ is the concentration of ATP Standard in the cuvette (10 pL (O'® mol/L in a total reaction volume 
of 1 mL).
B. Microplate luminometer
1. Add sample and Tris-EDTA Buffer to give a total volume of 160 pL in the cuvette.
2. Add 40 pL ATP Rea^nt SL.
3. Measure the light emission corresponding to sam^ de ATP, Lng>-
4. Add 10 pL of ATP Standard diluted 1/5 in Tris-0)TA buffer.
5. Measure the light emission corresponding to sample plus standard ATP, Lmpfitd.
6. Calculate the sample ATP concentration in the cuvette by the following equation:
ATPanp” 10 X  Innp/ ( Lmptitd “ Innp)
The foctor 10'^  is the concentration of ATP Standard in the cuvette (10 pL 0.2 x 10 ^  mol/L in a total reaction 
volume of 0.2 mL).
Procedural notes
1. The sample volume should be chosen to gtye an ATP level in the cuvette in the interval 10'" -10^ mol/L 
(lower limit somewhat dependent on luminomder senstrvity). For maximum precision a sample volume 
should be chosen to give an ATP level in the interval 10'" -10^ mol/L. High saiiq>le AlP levels 
aMUoachiog the concentration obtained fiom the ATP Standard tend to give too low values on Lmp^ td 
resulting in an overestimation of ATPmp- The sanqde volume should also be chosen to avoid unrtecessary 
inhibition of l i^  emission from sanqde components (e. g. extractant). An inhibition of iq> to 50% is 
normally not a problem, since the effect is compensated for ly  the internal ATP Standard.
2. The ATP StatKfard volume should be as low as possiUe with a retained precision. Ideally the volume 
should be <1% of the total reaction volume, since the dilution effect coming from the addition of ATP 
Standard otherwise can not be neglected. With a total reaction volume of 1 mL it is accqjtabte to use 10 
pL. With a total reaction volume of200 pL an ATP Standard volume of 10 pL is somewhat too high, but 
has to be accq)ted since lower volumes of ATP Standard can not normalfy te added with h i^  precision.
3. The light emission should be measured as soon as possible after addition of reagents (ATP Reagent and 
ATP Standard, resp ). Maximum light emission is normally obtained within a few seconds and will then 
start to decay by 0.5 %/min.
4. Every series of assays should include at least two blanks in the tegirming and at the end. Blanks should 
contain all reagents added in preparation of samites (e. g. extractants used for releasing ATP from cells) 
and should be assayed and calculated exactly as normal samples. Blanks calculated by the formula above 
are subtracted fiom sample ATP valws calculated in the same way. The ATP concentration in the original 
biological sample is then calculated by multiplying with the dilution in the assay and in the prepaaüon of 
the sampWe for the assay.
Appendix 3
Data sheet for CVC tips
Copies of the sheet on the following page were supplied to St George’s Hospital 
(London) Medical Microbiology Department. The details were filled out for each 
CVC tip retained for this study. The corresponding number (1 to 20) from the 
sheet was written on the lid of the sample pot containing the CVC tip. The label 
below was placed on the sample pot and the relevant details recorded.
For CRS Research Project
For One Catheter Tip Only
Patient Number:
Date Received:
Store at 4°C
The laboratory number corresponded to the department’s code given to each 
sample received in the laboratory. This was recorded so that clinical data could 
be traced on certain patients, however it was not required as ethical approval was 
not granted to access patient details.
The catheter type was recorded as either, CVC or PICC. On occasion, further 
details were recorded, such as the source of the CVC (femoral, subclavian or IJ). 
Other CVC tips were investigated.
The results of the Maki culture were also recorded, as well as the predominant 
species identified. In cases of mixed growth as many isolates as possible were 
identified.
Date Number of samples.
Sample
Number
Laboratory
Number
Date catheter 
removed
Catheter type CPU (Maki) Species
1
2
3
4
5 ,
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
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